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Abstract 
 
Nucleic acid recognition is an important mechanism that enables the innate immune 
system to detect both microbial infection and tissue damage. To minimize the 
recognition of self-derived nucleic acids, all nucleic acid sensing signaling receptors 
are sequestered away from the cell surface and are activated either in the cytoplasm 
or in endosomes. In endosomes, nucleic acid sensing relies on members of the toll-
like receptor (TLR) family. In conditions of infection or damage, however, the immune 
system must allow recognition of extracellular nucleic acids. But, how these are 
sensed and internalized is not yet completely understood. Entry of nucleic acids has 
long been considered to rely on microbe or cell debris uptake into cells before 
release of their contents including the nucleic acids. It is now clear that free 
extracellular nucleic acids exist, which can be detected and internalized thanks to 
extracellular receptors. 
The receptor for advanced glycation end-products (RAGE) is a multiligand cell 
surface receptor that has been studied the past twenty years for its role in 
development of a plethora of inflammation states such as those occurring during 
microbial infection, sterile injury, neurodegeneration, auto-immunity and cancer. 
RAGE was shown to trigger inflammatory signals, promote immune cell maturation, 
proliferation and motility thereby sustaining and exaggerating the inflammatory state. 
To do so, RAGE senses heterogeneous types of molecules that accumulate during 
such inflammatory conditions and which often can trigger expression of RAGE itself. 
These ligands include advanced glycation end-products (AGEs), amyloid fibrils such 
as amyloid-β, members of the S100 protein family and high-mobility group box 1 
(HMGB1).  
Data presented in this thesis introduces nucleic acids as new class of ligands for 
RAGE. First, data demonstrate the binding of DNA to RAGE extracellular domain 
and localizes this binding to the V and C1 immunoglobulin-like domains. Biochemical 
assays and crystallography analysis show that DNA binds with RAGE through 
interaction between the DNA phosphate backbone and a positively charged amino-
acid surface present on RAGE V-C1 domain. Flow cytometry and confocal 
microscopy experiments show that stimulatory DNA, a specific activator of the 
endosomal DNA receptor TLR9, is recruited at the surface of cells expressing RAGE 
and thereby internalized more efficiently. Thus, RAGE expression increases 
subsequent TLR9 activation and downstream NFκB activity.  
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Since DNA binds to RAGE in a base-unspecific manner, a potential interaction of 
RNA with RAGE is further analyzed in the second part of this thesis. Results first 
prove that single stranded RNA (ssRNA) indeed binds to RAGE. Comparing DNA 
and RNA binding to RAGE, competing assays show that RNA binds to RAGE at a 
similar site than DNA. Confocal microscopy and flow cytometry experiments show 
that RAGE expression at the cell surface recruits RNA and promotes internalization 
that can be abrogated by truncation of RAGE V-C1 domain. As for TLR9, RAGE 
expression increases the activation of the RNA-specific receptors, TLR7, TLR8 and 
TLR13. Confirming these results, RAGE deficiency strikingly reduces the activation 
of bone marrow cells upon stimulation with a TLR13-specifc RNA agonist. Deeper 
analysis of mechanisms involving RAGE in TLR-dependent RNA-sensing show that 
the effect of RAGE relies on actin polymerization and dynamin-dependent cell 
internalization. Furthermore, truncation of RAGE intracellular signaling domain 
indicates that direct RAGE downstream signaling is negligible.  
Finally, study of the effect of RAGE on double stranded RNA (dsRNA) sensing 
presents contradictory results. Indeed, although TLR3-specific dsRNA binds to 
RAGE efficiently, RAGE expression inhibits TLR3 activation. Surprisingly, upon cell 
stimulation with a dsRNA synthetic analog, poly (I:C), RAGE expression increases 
immune activation, indicating a possible role for RAGE in cytosolic RNA sensing.  
Together, these results illustrate RAGE as a pivotal membrane receptor for nucleic 
acids. Hence, data presented in this thesis indicates that RAGE is an integral part of 
the endosomal nucleic acid sensing system and calls for further analysis of the role 
of RAGE in cytosolic nucleic acid sensing and potentially non-coding RNA-mediated 
cell-to-cell communication. 
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1. Introduction 
 
1.1 Immunity: Veni, Vedi, Vici? 
 
The organism in its environment 
 
We live surrounded by microorganisms, most of which are potentially infectious and 
therefore referred to as pathogens. Yet we only rarely become ill. This is due to a 
strong defense system that comprises several layers of complex and regulated 
mechanisms. When the body encounters a microorganism, the first line of defense is 
mainly physical and chemical. Our skin represents an important physical barrier that 
keeps pathogens from entering deeper into our organism. Chemical elements such 
as anti-microbial enzymes secreted in the mucosal surfaces block or kill pathogens 
before they enter the body.  
But not all microorganisms are bad. Some help our body in daily tasks such as 
digestion and even participate in the defense of our body against microbial threats. 
The best example for this is the microorganisms present in the gut flora (1). They 
help to metabolize nutrients that the host’s own digestive system is unable to 
process. They contribute to the antimicrobial defense by directly secreting acids that 
disrupt the bacterial cell wall or by promoting secretion of host anti-microbial proteins 
(AMPs) through the activation of Paneth cells. They also modulate the function of the 
second layer of the host’s anti-microbial defense, namely the immune system.  
 
 
The immune system 
 
The immune system is divided into two distinct components: the innate immune 
system and the adaptive immune system. The innate immune system is readily 
available since birth and can directly combat a wide range of pathogens by secretion 
of antimicrobial and cytotoxic molecules as well as engulfment and further 
destruction of the pathogens in specialized cells during a process called 
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phagocytosis. In contrast, the adaptive immune system is responsible for a 
pathogen-specific and long lasting anti-microbial response. This response is 
developed upon first encounter with a particular pathogen and depends on 1) the 
production of antibodies specific to this pathogen and 2) the development of 
immunological memory, which can confer a lifelong protection against reinfection 
with the same pathogen. Both innate and adaptive immune responses act in concert 
and provide regulative feedback to each other.  The innate immune system is often 
the first to act against a new pathogen and once activated, it licenses the adaptive 
immune system for specific recognition and destruction of the newly encountered 
pathogen. The adaptive immune system will then feedback onto the innate immune 
system to modulate a more adequate response. 
The immune system actively recognizes and combats microbial pathogens. To this 
end, it must fulfill four main tasks.  
 
• First, it must detect the presence of an infection. This is done by both 
white blood cells of the innate immune system that provide an immediate 
response and by lymphocytes of the adaptive immune system.  
• The immune system must then contain or even eliminate the infection. It 
therefore brings into play immune effector functions such as the 
complement system, the production of antibodies by lymphocytes of the 
adaptive immune system and destructive tools provided by lymphocytes 
and innate white blood cells.  
• To avoid damaging the body, the immune system must also self-regulate 
and failing to do so can lead to the development of allergies and 
autoimmune diseases.  
• Finally, to protect the organism against frequent infection with the same 
pathogen, the immune system must develop an immunological memory 
to any newly encountered threat to provide an immediate and stronger 
immune response against reinfection with the same pathogen.  
 
Vaccination is an important medical tool that uses this last feature of the immune 
system to prepare our organism to fight against pathogenic microorganisms, even 
before first encounter. The immune system is activated using a mixture of pathogen-
derived molecules (antigens), which will be the target of new antibodies, together 
with immunogenic compounds that are known to strongly activate the innate immune 
system triggering the activation and regulation of the adaptive immune system.  
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The innate immune system: PAMP and DAMP recognition by PRRs 
 
Innate Immune Cells 
 
When a pathogen breaches the physical and chemical barriers formed by the skin 
and the mucosal epithelia of the airways and the gut, they are rapidly met by cells 
and molecules, which produce an immediate innate immune response. Most cells of 
the innate immune system derive from a common myeloid progenitor and are usually 
classified in four main groups: macrophages, granulocytes, mast cells and dendritic 
cells.  
 
Macrophages reside in most tissues and originate from the maturation of the blood 
circulating monocytes. In normal conditions, macrophages act mainly as scavenger 
cells where they clear the body of dead cells and cell debris by phagocytosis. 
However, upon infection and since macrophages are present in most tissues, they 
are often the first innate immune cells to act against microorganisms. They engulf 
and kill invading microbes and clear infected cells. Perhaps even more importantly, 
macrophages are often the first to generate inflammation through secretion of 
signaling proteins called cytokines that will activate and recruit other immune cells 
further promoting the inflammation.  
 
There are three types of granulocytes, namely neutrophils, eosinophils and 
basophils. These short-lived cells are mostly present in the circulation system until 
they infiltrate inflamed tissues. Neutrophils are the most important and numerous 
granulocytes (2). Specialised for intracellular killing of microbes, neutrophils can 
recognise and bind many pathogens. After phagocytosis, they are able to directly kill 
microbes by means of enzymes and anti-microbial peptides present in intracellular 
acidic granules. Neutrophils can secrete cytokines, release granular anti-microbial 
peptides (gAMPs) and enzymes that can degrade virulence factors and the bacterial 
cell wall, thereby directly killing microbes present in the extracellular milieu. To 
restrict and then kill microbes, neutrophils are also able to release a mixture of 
chromatin and gAMPs forming the so-called neutrophil extracellular traps (NETs) in a 
process often lytic for the neutrophils (3). Eosinophils and basophils are also capable 
of phagocytosis and contain intra-cellular acidic granules filled with enzymes and 
anti-microbial peptides. Eosinophils and basophils are less abundant than 
neutrophils and are believed to mainly play a role in the host’s defence against 
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parasites too big to be internalised by neutrophils and macrophages. They are also 
thought to be involved in the development of allergies. 
 
Mast cells differentiate in tissues and are found mainly around blood vessels or 
under the mucosal layers of the gut and the airways. Like granulocytes, mast cells 
contain granules that can be released upon cell activation. These cells are mainly 
studied for their role in allergic reactions. In fact, they express a high level of cell 
surface Fcε receptor (FcεRI) that possess high binding affinity for a type of antibody 
specific to allergenic molecules, namely immunoglobulin E (IgE). This confers IgE 
coated mast cells a high reactivity towards allergens, triggering rapid release of pro-
inflammatory mediators and inducing recruitment of other immune cells such as 
eosinophils, basophils, T and B lymphocytes. This further amplifies the inflammatory 
response and the production of IgE specific to the allergen. 
 
Since the main function of dendritic cells is to bridge the innate and adaptive 
components of the immune system, they are considered to be one of the most critical 
cell types of the immune system. Dendritic cells are believed to originate from both 
myeloid and lymphoid progenitor cells. Immature dendritic cells migrate from the 
bone marrow, through the blood stream before infiltrating tissues. Like macrophages 
and neutrophils, dendritic cells are capable of phagocytosis as they continually ingest 
large amounts of the extracellular fluid and its components in a process called 
macropinocytosis. Antigens derived from engulfed and degraded pathogens are 
presented by dendritic cells to T lymphocytes of the adaptive immune system and 
thereby initiate the specific anti-microbial response. Upon encounter with a pathogen, 
these antigen-presenting cells (APCs), can also be directly activated through the 
sensing of pathogen derived molecules. They subsequently secrete cytokines and 
other signals, which are vital for a complete activation of T lymphocytes and the 
modulation of both innate and adaptive immune responses.  
 
 
Innate Immune Receptors sense infection and tissue damage 
 
Activation of stromal and innate immune cells by pathogen relies on the recognition 
of pathogen-derived molecules otherwise called pathogen-associated molecular 
patterns (PAMPs). These molecules are common to many pathogens and are of 
diverse nature such as peptidoglycans, oligosaccharides and lipopolysaccharides 
(LPS) of the bacterial cell wall, or nucleic acids derived from the viral or bacterial 
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genome. Microbial-derived molecules are sensed by the so-called pattern recognition 
receptors (PRRs), proteins present either at the plasma membrane, in the cytoplasm 
or compartmentalized in intracellular membrane structures like the endosome. In 
1989, Charles Janeway was the first to introduce the concept of pattern recognition 
by receptors that would link innate and adaptive immune systems (4). First research 
in the field of PRRs was done to find the receptor for LPS, an immune-stimulatory 
component of endotoxin derived from Gram-negative bacterial cell wall. Intense 
research was carried out until, 10 years after Janeway’s postulate, Toll-like receptor 
(TLR)4 was finally proven to be the receptor for LPS (5-7). These seminal studies 
established the TLRs as real PRRs. Following this finding, other receptor families 
have been demonstrated to act as PRR. Numerous plasma membrane proteins of 
the C-type lectin receptors (CLRs) family were shown to sense a large array of 
heterogeneous ligands and mediate their endocytosis (8). For example, DEC-205 
was recently shown to bind CpG-rich DNA molecules (9). Furthermore, numerous 
cytoplasmic nucleic acid-sensing receptors were discovered. These include the RNA 
sensors of the retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs) RIG-I (10) 
and melanoma differentiation-associated protein 5 (MDA5) (11) or the nucleotide-
binding oligomerization domain (NOD)-like receptors (NLRs) absent in melanoma 2 
(AIM2) (12) and the γ-interferon-inducible protein IFI16 (13). Very recently, the DNA 
sensing enzyme cyclic-GAMP synthetase (cGAS) was discovered to act upstream of 
STING to induce an interferon (IFN) response (14, 15).  
Several other receptors were shown to act as PRRs in certain conditions, like several 
members of the scavenger receptor family such as the scavenger receptor type-A 
(SR-A) or the receptor for advanced glycation end-products (RAGE), which will be 
described in greater details later on. 
 
PRRs evolved to recognise pathogen-derived molecules and usually enable the 
immune system to differentiate between self and non-self. However, it has become 
apparent that, in the presence of tissue damage, certain PRRs are able to recognise 
misplaced or specifically secreted self-molecules that are referred to as damage-
associated molecular patterns (DAMPs). Such molecules can be of various natures 
and found misplaced in the extracellular milieu like nucleic acids in association with 
nuclear proteins, uric acids, adenosine tri-phosphate (ATP) or actively secreted like 
the alarmin high mobility group box 1 (HMGB1). As for PAMPs, DAMPs are sensed 
by cells of the innate immune system and will trigger an inflammatory response and 
subsequent tissue repair. 
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1.2 Toll-like receptors 
 
Toll-like receptor discovery 
 
The Toll-like receptors (TLRs) were one of the first families of PRRs to be discovered 
and have now been the subject of intense research for 15 years (16). The first steps 
in the field of TLR research were made in Drosophila melanogaster with the 
discovery of Toll, a protein showed to promote dorsoventral polarity in the early 
phases of D. melanogaster embryo development (17). It was further demonstrated 
that Toll activation upon infection induced expression of the antifungal peptide 
Drosomycin, proving the involvement of Toll in the anti-microbial response (18, 19). 
In tobacco plants, a similar defence mechanism against mosaic virus was found to 
involve the N protein, a receptor containing an amino-terminal end similar to Toll 
(20). This conserved N-terminal domain was later found in the mammalian IL-1 
receptor (IL-1R) cytoplasmic domain. This domain, conserved across the plant and 
animal kingdoms, was consequently called Toll–IL-1-resistence (TIR) domain. 
Moreover, other mammalian protein receptors had been found to have even more 
similarity to Toll than IL-1R. These proteins were predicted to have TIR domains and 
leucine-rich repeats similar to those found in Toll (21). These receptors, first named 
human Toll (hToll), were later re-named as Toll-like receptors (TLRs). At first, no 
function was attributed to mammalian TLRs but the structural similarity they shared 
with D. melanogaster Toll and mammalian IL-1R imposed suspicion for their 
involvement in innate immunity. Proof for this suspicion only came when TLR4 was 
identified as receptor for LPS (5-7). However, TLR4 was found to be a weak binding 
partner for LPS. Later studies showed that in reality, TLR4 senses formation of the 
complex of LPS with MD-2 (22, 23). Following the first discovery of TLR4 as LPS 
receptor, several other members of the TLR family were shown to sense other 
microbial components and it was eventually demonstrated that there are ten TLRs in 
human and twelve in mouse.  
Heterodimers of TLR2 with TLR1 or TLR6 as well as TLR5 and TLR11 localise to the 
plasma membrane (Fig. 1.1). TLR3, TLR7, TLR8 and TLR9 localise to the 
intracellular endosomal compartment. Furthermore, TLR4 can be found both at the 
plasma membrane and in the endosome when activated by LPS.  
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Ligand recognition by TLRs and downstream signaling 
 
All TLRs evolved to sense specific PAMPs (Fig. 1.1). At the plasma membrane, 
TLR2-TLR1 heterodimers recognize triacylated lipopeptides (24) while the TLR2-
TLR6 heterodimers sense diacetylated lipopeptides (25). TLR2 was also shown to 
sense many other microbial components of diverse natures such as peptidoglycan 
from gram-positive bacteria, fungal zymosan or hemaglutinin protein from the 
measles virus (26). TLR5 was shown to sense flagellin, a component of bacterial 
flagella (27). TLR5 also plays an important role in the regulation of the gut adaptive 
immunity via activation of TLR5 expressing lamina propria dendritic cells (28). Mouse 
TLR11 was found to be specifically activated by infection with uropathogenic 
Escherichia coli bacteria although no specific bacterial molecule was identified as 
ligand for TLR11 (29). It was only later shown that when in complex with TLR12, 
TLR11 contributes to resistance against Toxoplasma gondi by sensing profilin-like 
proteins (30, 31).  
Upon ligand binding by surface TLRs, downstream signal transduction is triggered by 
the recruitment of TIR-containing adaptor protein myeloid differentiation primary 
response gene 88 (MyD88). MyD88 associates with TLRs through interaction 
between TIR domains present in both proteins. In the case of TLR2 and TLR4, 
recruitment of MyD88 requires prior binding of MyD88 adaptor like (MAL) adaptor 
protein which also contains a TIR domain (32, 33). Following recruitment of MyD88, 
several members of the IL-1 receptor associated kinases (IRAK) family, namely 
IRAK1, IRAK2 and IRAK4, are engaged through interaction of their death-domains 
with MyD88 and form a large complex called the Myddosome (34). This enables 
activation of TNF-associated factor 6 (TRAF6), a ubiquitin-ligase able to activate 
transcription factors nuclear factor-κB (NFκB), activator protein 1 (AP1) and cAMP- 
responsive-element-binding protein (CREB) via IκB kinase (IKK)-α/β- or mitogen-
activated protein kinases (MAPKs)-dependent pathways (35-40). Once activated, 
these transcription factors promote the expression of pro-inflammatory cytokines 
such as interleukine-6 (IL-6) and tumor necrosis factor alpha (TNFα).  
Interestingly, TLR4 and TLR5 were also shown to trigger downstream signaling 
independently of MyD88 by recruiting the adaptor protein TIR domain-containing 
adaptor-inducing IFN-β (TRIF). In the case of TLR4, receptor endocytosis is a pre-
requisite for the secretion of type-I IFN (41). TLR4 engages TRIF through interaction 
with an other TIR-domain containing adaptor protein TRIF-related adaptor molecule 
(TRAM) (41, 42). Upon ligand binding, TLR5 recruits TRIF in a TRAM-independent 
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manner (43). Recruitment of TRIF to TLR4 and TLR5 induces activation of TNF-
associated factor 3 (TRAF3) followed by engagement of TANK-binding kinase-1 
(TBK1) and IKK-ε, which in turn phosphorylate the interferon regulatory factor 3 
(IRF3). Phosphorylation enables IRF3 dimerization and translocation to the nucleus 
where it induces expression of type-I IFN (44-46). Recruitment of TRIF also leads to 
activation of receptor-interacting protein 1 (RIP1) and further TRAF6-dependent 
NFκB activation (47).  
More TLRs are present in intracellular vesicles called endosomes. Interestingly, all 
endosomal TLRs were shown to sense microbial nucleic acids. TLR9 was discovered 
for its ability to sense CpG-rich single stranded DNA (48-51). TLR7 and TLR8 
recognize G- and U-rich single stranded RNA (ssRNA) (52-55) and TLR3 is activated 
by double stranded RNA (56). Finally, mouse TLR13 recognises bacterial 23s 
ribosomal RNA (rRNA) (57, 58). 
 
 
Figure 1.1 Toll-like receptors – Ligands and Signaling. 
Upon ligand binding, TLR signaling requires recruitment of adaptor proteins MyD88, MAL, 
TRIF or TRAM. Downstream of MyD88, formation of the Mydosome complex containing 
IRAK1, 2 and 4 induce activation of TRAF3 or TRAF6 leading to IRFs-dependent type-I IFN 
production or NFκB-, AP1- and CREB-dependent pro-inflammatory pathways, respectively. 
On the other hand, recruitment of TRIF leads to activation of IRF3 and subsequent production 
of type-I IFN or, through RIP1, leads to TRAF6-dependent pro-inflammatory pathways. 
Note: This figure was modified from (16) and used here with license agreement with the 
Nature publishing group. 
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Once activated, TLR7, TLR8, TLR9 and TLR13 recruit the adaptor proteins MyD88 
and after formation of the Myddosome by recruitment of IRAK1, 2 and 4, activate 
TRAF3. This leads to IKKα-dependent phosphorylation and dimerization of IRF5 and 
IRF7 (59, 60) and promotes expression of type-I IFN. Upon formation, the 
Myddosome can also recruit TRAF6 (61), which, as described above, results in 
NFκB activation followed by up-regulation of pro-inflammatory cytokines expression. 
In contrast with other endosomal TLRs, TLR3 recruits TRIF (62) and induces 
activation of IRF3 as well as RIP1-dependent TRAF6 downstream signaling (47, 63). 
 
 
Modulation of endosomal TLR activation 
 
Recognition of nucleic acids by endosomal TLRs is tightly regulated by several 
mechanisms that enable maturation of both ligand and receptor as well as co-
localisation and interaction in the endo-lysosomal compartment.  
 
Trafficking of endosomal TLRs 
 
Trafficking of endosomal TLRs is a first step for regulation of their function. All TLRs 
are produced at the membrane of the endoplasmic reticulum (ER) where protein 
folding was shown to depend on N-glycosylation and binding of the chaperone 
protein gp96 (64). TLRs from the ER traffic through the Golgi compartment and 
translocate to the endosome where signaling occurs (65, 66). This mechanism 
mainly depends on UNC93b1, a trans-membrane protein mostly present in the ER. A 
mutation in the Unc93b1 gene was shown to abrogate the response of TLR3, TLR7 
and TLR9 and was consequently called triple-deficient mutant (3d-mutant) (67). This 
finding revealed the importance of UNC93b1 for nucleic acid sensing by endosomal 
TLRs. UNC93b1 was later proposed to regulate trafficking of the TLRs by escorting 
them to the endosome (68, 69). A recent publications stated that a tyrosine-based 
sorting motif (YxxΦ) present in UNC93b1 differentially regulates mouse and human 
endosomal TLRs (70, 71). The YxxΦ motif of human UNC93b1 was shown to interact 
with adaptor proteins (AP)-1 and AP2, which proved to be crucial for UNC93b1 
trafficking to the endosome but seemed to be dispensable for TLR7, TLR8 and TLR9 
stimulation, implying that UNC93b1 trafficking to the endosome is dispensable for 
TLR7-9 to function (71). 
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Enzymatic maturation of endosomal TLRs 
 
Once trafficked to the endosome, compartment acidification occurring during 
endosomal maturation is critical for TLR7, TLR8 and TLR9 activation. Indeed, use of 
endolysosomal maturation inhibitors such as bafilomycin A and chloroquine (both 
able to disrupt the endolysosome acidification) inhibited sensing of CpG DNA by 
TLR9 (72, 73), nucleoside analogues by TLR7 and TLR8 (74, 75), and dsRNA by 
TLR3 (76). Interestingly, in-vitro study of the interactions of TLR9 with ssDNA and 
TLR3 with dsRNA showed higher affinity when placed in acidic conditions (pH 5.5) 
(77, 78). Since then, it was demonstrated that upon translocation towards the 
endolysosome, TLRs are cleaved to produce functional receptors in a process 
involving several proteases such as cathepsins and asparagine endopeptidase 
(AEP) (54, 79-81). Interestingly, these lysosomal proteases were already known to 
depend on acidification and to have an important role in antigen-processing and 
presentation to cells of the adaptive immune system (82).  
TLR3 cleavage was shown to depend on cathepsins B and H (83) and it was soon 
after proved to be important for sensing of dsRNA (84). This study showed that the 
cleaved N-terminal fragment (TLR3N) remained associated with the membrane 
bound fragment (TLR3C) and that both TLR3N and TLR3C were necessary for 
dsRNA sensing.  
Cleavage of TLR9 proved to rely on the collaboration of AEP and cathepsins in a 
multi-step processing fashion (81, 85, 86). Interestingly, as for TLR3, cleaved N-
terminal fragment (TLR9N) was shown to stay associated with TLR9C and the 
presence of both fragments was necessary for DNA recognition (87). This implied the 
existence of a conserved common regulation mechanism for endosomal TLRs 
activation. 
Mouse TLR7 cleavage was shown to mainly depend on cathepsins (81). 
Unsurprisingly, cleaved N-terminal domain of mouse TLR7 (TLR7N) was also found 
to stay associated with the membrane-bound C-terminal fragment (TLR7C) by 
formation of a disulfide bond (54). However, unlike mouse TLR7, human TLR7 and 
TLR8 are cleaved by proprotein convertase of the furin family (88, 89). This protease 
functions at neutral pH indicating the possible cleavage of TLR7 and TLR8 soon after 
synthesis. The TLR7N fragment produced by proteolytic processing of TLR7 was 
then found to remain bound to the TLR7C fragment and to be essential for correct 
trafficking of TLR7N-C complex to the endosome (90). Moreover, the products of 
TLR8 cleavage by the combined activity of cathepsins and proprotein convertase 
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were shown to associate after cleavage (89). However, no evidence for the role of 
the TLR8N fragment in receptor activation was then provided.  
 
Internalization of nucleic acids  
 
A third regulation process that limits endosomal TLRs activation is the need for 
nucleic acids to reach the endolysosome where further processing by nucleases 
enables recognition by the corresponding TLRs. There are several endocytic 
mechanisms that allow internalization of endogenous or pathogen-derived nucleic 
acids. Apoptotic cell debris and bacteria are phagocytized, viruses engage different 
endocytosis pathways while extracellular nucleic acids are internalized by receptor-
mediated pathways either directly or opsonized by complexation with protein or 
phospholipids (Fig. 1.2, (91-93)).  
Phagocytosis is an active and highly regulated mechanism mostly occurring in the 
specialised cells of the innate immune system, namely macrophages, granulocytes 
and dendritic cells. Phagocytosis relies on specific cell surface receptors and is 
mediated by Rho-family GTPases (94). For phagocytosis initiation, certain cell 
surface receptors must recognise their ligands to initiate actin polymerization and 
further membrane remodelling. These receptors include the mannose receptor, the 
Fc-gamma receptor (FcγR), complement receptors, scavenger receptors and dectin-
1. These receptors can bind directly to the target particles as, for example, Dectin-1 
receptor, which is known to bind β-glucans at the surface of Candida albicans in a 
mechanism enabling its phagocytosis (95, 96). Phagocytic receptors can also bind to 
the particles after their opsonization. For example, FcγR binds to IgG antibodies 
present at the surface of bacteria (97) and engages their phagocytosis.  
Viruses enter cells by different mechanism of endocytosis such as macropinocytosis, 
clathrin-mediated endocytosis and caveolar/lipid-raft-dependent endocytosis. Before 
internalization, viruses often bind to the cell surface. Binding to the plasma 
membrane occurs either via interaction with attachment factors or via interaction with 
specific virus receptors. Attachment factors merely enable virus recruitment at the 
cell surface. Viruses binding to such proteins use the cell incessant endocytosis 
mechanisms as entry portal.  However, specific virus receptors not only bind viruses 
to the cell but also induce changes in the virus, trigger cell signaling and 
internalization. This specificity of binding is an important determinant for cell tropism 
and species specificity. It also specifies the type of endocytosis used, which is often 
beneficial for the virus. For example, human immunodeficiency virus 1 (HIV-1) uses 
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binding of two distinct cell surface receptors inducing conformational change, which 
enables fusion (98) and internalization via macropinocytosis (99, 100). 
After internalization, acidification of the endosomal compartment will not only be 
critical for maturation of the TLRs but also for the lysis of internalized pathogen 
thereby liberating the nucleic acids they contain. These will potentiate a TLR-
dependent immune response. 
Finally, entry of extracellular nucleic acids can be achieved by binding to cell surface 
receptors such as scavenger receptors, complement receptors and the Fc-receptors. 
For example, the class A scavenger receptors MARCO and SR-A were shown to 
bind CpG-DNA and increase their uptake by macrophages (101). SR-A receptor was 
later shown to bind dsRNA at the surface of human lung epithelial cells (102). 
 
 
 
Figure 1.2 Internalization of nucleic acids. 
Extracellular nucleic acids can enter cells in different forms. They can be either opsonised in 
complex with antibodies and nuclear proteins forming immune complexes (IC) which enable 
their capture by recpetors such as Fc-receptors (FC-R) or B-cell receptor (BCR). Nucleic 
acids may also be captured directly or complexed with other proteins and lipids and interact 
with surface proteins such as RAGE, SR-A, MARCO or DEC-205. Finally, nucleic acids can 
be internalised inside microorganisms such as viruses and bacteria and will require the 
microorganism proteolysis to be realised and trigger immune response through activation of 
endosomal TLRs. 
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A recent study demonstrated that the endocytic receptor DEC-205, expressed at the 
surface of dendritic cells and B cells, senses extracellular CpG-rich DNA and 
increases its uptake, thereby facilitating TLR9-dependent DC maturation and B cell 
activation (9). Moreover, FcγR is known to promote binding and internalization of 
nucleic acids present inside immune complexes such as found during the 
development of systemic lupus erythematosus (SLE) (103, 104). In opposition to the 
role of FcγR in SLE, the complement protein C1q was shown to bind DNA of dying 
cells promoting their degradation by DNase I (105). This indicated the importance of 
C1q in down-regulation of immune activation. Interestingly, C1q deficiency is 
associated with development of SLE (106, 107).    
 
 
Structure of endosomal TLRs: further clues on activation mechanism 
 
All TLRs are composed of an intracellular TIR-domain, a single trans-membrane 
domain and an extracellular leucine-rich repeat (LRR) domain. TLR3 has 23 LRRs 
while TLR7, 8 and 9 possess 26 LRRs. Furthermore, TLR7, TLR8 and TLR9 LRR 
domains are divided into two separated clusters by a flexible stretch of amino-acids 
forming a loop between LRR 14 and 15 called the Z-loop. The recent publication of 
human TLR3, TLR8 and TLR9 crystal structures in complex with their ligands has 
brought more insight into the mechanisms governing the endosomal TLR activation 
and provided further evidence for the requirement of their enzymatic processing.   
The solved crystals of the extra-cellular domain (ECD) of TLR3 presented a 
horseshoe-like conformation of its LRR domain (108, 109). Except for one side of the 
horseshoe, the LRR was mostly masked by N-linked glycosylation. The dsRNA 
binding site was therefore proposed to lie in the only glycan-free surface. Solving the 
crystal structure of mouse TLR3 in complex with dsRNA provided the last piece of 
the puzzle (110). This crystal showed that two TLR3 ECDs dimerize around a 
molecule of dsRNA. Each TLR3 ECD bound dsRNA at two sites located on opposite 
ends of the horseshoe. Both TLR3 ECDs interacted with each other at their C-termini 
thereby improving stability of the complex.  
A TLR9 ECD crystal in complex with agonistic and antagonistic DNA was solved very 
recently and revealed, as for TLR3, a horseshoe-like conformation of the LRR (49). 
More importantly, this crystal revealed that TLR9 ECD exists as a monomer, which 
can bind to either agonistic or inhibitory DNA with its N-terminal fragment (LRR 1-10). 
However, the DNA agonist used not only binds one TLR9 ECD on the N-terminal 
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fragment but also triggers dimerization by binding to the second TLR9 ECD on its C-
terminal fragment. The crystal further showed that while both cleaved and un-cleaved 
TLR9 bound to DNA, only cleaved ECDs were able to dimerize. This explained the 
previously mentioned studies demonstrating that TLR9 cleavage was crucial for its 
activity. Moreover, histidine residues clustered at the DNA-binding interphase, which 
could explain why acidic conditions are optimal for DNA-binding. Finally, dsDNA and 
methylated DNA had much weaker binding affinity with TLR9 ECD and reduced 
dimerization. This is in agreement with previous findings showing that DNA 
methylation strongly reduces its agonistic activity (51). 
Several crystal structures of the TLR8 ECD were recently published, each shedding 
more light on the TLR8 activation mechanism (53, 111, 112). Similarly to TLR3 and 
TLR9, crystal structures revealed that TLR8 ECD has a horseshoe-like conformation 
and can form dimers even in the absence of ligands. The first structure (112) 
presented the crystal of human TLR8 ECD in complex with small synthetic agonists 
CL075, CL097 and R848. Interestingly, the ECD dimerization interface approximately 
localised to the middle of the horseshoe (between LRRs 8 to 18) while C- and N-
termini stayed relatively separated (53 Å). Two synthetic molecules bound at two 
sites of the dimer interface: LRR11 to LRR14 - LRR16* to 18* interface and LRR11* 
to LRR14* - LRR16 to LRR18 interface. Upon binding, conformational change 
occurred by rotation of the horseshoe, which induced a rapprochement of the C-
termini from 53 Å to 30 Å. The authors concluded that upon ligand binding to full-
length TLR8, this rotation movement would lead to closer proximity of the intracellular 
TIR domains from both dimer partners and, in turn, could mediate downstream 
signaling. Surprisingly, when trying to solve the crystal structure of TLR8 ECD with 
real ssRNA (53), the authors found that TLR8 failed to bind to full ssRNA and instead 
bound to two degradation products: uridine and short UG di-ribonuclotides. Uridine 
interacted with TLR8 ECD dimers at the same site as previously found for small 
synthetic molecules (112). UG bound at the concave surface of LRR10 to LRR13 
with part of the Z-loop (residues 469 to 474) and therefore seemed to not contribute 
to the TLR8 ECD dimerization. However, when testing the binding of each 
component to TLR8 ECD, the authors found that uridine bound to TLR8 with a much 
weaker affinity than R848. But when in combination with full length RNA, uridine 
bound to TLR8 with an affinity similar to R848. Therefore, although the second site 
was dispensable to activate TLR8 upon stimulation with synthetic ligand, it proved to 
be essential for activation with ssRNA. Furthermore, these crystal structures 
confirmed that TLR8 cleavage products remain associated and further indicated their 
contribution to ligand recognition and receptor dimerization. 
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Up to now, there is no crystal structure of TLR7. However, knowing that both 
receptor sequences are highly similar and together with the fact that TLR7 and TLR8 
likewise sense R848 and ssRNA, it is fair to forecast the TLR7 activation 
mechanisms to be similar to those of TLR8. 
 
 
Nucleic acid digestion promotes endosomal TLR activation 
 
The finding that TLR8 senses degradation products of RNA is even more remarkable 
in the context of two new studies, which showed that TLR9 activity depends on 
DNase II, the only DNase present in the phago-lysosomal compartment (113, 114). 
Chan and colleagues showed that DNase II knockout prevented TLR9 activation by 
CpG-A DNA but had no effect on CpG-B DNA stimulation. CpG-A DNA is larger than 
CpG-B DNA and forms complex multimeric structures that are DNase II sensitive and 
promote a strong IFN response in peripheral blood mononuclear cells (PBMCs). On 
the contrary, CpG-B DNA exists as a linear ssDNA, is resistant to DNase II digestion 
and only induces a weak IFN but stronger pro-inflammatory cytokine release from 
PBMCs (115, 116). Knowing the ligand for TLR9 to be ssDNA, it is thus 
understandable that CpG-A DNA would need to be digested to bind and activate 
TLR9. Stimulation with a synthetic 11-12mer mimetic of DNase II digestion product, 
activated conventional dendritic cells (cDCs) even in the absence of DNase II. 
Moreover, stimulation of cDCs with bacterial DNA, mainly composed of dsDNA, also 
required DNase II activity. Confirming these results, Pawaria and colleagues reported 
that TLR9-dependent activation of B cells with DNA-immune complexes required 
DNase II activity (114). Similarly to CpG-A DNA, DNA-containing immune complexes 
form large structures that would need prior processing to stimulate TLR9.  
Until now, no study pinpointed the actual enzyme(s) responsible for RNA degradation 
preceding TLR8 activation. However, it is very likely that such an enzymatic process 
exists that would increase endosomal concentration of uridine and other short 
sequences potentiating TLR8 activation following previously described structural 
mechanisms (53). 
 
In summary, activation of endosomal TLRs by specific nucleic acid sequences is a 
highly regulated process with several checkpoints: nucleic acid ligands need to be 
internalised and processed, TLRs have to be present in the right compartment and 
activated by proteolytic cleavage that requires compartment acidification which is 
also required for stronger ligand-receptor interaction. 
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1.3 Receptor for advanced glycation end-products (RAGE) 
 
RAGE expression and structure 
 
The Ager gene locus coding for the receptor for advanced glycation end-products 
(RAGE) is located on the reverse strand of chromosome 6 (32,180,968-32,184,324), 
in close proximity with the genes encoding for TNFα and MHC class III in human and 
mouse. Ager is 3,36 kb long and contains 11 exons, all expressed in the main variant 
of full-length RAGE. The transcript is 1,492 kb long and codes for a 404 amino acid 
long protein. RAGE is a type 1 transmembrane protein of the immunoglobulin 
superfamily. It is composed of three extracellular immunoglobulin-like domains (V, 
C1, and C2), one trans-membrane domain and a short cytoplasmic domain (Fig. 
1.3). Gene sequence alignment and structure comparison studies suggested that 
RAGE appeared in mammals and evolved from a family of cell adhesion molecules 
(CAMs), with the basal cell adhesion molecule (BCAM) being its closest relative. In 
agreement with this hypothesis, RAGE still promotes cell spreading and cell-cell 
adhesion (117).  
 
Up to approximately 20 splice variants of RAGE have been found in human and 
mouse from which, however, only a minor part are translated (118). Indeed, more 
than 50% of RAGE splice variant were predicted to follow the non-sense mediated 
mRNA decay pathway (118). Over all, the two major variants detectable in vivo and 
that display functions are the membrane bound, full-length RAGE and a soluble 
variant (RAGE_v1 or esRAGE) resulting from inclusion of part of intron 9 and 
deletion of exon 10 with a frame-shift before exon 11 creating a unique C-terminal 
sequence (Fig. 1.3).      
In physiological conditions, RAGE expression is low in all tissue except for the lung 
where RAGE is constitutively expressed and localizes to type I epithelial cells (119).  
Under certain inflammatory conditions such as cancer, diabetes, chronic 
inflammation or in neurodegenerative disorders, RAGE expression is increased and 
can be found in endothelial cells and smooth muscle cells of the vasculature, in 
neurons and microglial cells of the central nervous system (CNS) as well as in 
distinct immune cells such as T and B cells, monocytes, dendritic cells and 
granulocytes (120-130).  
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Figure 1.3 RAGE isoforms and ligands. 
RAGE possesses three extracellular immunoglobulin-like domains (V, C1 and C2), one 
transmembrane domain and a short cytosolic tail. Three main RAGE isoforms exist: a 
membrane-bound full-length isoform (RAGE), a soluble version containing only the 
extracellular domains resulting from alternative splicing (esRAGE) and another soluble 
version similar to esRAGE and resulting from surface protein shedding (sRAGE).  
Four main RAGE ligand families are represented as cartoons (please see text for more 
details). The protein sequence of RAGE is indicated with colour coding corresponding to each 
extracellular domain. Underlined sequence represents predicted binding site for mDia-1. Exon 
splicing of both RAGE and esRAGE are indicated. Hatched box represents intron 9 inclusion. 
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Importantly, the promoter region of Ager gene was shown to possess binding sites 
for transcription factors such as NFκB (-1543 and -587 bp) and SP1 (-245 and -40 
bp) (125, 131). 
Biochemical studies showed that the V- and C1-domains form an independent 
structural unit separated from the C2-domain by a flexible linker (132). Crystal 
structure of the V-C1 ectodomains confirmed the structural unit formed by the V and 
C1 domains with the presence of several interdomain hydrogen bonds and 
hydrophobic interactions (133, 134). Structure analysis found a highly positively 
charged surface along both V and C1 domains and predicted this surface to be 
responsible for binding of mostly negatively charged ligands. Further biochemical 
and structural studies revealed RAGE ectodomain to exist as a pre-formed tetramer 
via interaction of V and C1 domains across molecules and which extends to larger 
oligomers upon ligand binding (135, 136). Several studies found the V-C1 structural 
unit to be the ligand-binding domain of RAGE with the V-domain being the main 
contributor to the ligand-receptor interaction (132, 137-142). Only one ligand was 
found to bind to the C2-domain (S100A6) and was shown to induce cell apoptosis 
while a similar molecule (S100B) that binds to the V-C1 domain was shown to induce 
cell proliferation (139). 
 
 
RAGE: one receptor fits many ligands 
 
The literature suggests that a heterogeneous group of molecules exist as ligands for 
RAGE (Fig. 1.3), including advanced glycation end-products (AGEs) (143), β-sheet 
fibrils (like amyloid-β) (124), several members of the S100 protein family (140) and 
the alarmin high mobility group box 1 (HMGB1) (144). This diversity of ligands 
identified RAGE as a key modulator in the development of pathologies such as 
diabetes (145, 146), cardiovascular diseases (147, 148), Alzheimer’s disease (149), 
systemic lupus erythematosus (SLE) (150, 151), sterile inflammation and cancer 
(152). 
 
 
Advanced Glycation end-products (AGEs) 
 
RAGE was first identified as receptor for advanced glycation end-products (AGEs), 
the role from which its name originated (143). AGEs are produced by the non-
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enzymatic reaction between reducing sugars and proteins, lipids or nucleic acids. 
AGE formation is enhanced by inflammatory conditions, during renal failure, 
hyperglycemia or in certain oxidative stress conditions, all of which are often 
associated with diabetes or aging (153). AGEs can form either locally or more 
generally. The former is exemplified by joint amyloid, which is composed of AGE-β2-
microglobulin and is found in patients with dialysis-induced amyloidosis. RAGE was 
found to mediate recognition of this type of amyloid by mononuclear phagocytes in 
the arthritic joint and was shown to promote further monocyte chemotaxis (154). In 
diabetes, the presence of RAGE and AGEs is found to be increased in the 
vasculature and other tissues (155). Interaction of AGEs with RAGE at the surface of 
endothelial cells was shown to induce expression of vascular cell adhesion molecule-
1 (VCAM-1), an adhesion molecule that mediates early stages of atherosclerosis by 
recruiting peripheral blood cells (148, 156). This adds to the intrinsic adhesion 
function of RAGE and argues for RAGE as an important mediator of immune cell 
chemotaxis in early stages of inflammation. 
 
 
Amyloid- β (Aβ) 
 
RAGE expression is increased during development of neurodegenerative diseases 
and localizes to the site of senile plaques in neurons, microglia and endothelial cells 
(124, 157, 158). Interestingly, RAGE was found as one major cell surface binding 
protein for amyloid-β (Aβ) (124, 159). Aβ originates from the cleavage of the 
transmembrane β-amyloid precursor protein (APP) leading to the generation of 40 or 
42 amino acids long Aβ, which can form soluble oligomers, beta sheets containing 
fibrils, and insoluble aggregates. When accumulating in the brain tissue, Aβ induces 
cell inflammation, neuronal cell death and extended neurodegeneration. RAGE was 
shown to mediate internalization of Aβ by neurons and to promote pro-inflammatory 
signaling in neurons and microglia, thereby contributing to synaptic dysfunction, 
general neuroinflammation and Aβ accumulation (160-162). Confirming these results, 
blockade of RAGE prevented Aβ aggregates-induced neurotoxicity (137). It is also 
worth noting that RAGE was shown to mediate the transport of Aβ across the blood-
brain barrier and promoted Aβ accumulation in the brain (163, 164). 
As mentioned previously, RAGE can bind to other types of amyloid fibrils such as 
those found in the joints of long-term hemodialysis patients (154). 
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S100 protein family 
 
Members of the calcium ion binding S100 protein family have proved to be important 
cytosolic mediators of several cellular processes such as calcium homeostasis, 
energy metabolism, cell growth and differentiation (165). However, some S100 
proteins have been shown to be secreted in a multitude of pathological conditions 
such as cancer (139, 166-169), myocardial injuries (170, 171) and airway diseases 
(172). Interestingly, most extracellular functions of S100 proteins seem to be 
occurring through RAGE although they induce different outcomes depending on the 
cells targeted. S100B was shown to promote neuron survival and neurite outgrowth, 
S100A6 promotes a RAGE-dependent production of reactive oxygen species (ROS) 
and apoptosis (139). Like S100B, S100A11, once secreted from cancerous 
keratinocytes, was found to signal through RAGE to promote cell survival and 
proliferation (167). Similarly, S100P was shown to promote cell survival and 
proliferation through RAGE in colon cancer (169, 173). S100A8/A9 heterocomplex 
was found to promote RAGE-mediated tumor cells growth (174) or endotoxin-
induced cardiomyocytes dysfunction (171). S100A7 was shown to have chemotactic 
function towards granulocytes and this depended on RAGE (175). Finally, S100A12 
sensed by RAGE induces production of mucin in the respiratory tract, thereby 
promoting chronic airway diseases such as severe asthma (172).  
 
 
High mobility group box-1 (HMGB1) 
 
High mobility group box-1 (HMGB1) is one of the most important but also most 
complex ligands of RAGE. HMGB1 binding to RAGE was demonstrated shortly after 
RAGE discovery (144) and RAGE proved to mediate the previously described role of 
HMGB1 in neurite outgrowth during the development of the nervous system (144, 
176). HMGB1 was first described for its role in the nucleus where it binds to DNA and 
thereby regulates chromatin structure and gene expression (177-179). A few years 
later, HMGB1 was shown to be actively secreted by macrophages and monocytes 
stimulated with LPS (180-182) or by necrotic cells promoting inflammation through 
activation of monocytes (183). Similarly to some S100 proteins, extracellular HMGB1 
was shown to act as chemoattractant for myeloid cells (184), smooth muscle cells 
(185) and mesangioblasts thereby promoting muscle tissue repair (186). In DCs, 
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HMGB1 release and sensing by RAGE was shown to be critical for homing to the 
lymph nodes and further cross-activation of T lymphocytes (128-130). In endothelial 
cells, HMGB1 was further shown to promote expression of RAGE and surface 
adhesion proteins (ICAM-1 and VCAM-1) as well as inducing RAGE-dependent 
cytokine production (187-189). A further role of RAGE in extracellular HMGB1 
sensing was recently found in the context of sterile injury. HMGB1, originating from a 
brain injury, signaled through RAGE in the lung mediating pulmonary dysfunction 
after lung transplantation (190, 191). Interestingly, microglial-expressed RAGE had 
also shown to mediate part of HMGB1 deleterious function in the ischemic brain 
(192).  
Fueling the complexity of HMGB1 biology, HMGB1 was found to form complexes 
with cytokines and immune-stimulatory molecules exacerbating their activity (193). 
Interestingly, in immune complexes, HMGB1 was found to bind to DNA increasing 
TLR9 activation through a RAGE-dependent DNA internalization mechanism (126, 
194). Furthermore, oxidation states of released HMGB1 showed to be mutually 
exclusive and gave HMGB1 either pro-inflammatory and pro-survival function or 
chemotactic and pro-apoptotic properties (195, 196). For example, reduced HMGB1 
secreted by cancer cells during anti-cancer treatment bound to RAGE and through 
induction of autophagy promoted local cell survival. However, stimulation with 
oxidized HMGB1 induced cell apoptosis (197). 
 
 
RAGE signaling 
 
As described earlier, RAGE engages many ligands and is expressed in a rather large 
array of cell types and tissues. It is therefore not surprising for RAGE signaling to be 
complex and devoid of a general scheme that could be applied to every 
circumstance (198). It seems clear that many factors influence RAGE downstream 
signaling including the cell type studied, the activating ligand and the presence of 
other co-receptors. As previously underlined with the description of RAGE ligands, a 
large variety of outcomes derive from RAGE signaling, namely cell maturation, 
proliferation, migration, autophagy, apoptosis and inflammation (Fig. 1.4).   
 
One factor that seems to modulate many signals downstream of RAGE is 
mammalian Diaphanous-related formin 1 (mDia1). mDia1 is a cytosolic protein and 
member of the formin protein family, which modulates actin and microtubule 
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polymerization and thereby controls cell migration and division. mDia1 binds to the 
cytoplasmic domain of RAGE via interaction between the formin homology domain 1 
(FH1) of mDia1 and RAGE amino-acids 364 to 368 (QRRQ, see Fig. 1.3) (199, 200). 
mDia1 is essential for activation of Rho-family GTPases downstream of RAGE. In 
several cell types, the Rho-family GTPases Ras-related C3 botulinum toxin substrate 
1 (Rac-1) and cell division control protein 42 (Cdc42) become activated by RAGE 
(199, 201, 202). Indeed, once phosphorylated by the non-receptor tyrosine kinase 
Src (GTP-bound form), Rac-1 and Cdc42 activate the serine/threonine kinase PKB 
leading to activation of NFκB (202). Via activation of the serine/threonine c-Jun N-
terminal kinases (JNK), Rac-1 also induces activation of AP-1 (202).  
Moreover, through NADPH oxidase 1 (NOX1)-dependent ROS production, Src and 
Rac-1 activate the PI3K, PKB and GSK3β phosphorylation cascade leading to 
increased cell migration and vascular repair (201). 
 
 
Figure 1.4 RAGE signaling. 
Upon binding of certain ligands, RAGE downstream signaling involves caveolin (CAV-1)-
dependent internalization and recruitment of the adaptor mDia-1. This leads to activation of 
Ras, Rac-1 and Cdc42 Rho-family GTPases, which will lead to MAP kinase- and c-Jun 
kinase-dependent phosphorylation cascade. Activation of p38, ERK and c-Jun will trigger 
activation of NFκB and AP-1 transcription factors. Together with activation of the JAK/STAT 
pathway, these will increase expression of pro-inflammatory and cell proliferation genes. 
RAGE activation also leads to ROS production and promotes cell migration through PI3 
kinase- or TGFβ-dependent pathways. 
This cartoon represents only the main pathways known for RAGE downstream signaling and 
is non-exhaustive.  
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ROS-induced cell migration following RAGE activation was also suggested to occur 
through up-regulation of TGF-β expression leading to increased activation of its 
putative receptor TGF-βR and further signaling through RohA and ROCK (203, 204). 
A similar mechanism involving the Ras GTPase has also been found downstream of 
RAGE. Upon activation, Ras engages MAPK/ERK kinase (MEK), further triggering 
ERK1/2- and p38 MAPK-dependent NFκB activation (205-207). However, there is 
also evidence for the direct binding of ERK1/2 with RAGE cytosolic domain indicating 
a possible Cdc42/Rac-1/Ras independent RAGE signaling (208). Furthermore, a 
study revealed the possible HMGB1-induced activation of p38 MAPK downstream of 
Rac1/Cdc42 pathways, which requires prior activation of MKK6 (209).  
Moreover, upon ligand binding, RAGE was shown to mediate activation of Janus 
kinase 2 (JAK2) leading to phosphorylation of signal transducer and activator of 
transcription 1 (STAT1) and STAT3 and their translocation to the nucleus (210, 211). 
 
 
Regulation of RAGE function 
 
The first regulation mechanism that controls RAGE activity depends on post-
translational modification. Indeed, RAGE possesses two N-glycosylation site, (Asn25 
and Asn81) that seem to promote ligand binding to RAGE. In fact, S100A12 binding 
to RAGE was shown to be promoted by N-glycan (212). Moreover, study of a single 
nucleotide polymorphism (SNP) showed that the G82S mutation induced by the SNP 
led to an increased in N-glycosylation of Asn81, which increased binding of S100B to 
mutant RAGE (213). This further comforted the idea that N-glycosylation of the 
RAGE ectodomain is important for ligand binding.  
Post-translational shedding of RAGE from the cell surface triggers negative 
regulation of RAGE. Metalloproteinases ADAM10 and MMP9 were shown to cleave 
RAGE extra-cellular domain in close proximity to the plasma membrane leading to 
the release of a soluble form of RAGE (sRAGE) containing all Ig-like domains (Fig. 
1.3, (214, 215)). Shedding could be induced by PMA in a protein kinase-C (PKC) 
dependent manner (215). Further studies showed that RAGE shedding could be 
induced by increased Ca2+ levels (induced by ionomycin treatment) (216). Moreover, 
activation of several G protein-coupled receptors (GPCRs) was later found to 
promote RAGE shedding by ADAM10 and MMP9 (217).  
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Soluble RAGE not only regulates full-length RAGE activity by decreasing the 
proportion of membrane-bound and therefore signaling-competent RAGE. In fact, 
production of soluble RAGE, that is either by alternative splicing (esRAGE) or by 
shedding (sRAGE), procures a source of decoy receptor capable of ligand binding 
but unable to induce signaling. The level of soluble RAGE has been proposed as 
both a biomarker in many pathological conditions and as pharmacological tool that 
could be used to reduce RAGE effects in disease development (218, 219). This fits 
with the previous use of purified RAGE ectodomain as inhibitor for RAGE, which 
induced a dramatic reduction of tumor growth (123). A noteworthy study showed that 
esRAGE antagonizes tumorigenesis (220). Moreover, Koch and colleagues 
proposed an additional mechanism by which soluble RAGE could inhibit signaling 
(133). They predicted that the presence of soluble RAGE in the extracellular milieu 
could interfere with the oligomerization necessary for RAGE activation. As previously 
described, RAGE exists as an oligomer in the absence of ligand. It is however 
believed that upon ligand binding, the increasing size of RAGE oligomers would be 
responsible for signaling by a clustering of the intracellular domains. Formation of 
heterodimers of membrane-bound RAGE with soluble RAGE would thus decrease 
clustering of the intracellular domain and therefore inhibit signaling. 
 
Furthermore, RAGE translocation to the plasma membrane was shown to be 
modulated in endothelial cells. Frommhold and colleagues showed by immuno-
histochemistry that, upon trauma-induced inflammation, RAGE was rapidly (20 
minutes) translocated to the cell surface (221, 222). Similar results could be found 
upon TNFα stimulation (222). This translocation of RAGE to the cell surface 
happened within only a few minutes, which led the authors to predict the presence of 
readily available intra-cellular storage of RAGE in endothelial cells.  
 
There is also some evidence for a requirement of RAGE internalization prior to 
signaling. This would not be uncommon. In fact, receptor endocytosis as a 
mechanism enabling signaling has been known for some time to be important for 
many cell surface receptors (223). Interestingly, RAGE internalization upon ligand 
binding was shown to be important for transduction of ERK-dependent signaling 
(224). Confirming these findings, diaphanous-related formins are known to be 
essential for actin remodeling during formation of cell membrane filopodia and help 
endosomal mobility (225). Further evidence for RAGE internalization is the fact that 
RAGE interacts with an important component of caveolae, namely caveolin-1 (Cav-1) 
(226). In fact, in smooth muscle cells, ligand binding to RAGE induced a Cav-1 and 
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Src-dependent ERK1/2 and p38 MAPK activation leading to NFκB nuclear 
translocation and further induction of IL-6 expression (226). RAGE-dependent 
STAT3 activation was also dependent on Src activation and intact caveloa (226). 
This is in agreement with a study showing that, upon treatment of Schwann cells with 
anti-RAGE antibodies, RAGE recycles in a Cav-1/Src dependent manner (227). It is 
also worth noting that this work showed that internalized RAGE could encounter 
endogenous RAGE ligand, S100B, and following recycling to the plasma membrane, 
would promote S100B secretion. 
Together, this data suggests that RAGE binds ligands at the cell surface and further 
triggers their uptake, via caveolae, into intracellular compartment where signaling 
occurs.  
 
 
1.4 Project rationale and thesis aims 
 
Nucleic acids of microbial origins have been extensively studied for their role in 
sensing of infection by the host immune system. They are now under special 
scrutiny. Indeed, when originating from the organism itself, nucleic acids function as 
danger signals. In normal conditions, they promote tissue repair but they can also be 
deleterious when the immune system fails to regulate itself and engages into auto-
immunity. While several origins exist for extra-cellular nucleic acids, their sensing is 
limited to the endosomal TLRs. However, how such extra-cellular nucleic acids are 
internalized before further activation of their putative receptors is only poorly 
understood. 
The first hint of a function of RAGE in nucleic acid sensing came from the work of 
collaborators who demonstrated the importance of RAGE as a transporter of 
DNA/HMGB1 complex towards TLR9 (126). While undertaking collaborative work for 
this publication, Dr. Cherilyn M. Sirois and Prof. Eicke Latz found for the first time 
that RAGE could bind directly to stimulatory DNA. This discovery was the first 
milestone for a project aiming to evaluate the role of RAGE in DNA internalization 
and trafficking towards the endosome and TLR9. This project produced a publication, 
which was the fruit of a collaborative effort (228). The results presented in the first 
part of this thesis briefly summarize the most important discoveries presented by this 
publication and mainly focus on the work done by the author of the present thesis. 
This work aimed at evaluating the effect of RAGE expression on the TLR9-
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dependent immune activation following extracellular stimulation with CpG-rich DNA 
and to investigate a possible interaction between RAGE and TLR9 in these settings.  
The results presented in the second section of this thesis ask whether RAGE also 
affects RNA sensing. Several aims emerged, each bringing answers to this question. 
First, biochemical experiments aimed at confirming the possible interaction of RNA 
with RAGE ectodomain. Ensuing work further investigated the biological influence of 
RAGE expression on the recruitment of RNA to the plasma membrane and its 
subsequent internalization. Furthermore, gain and loss of function studies examined 
the role of RAGE in the immune activation induced by extracellular stimulation with 
TLR3, TLR7, TLR8 or TLR13 specific RNA agonists. Finally, experiments were 
designed to further comprehend the cellular mechanisms involved in RAGE-RNA 
complex internalization and considered the possible induction of direct RAGE 
signaling downstream of RNA binding.  
The work described in this thesis presents nucleic acids as new ligands for RAGE 
and helps with the general understanding of RAGE function in the development of 
pathologies involving extracellular nucleic acids such as SLE. This work further calls 
for evaluation of nucleic acid as pharmaceutical therapeutic to combat or prevent 
development of such deleterious pathologies. This thesis also opens the way for 
further investigation into the role of RAGE in other functions entrusted to nucleic 
acids in the extra-cellular milieu. 
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2. Materials and Methods 
2.1 Materials 
List of instruments 
 
Instrument Name Company 
Aria flow cell sorter BD 
Centrifuge 5424, for 1.5 mL tubes 
Rotor: FA-45-24-11 
Eppendorf 
Centrifuge 5810 R, for 15/50 mL tubes and 96 well plates 
Rotor: A-4-81 & F-34-6-38 
Eppendorf 
Chilling Jar, freezing container True North 
Cooling centrifuge 5430 R, for 1.5 mL tubes 
Rotor: FA-45-24-11 Kit 
Eppendorf 
DMIL LED, tissue culture microscope Leica 
EV202, electrophoresis power supply Consort 
EV243, electrophoresis power supply Consort 
Fortessa flow cytometer BD 
L2, L20, L200, L1000 micropipettes (0.1µL to 1mL) Rainin 
MACSmix tube rotator Miltenyi 
Mr. Frosty, freezing container Nalgene 
NN-E245W, microwave oven Panasonic 
Novex mini cell, gel electrophoresis chamber Life technologies 
Odyssey Western-Blot scanner LICOR 
Pipet boy acu, pipetting device Integra Biosciences 
PS304 Minipac II, electrophoresis power supply APELEX 
Quant 6, qPCR cycler Life Technologies 
SpectraMax i3, multi-function plate reader Molecular Devices 
TALI, cell counter Life Technologies 
TCS SP5, Confocal microscope Leica 
VersaDoc 4000 MP fluorescent gel scanner BioRad 
Xcell II Blot Module, blotting chamber Life technologies 
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List of plastic apparatus and consumables 
 
Product Name Company 
0.45 µm filters, 0.22 µm filters Merck Millipore 
1.5 mL Tubes Eppendorf 
14 mL tubes for bacteria MiniPrep culture VWR 
15 mL and 50 mL Tubes Greiner bio-one 
2 mL Tubes Sarstedt 
5 mL, 10 mL and 25 mL serological pipettes Greiner bio-one 
96 well ELISA plates Nunc 
96 wells plates for cell culture Greiner bio-one 
Cell strainer (70 µm) VWR 
MaxiSorp 96-well ELISA plate  Nunc 
Needles Braun Meslungen 
Pipette tips filtered and unfiltered Rainin 
Syringes BD Bioscience 
T175 Tissue culture flask Greiner bio-one 
T75 Tissue culture flask  Greiner bio-one 
U-shape white 96 wells plate Costar 
V-shape 96 wells plate Greiner bio-one 
 
List of Kits and Reagents 
 
Product Name Company 
4-12% NuPAGE Bis-Tris gels 1.5 mm, 10 well/15 well Life Technologies 
Agarose Biozym 
Ampicillin Sigma Aldrich 
Benzonase nuclease Sigma 
Bichoninic acid (BCA) assay Thermo Scientific 
Bovine serum albumin (BSA) Roth 
Coelenterazine Promega 
Complete protease inhibitor Roche 
Cytochalasin D Sigma Aldrich 
DRAQ5 eBioscience 
Dulbecco’s Modified Eagle Medium (DMEM), high glucose, Life Technologies 
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with glutamine 
Dulbecco’s Phosphate Buffered Saline (DPBS) Life Technologies 
Dynabeads Protein A Life Technologies 
Dynabeads Streptavidin Life Technologies 
Dynasor Sigma Aldrich 
ELISA substrate solutions BD Bioscience 
Erythrocyte lysis buffer Miltenyi 
Ethidium bromide Sigma Aldrich 
Ethylenediaminetetraacetic acid (EDTA, 0.5 M, pH 8.0) Life Technologies 
GeneJuice Merck Millipore 
Glycerol Merck 
Human IL-8 ELISA BD Biosciences 
Isopropanol Roth 
LB Agar (Lennox L agar, 10 g Peptone 140, 5 g Yeast 
Extract, 5 g NaCl, 12 g Agar per 1 L) 
Life Technologies 
LB Medium (Luria/Miller, 10 g Tryptone, 10 g Yeast Extract, 
10 g NaCl per 1 L) 
Roth 
LDS sample buffer (4x, 8% LDS, 40% glycerol, 2.04 mM 
EDTA, 0.88 mM SERVA Blue G, 0.7 mM Phenol Red, 564 
mM Tris, pH 8.5) 
Life Technologies 
Methanol Roth 
MOPS buffer (20x, 50 mM MOPS, 50 mM Tris 0.1% SDS, 1 
mM EDTA, pH 7.7) 
Life Technologies 
Mouse IL-6 HTRF kit Cisbio 
Mouse TNFα HTRF kit Cisbio 
NaCl Roth 
Nonidet P-40 AppliChem 
Passive lysis buffer (5x) Promega 
PCR master mix (2x) Fermentas 
Phenylmethylsulfonyl fluoride (PMSF) Roth 
Phosphate Buffer Saline (PBS, 10x) Pan Biotech 
Poly-L-lysine solution (0.01% m/v) Sigma Aldrich 
Polyvinylidene fluoride (PVDF) membrane, Immobilon-FL Merck Millipore 
PureLink Quick Gel Extraction Kit Life Technologies 
PureLink Quick Plasmid Maxiprep Kit  Life Technologies 
PureLink Quick Plasmid Miniprep Kit Life Technologies 
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Reducing agent (10x, 500 mM dithiothreitol in stabilized form) Life Technologies 
Restriction enzymes (FastDigest NotI, AscI, MreI) Fermentas 
RNeasy Plus Mini Kit Qiagen 
RPMI-1640 high glucose, with glutamine Life Technologies 
SecinH3 Tocris 
Sodium dodecyl sulfate (SDS) Sigma Aldrich 
SteadyGlow Promega 
StemPro Accutase Life Technologies 
T4 DNA Ligase, HC Fermentas 
Tris Acetate EDTA (TAE) pH 8,5 (50x, 2M Tris, 1M acetic 
acid, 50mM EDTA) 
Roth 
Tris Buffer Saline (TBS, 10x, 400 mM Tris, 3 M NaCl, pH 7.4) Santa Cruz  
Tris HCl pH 7.4 (1M stock) Roth 
Tris-Glycine (10x, 0.25M Tris, 1.92M glycine, pH 8.5) Thermo Scientific 
Triton X-100 Roth 
Trypan-Blue, dead cell staining Sigma Aldrich 
Trypsin-EDTA (0.05%) Life Technologies 
Tween 20 Roth 
β-mercaptoethanol Sigma Aldrich 
 
List of antibodies 
 
Antibody Target Host Company Cat. Number 
GFP (Aequorea victoria) Rabbit Life Technologies A11122 
human RAGE Mouse Merck Millipore MAB5328 
human TLR9 Rat eBioscience 14-9099-82 
TagRFP Rabbit Evrogen AB233 
human β-actin Rabbit LICOR 926-42210 
 
List of primers and DNA sequences 
 
Name Cloning primer sequence 
R790 5’-TTTGGCGCGCCTGCCACCATGGCAGCCGGAACAGCAGTTGG-3’ 
R791 5’-AAAGCGGCCGCTCACCGCCTTTGCCACAAGATGAC-3’ 
R792 5’-AAAGCGGCCGCTCAAGGCCCTCCAGTACTACTCTC-3’ 
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R1107 5’-TTTTGGCGCGCCTGCCACCATGG-3’ 
R1108 5’-TTTTGCGGCCGCAGGCCCTCCAGTACTACTCTCGCC-3’ 
R1161 5’-GGACCGATCCAGCCTCCGCG-3’ 
R1162 5’-ACCTACTACTGCCCCCCACAGAC-3’ 
R1163 5’-CTGTGGGGGGCAGTAGTAGGTCCCCGTGTCTGGGAGCCTGTG-3’ 
R1164 5’-TTTGCGGCCGCTCAAGGCCCTCC-3’ 
 
Name qPCR primer sequence 
Ager – forward  5’-AGAACATCACAGCCCGGATT-3’ 
Ager – reverse 5’-TTCCTGTGTTCAGTTTCCAT-3’ 
Tlr4 – forward  5’-AGCCATTGCTGCCAACATCA-3’ 
Tlr4 – reverse 5’-GCCAGAGCTACTCAGAAAC-3’ 
Tlr9 – forward  5’-TGAGCCACACCAACATCCTG-3’ 
Tlr9 – reverse 5’-GTCACCTTCACCGCTCCTGT-3’ 
Tlr13 – forward  5’-TGTCTGCTCTGGTGGACTTG-3’ 
Tlr13 – reverse 5’-GAGGAGTGAAGGCGTCTTTG-3’ 
Hprt – forward  5’-TGAAGTACTCATTATAGTCAAGGGCA-3’ 
Hprt – reverse 5’-CTGGTGAAAAGGACCTCTCG-3’ 
 
 
Name Stimulatory RNA and DNA sequences 
TLR7-RNA  5’-ACUG1CG1AG1CUU-X-UUCG1AG1CG1UCA-5’ 
TLR8-RNA 5’-YUGCUGCCUUUG-X-GUUUCCGUCGUY-5’ 
TLR3-RNA 
 
5’-CAAGGCAAGCAUUCG(C)35-3’            
5’-CGAAUGCUUGCCUUG(I)35-3’ 
Sa19-RNA 5’-GGACGGAAAGACCCCGUGG-3’ 
NS-RNA 5’-AAAAAAAAAAA-Z-AAAAAAAAAAA-5’ 
2006-DNA  5’-TCGTCGTTTTGTCGTTTTGTCGTT-3’ 
2137-DNA 5’-TGCTGCTTTTGTGCTTTTGTGCTT-3’ 
1826-DNA  5’-TCCATGACGTTCCTGACGTT-3’ 
 
Note: TLR7-, TLR8-, TLR3- and NS-RNA oligoribonucleotides were synthesised and 
generously provided by Idera Pharmaceuticals.  
G1 is 7-deazaguanosine, X is 1,2,3-propanetriol, Y is 1,3-propanediol and Z is a 
glycerol linker. Underlined sequences define complementary sequences. 
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Solutions 
 
Name Buffer protocol 
1x RIPA lysis 
buffer 
For 10 mL: 5 ml 2x RIPA lysis buffer stock, 4.6 mL ddH2O, 0.4 
mL 25x complete protease inhibitor, 5 µL 100 µM PMSF. 
1x TBS (-T) For 1L: dilute 50 mL 20x TBS buffer in 950 mL double distilled 
H2O (ddH2O). Final concentration: 20 mM Tris, 150 mM NaCl, 
pH 7.4. Note: for TBS-T, add 1mL Tween 20 (0.1% v/v) 
2x RIPA lysis 
buffer stock 
  
For 500 mL: 2.4 g Tris base, 8.8 g NaCl, 2 mL 0.5 M EDTA, 10 
mL Triton X-100, 1 g SDS, 100 mL, 450 mL ddH2O; pH to 7.4; 
adjust volume to 500 mL and filter through 0.2 µm filter. 
Complete DMEM 
culture medium 
Purchased DMEM medium was completed with 10% fetal calf 
serum (FCS), 100U/mL penicillin and 100µg/mL streptomycin 
Complete RPMI 
culture medium 
Purchased RPMI-1640 medium was completed with 10% fetal 
calf serum (FCS), 100U/mL penicillin and 100µg/mL 
streptomycin 
ELISA diluent For 50 mL: dilute 5 ml FBS in 45 mL PBS. 
ELISA IL-8 capture 
buffer 
For 1L: 7.13 g NaHCO3, 1.59 g Na2CO3; add 750 mL ddH2O; pH 
to 9.5 with 10N NaOH; adjust volume to 1L and store at 4ºC. 
EMSA assay 
buffer 
For 50 mL: mix 0.44g NaCl, 2.5 mL 1M Tris pH7.4 and 5 mL 
glycerol. Adjust to 50 mL with ddH2O.  
Final concentration: 150 mM NaCl, 50 mM Tris pH7.4, 10% 
glycerol 
Glycine-methanol 
transfer buffer 
For 1L: 10 mL 10x Tris-Glycine buffer, 150 mL methanol, 840 
mL ddH2O; store at 4ºC. Final concentration: 25 mM Tris, 192 
mM glycine, 15% methanol (v/v). 
MOPS running 
buffer 
 
For 1L: dilute 50 mL 20x MOPS buffer in 950 mL ddH2O. Final 
concentration: 2.5 mM MOPS, 2.5 mM Tris, 0.005% SDS, 0.05 
mM EDTA, pH 7.7 
TBS - 3% BSA 
 
For 500 mL: 15 g BSA, 25 mL 20x TBS buffer, adjust to 500 mL 
with ddH2O; mix until completely dissolved; filter through 0.2 µm 
filter and store at 4ºC. 
Tween-TBS - 3% 
BSA 
 
For 500 mL: 15 g BSA, 25 mL 20x TBS buffer, 500 µL Tween 
20, adjust to 500 mL with ddH2O; mix until completely dissolved; 
filter through 0.2 µm filter and store at 4ºC. 
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2.2 Methods 
Cloning strategy 
 
For all cloning experiments, primers were synthesised by Metabion. PCR mix was 
purchased in a pre-mixed form containing the Taq DNA polymerase. General PCR 
program was as follows (unless specifically stipulated): 
   
  - Step 1: 94ºC - 60s 
  - Step 2: 94ºC - 30s 
  - Step 3: 65ºC - 60s           x35 
  - Step 4: 72ºC - 60s/kb 
  - Step 5: 72ºC - 120s 
 
Design of full-length RAGE coding pRP plasmid – Escherichia coli bacteria 
containing the Ager coding sequence (gene bank number: DQ896821) in a pLenti 
plasmid (Precision Lenti-ORF library, GE Dharmacon) were cultured for 16h in 7mL 
LB medium supplemented with ampicillin (0.1mg/mL). Plasmid DNA was then 
purified using the PureLink Miniprep kit following manufacturer’s protocol. Ager 
coding sequence was extracted by PCR using primer pair R790/R792. This enabled 
not only extraction of the Ager coding sequence but also addition of a 5’ AscI and a 
3’ NotI restriction sites.  PCR product was directly purified using the PureLink Quick 
Gel Extraction kit and digested with FastDigest AscI and NotI restriction enzymes. 
pRP plasmid was also digested using the same restriction enzymes (please refer to 
annex 7.1 for pRP plasmid sequence). Restriction products were subsequently 
electrophoresed in a 1% agarose gel containing ethidium bromide for DNA staining 
and run in 1x TAE buffer at 100V for approximately 20 min. Bands corresponding to 
either Ager or opened pRP plasmid were isolated and DNA was purified using 
PureLink Quick Gel Extraction kit. Ager coding sequence was inserted into pRP 
plasmid by incubating both purified Ager insert and opened pRP plasmid together 
with T4 DNA Ligase for 30 min at 22ºC.  
 
Design of cytosolic domain truncated RAGE coding pRP plasmid - Ager coding 
sequence was extracted from the Precision Lenti-ORF plasmid by PCR using primer 
pair R790/R791. This enabled extraction of Ager coding sequence until the start of 
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the cytoplasmic domain and addition of a 5’ AscI and a 3’ NotI restriction sites. PCR 
product was then processed as described for the full-length Ager sequence.  
 
Design of RAGE-colour coding pRP plasmid – Ager coding sequence was extracted 
by PCR using the previously described full length RAGE pRP plasmid as DNA 
template and R1107/R1108 primers. This enabled extraction of Ager sequence 
between AscI-NotI restriction sites without the 3’ end stop codon. PCR product as 
well as pRP plasmid were then digested with AscI and NotI restriction enzymes. 
Insert was ligated into opened pRP plasmid by incubation with T4 DNA Ligase for 30 
min at 22ºC. TagRFP or mCitrin color coding sequences were obtained by digestion 
of already existing plasmids with NotI and MreI FastDigest restriction enzymes. pRP 
plasmid containing Ager coding sequence with deleted stop codon was also digested 
using NotI/MreI restriction enzymes. Digested insert and plasmid were loaded on a 
1% agarose gel. Bands were isolated and gel-purified as described above. TagRFP 
and mCitrin sequences were then inserted in 3’ of the Ager coding sequence by 
incubation of insert and plasmid with T4 DNA Ligase for 30 min at 22ºC. 
 
Design of V-C1 domain truncated RAGE-color coding pRP plasmid – Sequence 
coding for Ager membrane localization signal was extracted by PCR using full-length 
Ager plasmid (described above) as DNA template with R1161/R1162 primer pair. 
This added a 3’-end sequence corresponding to the start of RAGE C2 domain.  Ager 
coding sequence from the C2 domain (in 5’) down to the 3’ NotI restriction site was 
extracted by PCR using R1163/R1164 primer pair. This enabled addition of a 5’ 
sequence corresponding to the 3’ end of RAGE membrane localization signal. 
Products from both PCR were purified as described previously. Purified PCR 
products were then mixed and complementary sequences were annealed for 5 
cycles in absence of primers. Double strand was then completed on both side of 
annealed sequences with added primers R1161 and R1164 for another 30 cycles. 
PCR product was subsequently digested with FastDigest AscI and NotI restriction 
enzymes, loaded onto a 1% agarose gel containing ethidium bromide and isolated 
band were gel purified as described before. Insert was finally ligated into AscI-NotI 
opened pRP plasmid containing either TagRFP or mCitrin fluorescent proteins 
coding sequences by incubation with T4 DNA Ligase for 30 min at 22ºC. 
 
After ligation, all plasmids were transformed into DH5α competent Escherichia coli 
bacteria: 15µL competent bacteria were incubated on ice for 30 min with 3 µL ligation 
mix. DNA-bacteria mix was then incubated for exactly 1 min at 42ºC directly followed 
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by 2 min on ice. Bacteria were further resupended with 300 µL LB medium and 
incubated at 37ºC for 1h. 100 µL bacteria suspension was spread onto an LB agar 
plate containing ampicillin (0.1 mg/mL) and incubated at 37ºC for 16h. Single clones 
were picked using a L200 pipette tip and injected into 7 mL LB medium before 16h 
incubation at 37ºC. Plasmid DNA was purified using PureLink Miniprep kit. Glycerol 
stocks were prepared by adding 600 µL bacteria culture to 400 µl 50% glycerol (v/v 
in H2O) and subsequent freezing at -80ºC. After test-digest (using FastDigest 
NotI/AscI or NotI/MreI enzyme pairs) and sequencing (ordered at GATC Biotech), 
plasmid DNA stocks were prepared by incubating a “scrape” of still frozen glycerol 
stock from previously generated clonal bacteria in 500 mL LB medium containing 
ampicillin (0.1mg/mL) for 16h at 37ºC. Finally, plasmid DNA was purified using 
PureLink Maxiprep kit. DNA Stocks were frozen at -20ºC for long-term storage.  
 
Other plasmids – NFκB-gLuc and EF-1α-fLuc reporter plasmids were generously 
donated by Dr. Thomas Zillinger. The NFκB-gLuc plasmid contained the Gaussia 
luciferase-coding gene (gLuc, Gaussia princeps) under the control of an NFκB target 
promoter (containing five NFκB transcription factor binding sites). Gaussia luciferase 
was used because it is secreted upon expression therefore enabling simple read-out 
of NFκB activity. The EF-1α-fLuc plasmid contained the Firefly luciferase-coding 
gene (fLuc, Photinus pyralis) under the control of the constitutive EF-1α promoter. 
The effect of immune activation on EF-1α expression is negligible and was therefore 
used as a measurement of “background” cell activity and viability. 
Viral packaging vector (Gag-pol) coding for HIV group specific antigen (Gag) and 
reverse transcriptase (pol) as well as viral envelope vector (VSV-G) coding for 
glycoprotein G of the Vesicular stomatitis virus (VSV) were obtained through a 
donation by Dr. Doug T. Golenbock, University of Massachusetts Medical School 
(UMASS). When transfected into cells together with a pRP transfer vector, these 
plasmids enable the formation of HIV-like viral particles able to infect mammalian 
cells and integrate the cDNA sequence contained between the two long terminal 
repeats (LTRs) present in the transfer vector. 
 
General cell culture 
 
TLR-expressing human embryonic kidney (HEK) 293 cells were purchased from 
InvivoGen. HEK293T, expressing the large T antigen of simian virus 40, were from 
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ATCC. HeLa cells were obtained courtesy of Professor Friedemann Weber’s 
laboratory (Marburg, Germany). U373 glioma epithelial cells expressing TLR9-YFP 
fusion protein either alone or together with RAGE were produced by Dr. Cherilyn 
Sirois at the University of Massachusetts Medical School (UMASS). 
Cells were routinely cultured in DMEM completed with 10% fetal calf serum (FCS), 
100U/mL penicillin and 100µg/mL streptomycin. Depending on the usage, cells were 
cultured in T175 or T75 flasks and grown until reaching a confluence of 90%. They 
were then detached from the flask using either Trypsin (containing 2mM EDTA) or 
Stem Pro Accutase and passaged 1:5 (HEK293, HEK293T) or 1:10 (HeLa) to a new 
flask. To produce cell stocks, cells from an early passage (passage 2-3) were 
centrifuged and resuspended in FCS containing 10% DMSO. Immediately after 
resuspension, cells were transferred to cryo-tubes and placed in freezing container 
filled with isopropanol. Freezing containers were stored at -80°C for 24h. Cryo-tubes 
were finally transferred to -150°C for long-term storage. 
Cells to be used for experiments were placed in a 50 mL tube and centrifuged at 
340g for 5 minutes. Supernatant was discarded and cells were resuspended in 5 mL 
complete DMEM. After a 5-fold dilution of the cell suspension in trypan blue (to stain 
dead cells), cell density was assessed with a Neubauer hemocytometer. Cells 
present in the four outer corners of the chamber were counted and cell density was 
calculated using the following equation: 
 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 = 𝑐𝑜𝑢𝑛𝑡4 ×  5  ×  100 = 𝑥  . 10!𝑐𝑒𝑙𝑙𝑠/𝑚𝐿 
 
Cell suspensions were diluted to the appropriate density and cells were seeded into 
tissue culture plates. Plates were left untouched on the sterile bench for 10 minutes 
to enable cells to sediment in a homogeneous manner to the bottom of the wells. 
 
Generation of stable cell lines 
 
Cells stably expressing RAGE were produced using a HIV-based retrovirus system. 
cDNA sequences coding for full-length or mutant human RAGE in fusion with either 
TagRFP or mCitrine fluorescent protein were transferred to a pRP plasmid between 
two LTR sites (as described previously, see Cloning strategy). On day 1, HEK293T 
cells were seeded at a density of 3x106 cells per 10 cm tissue culture dish. On day 2, 
HEK293T cells were transfected with 10 µg Gag-pol plasmid and 1µg of VSV-G 
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plasmid together with 10 µg of pRP plasmid coding for RAGE-TagRFP or RAGE-
mCitrine. Plasmids were diluted as desired in serum-free DMEM, combined with a 
cationic lipid based transfection reagent (GeneJuice) and further incubated 20 min at 
room temperature to allow formation of DNA-cationic lipid complexes. DNA-
containing cationic lipid complexes were then added to HEK293T cells in the 
absence of FCS. After 6 hours incubation at 37°C, 5%CO2, FCS was added to a final 
concentration of 10%. On day 3, cell supernatants were replaced by new complete 
DMEM containing 30% FCS and incubated for 48h at 37°C, 5% CO2. On day 4, 
target cells were seeded in 6 well plates at a density of 1.105 cells (HeLa) or 2.105 
cells (HEK293) per well in 3 ml of complete DMEM (10% FCS) and incubated at 
37°C with 5% CO2 overnight. 72h post-infection (day 5), virus-containing 
supernatants were harvested, filtered with a 0.45 µm PVDF syringe filter and applied 
to the target cells (3mL per well). After 24h, supernatants were removed from 
infected cells and replaced by fresh complete DMEM containing 10% FCS. Cells 
were expanded until reaching density of 80% in a T175 tissue culture flask. Cells 
positive for fluorescence were finally sorted using an Aria flow cell sorter with help 
from the FACS Core facility in Bonn, Germany.  
 
Bone marrow isolation and stimulation 
 
Eleven-week-old C57/BL6 WT and RAGE-deficient (KO) female mice were 
anesthetized using isofluoran vapours and subsequently sacrificed by cervical 
dislocation before harvesting femur and tibia bones. Bone marrow cells were isolated 
by flushing cut bones with 5mL complete RPMI medium per bone and using a 25-
gauge needle. Cells were thoroughly resuspended and subjected to erythrocyte lysis. 
Finally, cell suspensions were filtered through a 70µm cell strainer and counted prior 
to plating and stimulation.  
Cells were stimulated with TLR13 agonist (Sa19-RNA, 0.1µg/mL and 0.5µg/mL), 
TLR9 agonist (ODN 1826, 0.1 µM) or LPS (0.1µg/mL). TNFα and IL-6 cytokine 
secretion in the cell supernatant was sampled over 4h at different time points and 
quantified using mouse TNFα or IL-6 HTRF kit (please see below for detailed 
protocol). Animal experiments were performed in accordance with German animal 
protection law.  
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Enzyme-linked immunosorbent assay (ELISA) 
 
HEK293-XL cells stably expressing TLR9 were seeded in 96-well plates at a cell 
density of 3.104 cells/well. After overnight incubation at 37ºC, 5% CO2, cells were 
transiently transfected with non-tagged full-length RAGE or a control plasmid 
encoding for mCherry using GeneJuice transfection reagent. On the following day, 
cells were stimulated with a gradient of ODN 2006. Cells were also stimulated with 
the cytokine TNFα as control for RAGE-indepenent immune activation. Cells were 
then incubated at 37ºC for 16h. After incubation, 96-well plates were centrifuged at 
340 g for 5 min and cell supernatant was harvested and frozen until use in ELISA. 
For quantification of human IL-8 secretion in the cell supernatant, MaxiSorp 96-well 
plates were coated with capture antibody diluted in coating buffer and incubated 
overnight at 4ºC. Plates were then washed 3x in wash buffer before blocking with 
PBS containing 10% FBS for 1h at room-temperature. After another three washes, 
standard and diluted supernatants (1:2) were incubated on the plate for 2h at room 
temperature. Following incubation, plates were washed 5x and subsequently 
incubated for 1h with working detector containing both biotinylated detection antibody 
and streptavidin-bound horseradish peroxidase (HRP). Finally, plates were washed a 
total of seven times before adding HRP-substrate solution. Plates were incubated 
approximately 20 min before adding sulfuric acid stop solution. Absorbance at 450nm 
was measured using SpectraMax i3 plate reader. Quantification of IL-8 cytokine 
concentration was finally calculated by fitting absorbance of each well to the standard 
curve. 
 
Luciferase Assays 
 
HEK293-XL cells stably expressing TLR7, TLR8, TLR9 or TLR13 were seeded in 96-
well plates at a cell density of 3.104 cells/well. After overnight incubation at 37ºC, 5% 
CO2, cells were transiently transfected with non-tagged full-length RAGE or a control 
plasmid encoding for mCherry, together with an NFκB (5xκB) driven luciferase 
reporter, using GeneJuice transfection reagent. On the following day, cells were 
stimulated with TLR specific DNA or RNA agonist at the indicated doses. As 
specificity control, cells were stimulated with TLR7/8 specific small synthetic agonist 
R848 or a non-stimulatory RNA (NS-RNA) at the specified doses. 
To control for RAGE-indepenent immune activation, cells were also stimulated with 
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cytokine TNFα or IL-1β at the indicated doses. Cells were then incubated at 37ºC for 
6h, 16h (Results – Part 2) or 20h (Results – Part 1). After incubation, 96-well plates 
were centrifuged at 340g for 5 min. To measure NFκB-dependent release of gaussia 
luciferase, cell supernatants were subsequently harvested and transferred to a new 
96-well plate. 25µL of each sample was then transferred to a U-shape white 96-well 
plate before adding 25µL of diluted Coelenterazine (1µg/mL in water).  
When using cell endocytosis inhibitors, EF-1α-driven firefly luciferase reporter was 
used to control for cell viability. To measure firefly luciferase activity, cells were lysed 
in 50µL passive lysis buffer directly after supernatant harvest. Cells were incubated 
in lysis buffer for 10 min with orbital rocking. 25µL of cell lysate was then transferred 
to a U-shape white 96-well plate before adding 25µL of Steady-Glow luciferase 
reagent. For gaussia and firefly luciferase, luminescence emission was immediately 
measured with SpectraMax i3 plate reader. 
 
Homogeneous Time Resolved Fluorescence (HTRF) 
 
TNFα and IL-6 cytokines secretion from mouse bone marrow cells was quantified 
using homogeneous time resolved fluorescence (HTRF). This system is based on 
Förster resonance energy transfer (FRET). Two antibodies targeting different 
epitopes on the same target molecule are mixed together with a sample containing 
the antigen. When binding to the target antigen, both antibodies are placed in close 
proximity enabling energy transfer between a donor fluorescent molecule, europium 
cryptate, placed on one antibody and an acceptor fluorescent molecule, XL665, 
placed on the other antibody.  
Bone marrow cells were stimulated as described above. Several 30µl samples of 
supernatant were taken over time (30 min, 1h, 2h, 3h and 4h post-stimulation). At the 
end of the stimulation time, all samples and standard were incubated overnight with 
donor/acceptor antibody mix. Finally, fluorescence emission at 620 nm (donor) and 
665 (acceptor) were measured and the ratio 665nm/620nm was calculated prior to 
determination of cytokine concentration by fitting sample data to the standard curve. 
 
Confocal Imaging 
 
To study membrane binding of RNA to RAGE, µ-Slide 8 well microscopy dishes were 
first pre-coated by incubation with 200µL poly-L-lysine (0.01% m/v) for 30 min at 
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37ºC. Dishes were then washed twice with PBS. HEK293-XL TLR8-HA cells 
expressing either RAGE FL or RAGE ΔVC1 fused to a C-terminal Tag-RFP were 
then seeded in 200µL complete DMEM at a cell density of 1.105 cells/well. After 
overnight incubation at 37°C, 5% CO2, cells were incubated at 37ºC for 15 min with 5 
µM final concentration of biotinylated RNA or DNA labelled with streptavidin-
AlexaFluor488 (20 min incubation of 50 µM biotin-RNA/DNA and 10 µM streptavidin-
AlexaFluor488 in PBS) or with FAM labelled ORN Sa19. Supernatants were then 
replaced by complete DMEM medium containing DRAQ5 (1:2000) and cells where 
incubated for an extra 10 min at 37ºC before imaging.  
To study RAGE-dependent internalization of RNA, HeLa cells expressing RAGE FL 
or RAGE ΔVC1 fused to a C-terminal TagRFP were seeded in µ-Slide 8 well 
microscopy dishes in 200µL complete DMEM and at a cell density of 2.104 cells/well. 
After overnight incubation at 37°C, 5% CO2, cells were incubated for 5 min at 37ºC 
with 5µM biotinylated RNA labeled with streptavidin-AlexaFluor488 (as described 
above). Cells were then washed twice in PBS and either directly fixed (5 min time 
point) or incubated for a total time of 60 min at 37ºC, 5% CO2. Cells were fixed in 3% 
PFA containing DRAQ5 (1:2000) and incubated at 37ºC for 30 minutes before PBS 
wash and imaging.  
Live and fixed cells were imaged with a Leica SP5-AOBS-SMD confocal microscope.  
 
 
Imaging settings:  Image size: 2048x2048 pixels, 16 bits, 246 µm/pixel 
   Scan mode: XYZ 
   Pinhole opening: 110 µm 
   Sequential Scan with 4 channels 
   400 Hz, 4 line averaging  
Objective:   63x objective, water immersion 
Laser power:   Argon laser, 20%  
   Helium/Neon (HeNe), ON   
   Diode-pumped solid-state (DPSS), ON 
Transmitted light: 488 (20%), 561 (20%), 633 (10%) 
PMT settings (measured spectrum): AlexaFluor 488: 499-542 nm 
     TagRFP: 567-629 nm 
     DRAQ5: 642-789 nm 
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For RNA internalization, confocal images from three independent experiments were 
analysed using Cell Profiler software ((229), www.cellprofiler.org). RAGE channel 
was used to define primary objects first using a global threshold enhancement 
followed by a 3-class Otsu algorithm. Fluorescence intensity of the RNA channel was 
then used to quantify the median correlations of RNA to RAGE in a pixel-by-pixel 
basis calculation of Pearson’s correlation coefficient within the objects. An area 
shape filtering for eccentricity was finally used to exclude linear membrane staining 
to put the focus on intracellular vesicles.  
 
Western Blot analysis 
 
Samples were prepared using NuPAGE LDS loading buffer together with NuPAGE 
reducing buffer and separated by NuPAGE 4-12% Bis-Tris poly-acrylamide gels in 
MOPS running buffer and at 100V for approximately 2h30. After gel electrophoresis, 
proteins were transferred to Immobilon-FL PVDF membranes using glycine-methanol 
transfer buffer at 32V for 1h30. Membranes were blocked in 3% BSA (w/v) diluted in 
TBS. Immunoblotting was performed in 0.1% Tween-TBS containing 3% BSA (w/v). 
Primary antibodies were diluted as follow: mouse monoclonal anti-human RAGE, 
1:500; rat monoclonal anti-TLR9, 1:500; rabbit monoclonal anti-β-actin, 1:1000; rabbit 
polyclonal anti-TagRFP, 1:5000. Donkey anti-mouse or anti-rabbit antibodies 
conjugated to either IRDye680 or IRDye800 were used as secondary antibodies and 
diluted at 1:2.104. Infrared signal was finally detected using Odyssey scanner (LI-
COR). 
 
Co-Immunoprecipitation (co-IP) 
 
For co-immunoprecipitation of TLR9 and RAGE, U373 glioma epithelial cells stably 
expressing either TLR9-YFP fusion protein alone or together with RAGE were used. 
Cells were stimulated for 1h at 37ºC with medium alone or with 1 µM CpG ODN 2006 
untagged or tagged with biotin. Cells were subsequently washed with cold PBS and 
then lysed in RIPA lysis buffer complemented with 0.1µM PMSF and 1x complete 
protease inhibitor. 50 µL of protein A Dynabead slurry was washed once with 200 µL 
cold PBS complemented with 0.02% Tween-20. Beads were then incubated 10 min 
with 1µg rabbit anti-GFP (in 200µL PBS-0.02% Tween-20). After protein 
concentration measurement using BCA assay kit, lysate concentrations were 
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adjusted across all samples by adding lysis buffer and 730 µg total protein was used 
per co-IP. Beads were washed once with 200µl PBS-0.02% Tween-20 before protein 
lysate was applied to the beads (1mL final volume). Lysates were incubated with 
anti-GFP antibody-coated beads for 2h30 at 4ºC using rotational mixing (MACSmix 
tube rotator).  Beads were finally washed 3x in PBS-0.02% Tween-20 and 
subsequently boiled at 95ºC for 5min with 30 µL reducing western-blot loading buffer. 
Proteins captured on the beads were resolved by SDS-PAGE. Bound TLR9 and 
RAGE were detected by western blot as described previously. 
 
Electrophoretic mobility shift assay (EMSA) 
 
RNA molecules labeled with Oregon-green or 6-Carboxyfluorescein (Fluo-RNA) were 
incubated at a fixed concentration of 250 nM with increasing amounts of purified 
RAGE ectodomain (V-C1-C2, from 1 to 10 µM) or BSA (10 µM) as negative control. 
To assess the specificity of the interaction, electrophoretic mobility of Fluo-RNA (250 
nM) with V-C1-C2 protein (2.5 µM) was competed with increasing concentrations of 
either unlabeled RNA molecules (corresponding to the sequence of the labeled 
RNA), CpG ODN 2006 or GpC ODN 2137 (RNA or 2006/2137-DNA; 0.63-40 µM, 
except for Sa19-RNA; 0.63-20 µM). All binding assays were prepared in assay buffer 
and at room temperature, allowing 10 min incubation time. Samples were loaded on 
NuPAGE 4-12% Bis-Tris poly-acrylamide gradient gels and electrophoresed at 90 V 
for 5h in TBE buffer with light protection. Oregon green or FAM fluorescence was 
detected using VersaDoc 4000 fluorescence imaging system with 90s exposition 
time. 
 
Fluorescence-activated cell sorting (FACS) 
 
To study the cell surface interaction of RAGE with RNA, HEK293-XL cells expressing 
either TLR7-HA or TLR8-HA together with RAGE FL or RAGE ΔVC1 fused to 
mCitrine were used. Cells detached from the tissue culture dish with StemPro 
Accutase were resuspended in complete DMEM and subsequently seeded in a V-
shape 96-well plate (1.105 cell/well).  Cells were then incubated at 37ºC for 15 min 
with 5 µM biotinylated RNA previously labeled with streptavidin-AlexaFluor647 (as 
described in confocal imaging section). Cells were then washed in FACS buffer 
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(PBS, 1% FCS) and kept on ice prior to fluorescence detection using Fortessa flow 
cytometer. 
 
Quantitative Real-Time PCR (qPCR) 
 
Bone marrow cells were harvested and stimulated as described above. At the end of 
the experiment, unstimulated cells were lysed in RLT buffer complemented with 1% 
(v/v) β-mercaptoethanol. Total RNA was subsequently isolated with RNeasy Mini Kit 
(Qiagen) following the manufacturer’s protocol. Concentration of isolated RNA was 
quantified by measuring absorbance of RNA solutions at 260 nm using SpectraMax 
i3. 1 µg RNA from each sample was then used to synthesize cDNA using an oligo-
dT(18) primer: mRNA and oligo-d(T) were mixed and incubated at 65ºC for 5min. 
Samples were then placed on ice for 2 min before adding 1x reaction buffer (stored 
as a 5x), 0.5 mM dNTPs, 5 mM DTT and 200U SuperScript III Reverse 
Transcriptase. Samples were subsequently incubated at 50ºC for 50 min followed by 
5 min at 85ºC. cDNA mix was diluted 1:200 in water before use in qPCR. The 
amount of cDNA was determined using the Maxima SYBR Green/ROX qPCR Master 
Mix mixed with mRNA-target specific primers (listed above) and each cDNA sample. 
PCR was finally run on QuantStudio 6 qPCR cycler. Gene expression was 
normalized to expression of the housekeeping gene Hprt (normalized threshold 
cycle, ΔCt). For analysis, data was transformed to power ΔCt (pΔCt) where pΔCt = 
2ΔCt to take into account the exponential nature of the PCR reaction. 
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3. Results – Part 1: RAGE is a cell surface DNA sensor 
that promotes TLR9-dependent inflammatory 
responses * 
 
3.1 DNA binds to RAGE extra-cellular V-C1 domain 
 
To determine whether immune-stimulatory DNA binds to RAGE, purified His-tagged 
V-C1-C2 ectodomain was incubated with an increasing amount of A-, B- and C-type 
CpG DNA. As analysed by Alpha-Screen homogenous binding assay, all CpG types 
bound to RAGE at low nanomolar apparent affinities (Fig. 3.1A). CpG-A bound the 
most efficiently to V-C1-C2. CpG-B had a slightly lower affinity than CpG-A while 
CpG-C presented the smallest affinity of the three types of DNAs to RAGE 
ectodomain. To further characterize the structural basis for DNA binding to RAGE, V-
C1-C2-His peptide was incubated with either full length CpG-B 2006 DNA (24 nt) or 
with different 3’-truncated DNA with sizes ranging from 20 nucleotides down to 7 
nucleotides (Fig. 3.1B). Interestingly, DNA molecules smaller than 15 nucleotides 
could not interact with RAGE. The binding affinity of CpG-B to V-C1-C2 was size 
dependent, longer DNA presenting a stronger affinity to the peptide than smaller 
ODNs. Double- or single-stranded CpG-B DNA had similar binding affinity to V-C1-
C2 (Fig. 3.1C). Surprisingly, bases were dispensable for the interaction. Indeed, 
phosphodiester- or phosphorothioate-linked deoxyribose backbone lacking bases 
also interacted with V-C1-C2-His peptide with a low nanomolar apparent affinity (Fig. 
3.1D). Phosphorothioate-linked (PS) deoxyribose backbone had a greater affinity 
with RAGE than phosphodiester-linked (PO) backbone. Together, these results show 
that DNA binds to RAGE ectodomain in a size-dependent but sequence-independent 
manner. The fact that structurally heterogeneous types of CpG DNA bind to RAGE 
with different affinities suggests that RAGE binds preferentially to more complex 
structures of DNA where CpG-A, a more branched form of DNA, has the best affinity 
to RAGE. To identify the DNA binding site present in RAGE, different recombinant 
constructs of the RAGE ectodomain, either full-length (V-C1-C2), V-domain alone 
(V), V-C1-domains (V-C1) or C1-C2-domains (C1-C2) were incubated together with 
                                                
* A modified version of some of the results discussed in this thesis section was published in 
the Journal of Experimental Medicine: Sirois et al. 2013, (228), annex 7.2.  
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an increasing amount of CpG-B ODNs (Fig. 3.2A). Full length V-C1-C2 peptide had 
the strongest affinity with DNA. V-domain alone or together with C1-domain (V-C1) 
also presented a strong affinity to DNA. On the contrary, the peptide containing C1-
C2 domains (C1-C2) showed no binding affinity to DNA. Interestingly, full-length V-
C1-C2 peptide had a stronger affinity to CpG DNA than V- or V-C1-domains. This 
result suggests that C1 and C2 domains have a stabilization role enabling a better 
binding of DNA to the V domain. This is in agreement with the known role for RAGE 
V-domain, which was previously shown to be essential for the interaction with other 
RAGE ligands (198). 
 
 
Figure 3.1 DNA binds to the extracellular domain of RAGE. 
Indicated concentrations of ODN were incubated with 40 nM his-tagged RAGEV-C1-
C2 and binding was assessed by AlphaScreen. Binding of phosphodiester backbone 
containing CpG type A, B and C DNA (A) or ODN 2006 full-length (24-mer) and 3’ 
truncated ODN of different length based on same sequence (B) or single stranded 
24-mer ODN 2006 and 24-mer ODN 2006 annealed to its complementary strand (C) 
were compared for binding to RAGE. (D) Deoxyribose backbone containing either 
phosphodiester (PO) or phosphorothioate (PS) type linkage in the absence of 
nucleobase was incubated with RAGE and tested for binding. 
Experiments presented in this figure were performed by Dr. Cherilyn M. Sirois and 
were part of the manuscript published in the Journal of Experimental Medicine (228). 
Please refer to manuscript Material and Method section for more technical details 
(please see joined manuscript). 
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Our collaborators (T. Sam Xiao laboratory) further determined the crystal structures 
of the RAGE V-C1 domain in complex with either a 22 nucleotides-long dsDNA 
molecule derived from vaccinia virus genomic repeat sequences (PDB accession 
number 3S59, Fig. 3.2B) or with a 22 nucleotide-long CpG motif-containing dsDNA 
molecule (PDB accession number 3S58). In summary, both crystal structures had a 
resolution of 2.8-Å and 3.1-Å respectively.  
 
 
Figure 3.2 RAGE extracellular V-C1 domain is essential for binding of DNA. 
(A) Localisation of DNA binding site in RAGE extracellular domain was analysed by 
AlphaScreen upon incubation of indicated concentrations of ODN 2006 with 40nM of 
either full-length RAGE extracellular domain (V-C1-C2) or isolated V domain (V), V-
C1 domain (V-C1) and C1-C2 domain (C1-C2). (B) Representation of the solved 
structure of two RAGE V-C1 domains in complex with a 22 nucleotides-long dsDNA 
molecule derived from vaccinia virus genomic repeat sequences (PDB accession 
number 3S59). Electrostatic charge surface of RAGE is shown on a scale of -10 kT/e 
(red) to +10 kT/e (blue) in three different orientations. The bound dsDNA is shown as 
an orange ribbon. 
Experiments presented in this figure were performed by Dr. Cherilyn M. Sirois (A) 
and Tengchuan Jin (B) and were part of the manuscript published in the Journal of 
Experimental Medicine (228). Please refer to manuscript Material and Method 
section for more technical details (please see joined manuscript). 
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The structures were solved using molecular replacement based on two previously 
published structures of V-C1 domains of RAGE (PDB accession numbers 3CJJ and 
3O3U,(133)). The two structures were nearly identical except for the two DNA 
sequences. They presented the formation of a “trans” homodimer with two V-C1 
monomers bound in a dyad conformation with their V-domains located at the dimer 
interface. One dsDNA molecule was bound in the pocket formed by the dimer. The 
dimer formed by interaction of the hydrophobic surfaces present on both V-domains 
showed an accumulation of highly positively charged amino acids at the protein:DNA 
interface (in blue), where the complementary negatively charged backbone of the 
dsDNA molecule was integrated.  
 
 
3.2 DNA is recruited at the surface of cells expressing RAGE 
 
To study the interaction of DNA with RAGE at the cell surface, an inducible 
expression system was first used. Cells transduced with the gene coding for human 
RAGE in fusion with mCitrine and under the control of a TRE-Tight tetracycline-
inducible promoter were treated with doxycycline for 24h to induce RAGE expression 
(Fig. 3.3A). Cells either expressing RAGE (RAGE on) or kept without doxycycline 
(RAGE off) were stimulated with 1µM ODN 2336 (CpG-A) labeled with 
AlexaFluor647. Analysis of cell fluorescence by flow-cytometry showed a marked 
increase in mCitrine fluorescence indicating the efficiency of the 24h doxycycline 
treatment and RAGE expression. Interestingly, RAGE-on cells bound more DNA than 
RAGE-off cells. There was a positive correlation between the amount of DNA bound 
by the cells and their RAGE expression. Cells that were not treated with doxycycline 
showed a slight binding of DNA when compared with non DNA-stimulated cells. 
However, this RAGE-unspecific binding of DNA remained much lower than the 
binding induced by RAGE expression. To further characterize the binding of DNA to 
RAGE at the cell surface, two constructs were designed to code either for full-length 
RAGE (RAGE FL) or for V-C1 truncated RAGE (RAGE ΔVC1) in fusion with a C-
terminal cytoplasmic TagRFP fluorescent protein (Fig. 3.3B). HEK 293 cells stably 
expressing either construct were used to study the binding of DNA to RAGE by 
confocal microscopy (Fig. 3.3C). Cells were stimulated with 5µM biotinylated DNA 
labeled with streptavidin AlexaFluor488.  After 15 minutes stimulation at 37°C, cells 
were washed and incubated with medium containing DRAQ5 for another 10 minutes 
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to stain nuclei before live imaging. Cells expressing RAGE FL presented a strong 
accumulation of fluorescent RAGE at the cell-to-cell boundary. This is expected since 
the V and C1 domains of RAGE were previously shown to dimerize in a trans 
conformation (Fig. 3.2B). 
 
 
 
Figure 3.3 DNA is recruited at the surface of cells expressing RAGE.  
Note: For detailed legend, please see opposite page. 
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On the contrary, cells expressing RAGE ΔVC1 did not show such accumulation of 
fluorescence and conserved a homogeneous repartition of the receptor along the 
membrane. After stimulation with labeled DNA, cells expressing RAGE FL recruited a 
pronounced amount of DNA at their cell surface, which almost entirely co-localized 
with RAGE. Cells expressing RAGE ΔVC1 showed no cell surface recruitment of 
DNA, strengthening our previous finding that localized the DNA binding site to the V-
C1 domains of RAGE. To control for the specificity of the binding, cells were also 
stimulated with streptavidin AlexaFluor488 alone. No AlexaFluor488 fluorescence 
signal was detected at the surface of either RAGE FL or RAGE ΔVC1 expressing 
cells confirming the specificity of the DNA binding to RAGE.  
Together, these results show that DNA binds to RAGE extracellular V and C1 
domains not only in-vitro but also at the surface of living cells.  
 
 
3.3 Protocol establishment for read-out of the impact of RAGE 
on the immune response to DNA stimulation 
 
To analyze the effect of RAGE on the immune activation induced by CpG DNA 
stimulation, a tertracycline-inducible system identical to the one described previously 
(Fig. 3.3A) was used.  
 
 
 
Figure 3.3 DNA is recruited at the surface of cells expressing RAGE. 
(A) HEK293T cells transduced with tetracycline-inducible RAGE-mCitrine coding 
gene were left un-induced (RAGE off, black population) or treated to induce RAGE 
expression (RAGE on, black population) and then incubated on ice with 1 µM Alexa 
Fluor 647-labelled ODN 2336 (CpG-A, red populations), washed, and analysed by 
flow cytometry. Data is representative of three similar experiments. (B) Schematic 
representation of the RAGE-fluorescent protein fusion constructs used in confocal 
microscopy. (C) HEK293-XL cells stably expressing RAGE FL or RAGE ΔVC1 fused 
to TagRFP were stimulated with biotinylated ODN 2006 (CpG-B) labelled with 
streptavidin-AlexaFluor488 (5 µM) for 15 min at 37°C. DRAQ5 was used as nuclear 
staining. To control for binding specificity, cells were also incubated with streptavidin-
AlexaFluor488 alone. Cells were finally imaged live by confocal microscopy. Main 
images represent merged channels corresponding to RAGE-TagRFP (red), labeled 
RNA (green) and DRAQ5 (blue). Scale bars represent 10 µm. Split channels are 
represented on the right with the same color-coding. 
Experiment presented in (A) was performed by Dr. Cherilyn M. Sirois and was part of 
the manuscript published in the Journal of Experimental Medicine (228). For more 
technical details concerning experiment in (A), please refer to the manuscript 
Material and Method section of the manuscript (please see joined manuscript). 
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Cells expressing either TLR9, tetracycline-inducible-RAGE or TLR9 together with 
tetracycline-inducible-RAGE were treated for 24 h with doxycycline to induce protein 
expression (+ Dox) or left without doxycycline for the same period of time (- Dox). 
Cells were then stimulated with an increasing dose of CpG-B ODN 2006 and TNFα 
as control for RAGE-independent immune activation (Fig. 3.4A). TLR9 or TNFα-
receptor activation was assessed by quantification of interleukine-8 (IL-8) cytokine 
release (ELISA). RAGE expression, upon doxycycline treatment, was controlled by 
western-blot using unstimulated cells lysed in SDS loading buffer (Fig. 3.4B). 
Interestingly, cells expressing both TLR9 and RAGE upon doxycycline treatment 
showed an increased immune response to CpG-B DNA stimulation compared to - 
Dox cells. However, cells expressing only TLR9 but that were still treated with 
doxycycline showed the same increased activation. This result implicated that the 
rise in IL-8 release was RAGE-independent and triggered by doxycycline. Of note, 
cells only expressing RAGE and lacking TLR9 did not respond to CpG-B DNA 
stimulation either with or without doxycycline treatment. Moreover, upon TNFα 
stimulation, cells treated with doxycycline showed almost no increase in IL-8 
secretion compared to cells left without doxycycline (Fig. 3.4A, right panel). This 
suggested that the effect of doxycycline was specifically targeting TLR9 activation 
sensitizing cells to CpG-B DNA stimulation without activating them directly. 
Moreover, background expression of RAGE was noticeable in the cells transduced 
with the tetracycline-inducible RAGE construct even without doxycycline treatment 
when compared to the TLR9 only expressing cells (Fig. 3.4B). This effect could be 
due to traces of doxycycline in the bovine serum used for cell culture or due to an 
imperfect control of the promoter by the TET-repressor. This background expression 
of RAGE together with the doxycycline effect on TLR9 activation made this 
experiment unreliable and difficult to analyse.  
 
Consequently, a new protocol was established, using transient transfection of RAGE 
and a reporter plasmid for assessment of NFκB activation. This reporter plasmid 
contained the sequence coding for gaussia luciferase (gLuc) under control of an 
NFκB-target promoter. Cells of the control group were transfected with a plasmid 
coding for mCherry fluorescent protein enabling visual control for transfection 
efficiency. Cells expressing either TLR9 or TLR7 were transfected with previously 
described plasmids. After 24h, cells were stimulated with a gradient of CpG-B DNA 
(ODN 2006) or TNFα and incubated for 16h prior to gLuc activity measurement in the 
cell supernatants (Fig. 3.4C). Although CpG DNA stimulation induced a substantial 
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secretion of gaussia luciferase, indicating robust NFκB activation, only a very poor 
effect of RAGE was noticeable. 
 
 
 
Figure 3.4 Protocol establishment for read-out of the impact of RAGE on the 
immune response to DNA stimulation. 
(A) HEK293 cells expressing either TLR9, tetracycline-inducible-RAGE or TLR9 
together with tetracycline-inducible-RAGE were left un-treated (- Dox) or treated for 
24 h with doxycycline to induce protein expression (+ Dox). Cells were subsequently 
stimulated for 16h with a dose titration of ODN 2006 and TNFα as a control for 
RAGE-independent immune activation. After incubation, cell supernatant was 
harvested and concentration of IL-8 cytokine was measured by ELISA. Data are 
shown as mean ± SD for double experimental replicates and are representative of at 
least 3 independent experiments. (B) Unstimulated cells from (A) were lysed in LDS-
loading buffer after harvest of supernatants. Samples were analyzed by Western-
blotting for RAGE expression. Anti-β-actin antibodies were used for loading control. 
(C) HEK293-XL cells stably expressing human TLR9 were transiently transfected 
with an NFκB-driven luciferase reporter together with full length non-tagged human 
RAGE or mCherry as control. Cells were stimulated for 20h with a dose gradient of 
ODN 2006 and TNFα prior to readout of luciferase activity in cell supernatants. Data 
is shown as mean ± SD for triple experimental replicates. 
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When comparing to cells transfected with mCherry, RAGE significantly increased 
NFκB activation only at the lowest stimulation point (125nM). However, no dose-
dependent increase of gaussia luciferase secretion was detected since even the 
lowest dose of CpG DNA induced a near-maximum luciferase expression. This 
indicated that the concentrations of CpG DNA used were too high and “over-loading” 
the cells, reducing the effect of RAGE. RAGE however showed no effect on TNFα 
stimulation at either doses used. Together, this pre-experiment indicated that RAGE 
could have a specific effect on DNA sensing at lower doses of CpG-B DNA, revealing 
the necessity of using a broader gradient of DNA concentrations.  
 
 
3.4 RAGE increases TLR9-dependent NFκB activation in 
response to DNA stimulation 
 
To further study the impact of RAGE on DNA sensing through TLR9, the previously 
established reporter assay was used, this time with a gradient of DNA extended to 
lower doses (Fig. 3.5). Additionally, to better understand the mechanism by which 
RAGE affects DNA induced NFκB activation, a second RAGE construct lacking the 
cytosolic domain was designed (RAGE ΔCyt, Fig. 3.5A). RAGE cytosolic domain 
was previously proposed to serve a signaling function upon binding of other RAGE 
ligands such as S100 proteins and AGEs. Consequently and as for other RAGE 
ligands, if binding of DNA to RAGE induced a direct signaling cascade through 
interaction of RAGE cytosolic domain with adaptor proteins like mDia-1, RAGE ΔCyt 
should abolish any such RAGE-dependent effect. Moreover, to examine the role of 
TLR9 in the DNA-induced immune response downstream of RAGE, TLR7 expressing 
cells were treated identically to TLR9 expressing cells. As expected, cells expressing 
TLR9 showed a dose-dependent increase in gaussia luciferase release upon CpG-B 
DNA stimulation while TLR7 expressing cells showed no response (Fig. 3.5B). 
Interestingly, cells expressing TLR9 together with RAGE presented an even stronger 
NFκB activity compared with cells expressing TLR9 alone (Control). Intriguingly, cells 
expressing TLR9 together with RAGE ΔCyt showed an identical increase in NFκB 
activity to the one found with RAGE FL, when compared to the control cells.  
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Figure 3.5 RAGE increases TLR9-dependent NFκB activation in response to 
DNA stimulation. 
(A) Schematic representation of the RAGE full length (RAGE FL) or cytosolic domain 
truncated (RAGE ΔCyt) constructs used in (B). Constructs were tested for expression 
by transient transfection of HEK293 cells and subsequent western-blot analysis of 
protein content of cell lysates (right side). (B) HEK293 cells stably expressing TLR9 
or TLR7 were transiently transfected with an NFκB–driven luciferase reporter and 
RAGE FL, RAGE ΔCyt, or mCherry (Control). Cells were stimulated for 20 h with a 
dose titration of ODN 2006 or a 48-mer DNA molecule corresponding to two ODN 
2006 sequences (2x CpG 2006) and R848 (1 µM) or TNFα (1 ng/mL) as controls. 
After incubation, cell supernatants were harvested and luciferase activity measured. 
Data is shown as mean ± SD for duplicate samples and is representative of four 
similar experiments. (C) Expression level of RAGE or RAGE ΔCyt in unstimulated 
cells from (B) was assessed by Western blotting. Anti-β-actin antibodies were used 
for loading control. 
Part of the experiment presented in (B-C) was included in the manuscript published 
in the Journal of Experimental Medicine ((228), please see joined manuscript). 
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This suggests that direct downstream RAGE signaling is either insignificant or 
nonexistent in this context. Cells expressing TLR7 together with either RAGE 
constructs showed no NFκB activity upon CpG-B DNA stimulation. Together with the 
previous finding, this showed that RAGE expression increases the activation of NFκB 
upon DNA stimulation in a TLR9-dependent manner. When stimulated with a longer 
DNA agonist (48-mer corresponding to 2x ODN 2006), TLR9 cells showed an 
enhanced NFκB activation when compared to cells stimulated with 24-mer ODN 
2006. However, cells expressing TLR9 together with RAGE presented an even 
greater increase of NFκB activation than found with 24-mer DNA stimulation and this 
at lower doses of DNA. 
Cells stimulated with TNFα showed a strong NFκB activation, which was comparable 
no matter whether cells expressed RAGE FL, RAGE ΔCyt or neither of them. TLR7 
expressing cells stimulated with R848, a small TLR7 specific agonist, showed a good 
NFκB activation without any apparent effect of RAGE expression.  
Together, these results showed that RAGE expression specifically increases TLR9-
dependent NFκB activation upon DNA stimulation. RAGE lowered the threshold of 
DNA concentration for efficient activation of TLR9.  
 
 
3.5 RAGE interacts with TLR9 
 
To study potential co-localization of RAGE with TLR9, the glioma epithelial cell line 
U373 was used, which expressed TLR9-YFP fusion protein either alone or together 
with RAGE. After 1h stimulation with biotinylated ODN 2006, cells were lysed and 
TLR9-RAGE interaction was assessed by co-immunoprecipitation (co-IP) (Fig. 3.6).  
Protein-A beads coated with anti-GFP antibodies were first used for co-IP with TLR9 
as bait (left panel). Interestingly, RAGE was co-precipitated with TLR9 as shown by 
the band appearing in lane 4 and which was absent from lanes corresponding to 
cells expressing TLR9 alone (lane 2-3). Moreover, when cells were stimulated with 
ODN 2006, the amount of RAGE co-precipitating with TLR9 strongly increased (lane 
5). This suggested that trafficking of RAGE to the endolysosomal compartment was 
increased upon DNA stimulation. It is also possible that the TLR9-RAGE interaction 
increases or is stabilized by DNA.  
When using streptavidin-coated beads for co-IP (middle panel), unstimulated cells 
(lanes 1 and 3) presented bands with a size corresponding to TLR9 full-length 
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suggesting the co-IP to be unspecific to some extent. In the RAGE immunoblot, a 
band consistent with the size of RAGE also appeared for non-stimulated cells (lane 
3). However, when cells were stimulated with biotinylated DNA, the amount of RAGE 
that co-precipitated strongly increased (lane 4). This suggested that RAGE interacted 
with DNA further confirming our previous results. More interestingly, in the TLR9 
immunoblot, bands of approximately 115 kDa only appeared when cells had been 
stimulated. The size of these bands corresponded to the size of the activated TLR9, 
which is truncated between LRRs 14 and 15 (80, 81). The specific co-precipitation of 
TLR9 with biotinylated DNA indicated that the interaction between TLR9 and its DNA 
ligand took place in the endolysosomal compartment. 
As control for TLR9 and RAGE expression, a western-blot was done using input 
samples. This showed a comparable expression of TLR9 across all conditions used 
in this experiment as well as a comparable RAGE expression in the corresponding 
cells.  
Confirming these results, flow cytometry as well as confocal microscopy experiments 
were undertaken to further study the influence of RAGE on DNA internalization and 
trafficking (results presented on Figure 6 of the manuscript published in the Journal 
of Experimental Medicine, (228), please see joined manuscript). 
 
 
 
 
Figure 3.6 RAGE interacts with TLR9. 
U373 cells expressing TLR9-YFP with or without RAGE were either left untreated or 
stimulated with untagged or biotin-tagged (for the biotin-IP) ODN 2006 for 1 h at 
37°C before cells lysis. TLR9 or biotin were subsequently immunoprecipitated using 
anti-GFP-antibody- or streptavidin-coated beads respectively. TLR9 and RAGE 
protein content was subsequently assessed by Western blotting using specific 
antibodies. Cell lysates were controlled for TLR9 and RAGE total expression (Input). 
* To control for co-IP specificity, beads were left non-coated (lane 1). No band 
appeared for TLR9 and only a smaller band appeared in the RAGE immunoblot and 
was therefore considered to be unspecific. Black arrowheads indicate bands for 
TLR9 or RAGE target proteins; nonspecific band is indicated by grey arrowhead. 
Data is representative of three similar experiments. 
Part of the data presented in this figure was included in the manuscript published in 
the Journal of Experimental Medicine ((228), please see joined manuscript). 
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These experiments showed that RAGE expression induces a greater internalization 
of DNA to the endolysosomal compartment where RAGE and DNA colocalize 
together with markers of the early (Rab-5a) and late (Rab-9a) endosomal 
compartments. 
Together, these results demonstrated that upon binding to RAGE at the cell surface, 
DNA is internalized and transported to the endolysosomal compartment where it is 
transferred to TLR9.  
 
 
3.6 Conclusion to Results – Part1 
 
The data presented in this section showed that DNA binds to RAGE through 
electrostatic interaction between the phosphate backbone of DNA and RAGE V-C1 
ectodomain. Upon binding to RAGE at the cell surface, DNA is internalized together 
with RAGE and traffics towards the endo-lysosomal compartment. Through this 
mechanism, RAGE expression increases DNA uptake, thereby lowering the 
threshold of the DNA concentration necessary for TLR9-dependent immune 
activation and amplifying subsequent NFκB activation. Results also indicated an 
interaction between RAGE and TLR9, which could be part of the mechanism 
involved in RAGE-dependent increase of immune stimulation.  
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4. Results – Part 2: RAGE senses RNA at the cell 
surface and promotes TLR7-, TLR8- and TLR13-
dependent inflammatory responses † 
 
4.1 TLR specific RNA agonists bind to RAGE ectodomain 
 
Results presented earlier indicated that DNA binds to RAGE via electrostatic 
interaction between the V and C1 domains of RAGE and the phosphate backbone of 
the DNA. Bases were dispensable for the interaction to take place. The backbone of 
RNA could therefore interact with RAGE in a manner similar to DNA.  
Hence, the interaction of RAGE with immune-stimulatory RNA molecules was 
subsequently studied. Electrophoresis mobility shift assay (EMSA) was first used to 
study the mobility of Oregon green (TLR7 and TLR8 agonists) or FAM (ORN Sa19) 
labeled RNA molecules (Fluo-RNA) in a polyacrylamide gel after incubation with 
RAGE (Fig. 4.1). At stable concentration of labeled RNA, increasing concentration of 
purified RAGE V-C1-C2 ectodomain induced a dose dependent shift in the mobility of 
the RNA, while BSA, used as negative control, did not. All RNA molecules showed 
similar interaction with V-C1-C2. Interestingly, at higher concentration of V-C1-C2 
protein, oligomers of lower electrophoretic mobility formed as shown by the 
appearance of bands in the higher part of the gel. This indicated that the V-C1-C2 
domain could oligomerise around the labeled RNA. To control that RAGE interacts 
with the RNA and not the label, unlabeled RNA corresponding to each specific RNA 
sequence was used as a binding competitor. As expected, the unlabeled RNA 
competed efficiently with the labeled RNA, demonstrating specificity of the 
interaction. Together, these results showed that RNA molecules, specific agonists of 
the endosomal TLR7, 8 and 13, indeed interact with the extracellular domains of 
RAGE. 
Interestingly, B-type DNA molecules (ODN 2006 and ODN 2137) could also compete 
with the TLR8 specific RNA for binding to RAGE (Fig. 4.2A-B respectively).  It is 
                                                
† A modified version of the results discussed in this part of the thesis is being peer reviewed 
for publication at the Journal of Immunology. 
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worth of note, that ODN 2006 also efficiently competed with TLR7 and TLR13 
specific agonists for binding to RAGE (data not shown). These results suggested that 
the site of RNA binding to RAGE is similar to the one used by DNA for interacting 
with RAGE. 
 
 
 
Figure 4.1 RNA binds to recombinant RAGE. 
RAGE binding to RNA agonists was assessed by electrophoretic mobility shift assay (EMSA). 
Oregon green (TLR7- or TLR8-RNA) or FAM (Sa19-RNA) labelled RNA oligonucleotides 
(Fluo-RNA, 250nM) were incubated with increasing amounts of recombinant RAGE 
extracellular domain (V-C1-C2; 1-10 µM) or BSA (10 µM). Increasing concentration of the 
corresponding un-labelled RNA (RNA; 0.63-40 µM, except for Sa19-RNA; 0.63-20 µM) were 
added to constant concentration of Fluo-RNA (250 nM) and with RAGE (2.5 µM). Shift in 
labelled RNA mobility was measured by fluorescence detection. Data is representative of at 
least two independent experiments. 
 
 
 
Figure 4.2 DNA can compete with RNA for binding to recombinant RAGE. 
(A-B) RAGE binding to RNA agonists was assessed by electrophoretic mobility shift assay 
(EMSA). Oregon green labelled TLR8-RNA oligonucleotides (250nM) was incubated with 
increasing amounts of recombinant RAGE extracellular domain (V-C1-C2; 1-10 µM) or BSA 
(10 µM). Increasing concentration of un-labeled ODN 2006 (A) or ODN 2137 (B) (0.63-40 µM) 
were added to constant concentration of TLR8-RNA (250 nM) and with RAGE (2.5 µM). Shift 
in labelled RNA mobility was measured by fluorescence detection. 
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Figure 4.2 DNA can compete with RNA for binding to recombinant RAGE. 
Note: For detailed legend, please see opposite page. 
 
 
4.2 RNA binds to cells expressing full-length RAGE but not to 
cells expressing truncated RAGE lacking the V-C1 domain 
 
The recruitment of RNA molecules at the surface of cells expressing RAGE was 
subsequently studied. To this end, HEK293-XL cell lines expressing TLR7-HA or 
TLR8-HA as well as either full-length RAGE (RAGE FL) or a mutant of RAGE lacking 
the V and C1 domains (RAGE ΔVC1) fused to mCitrine or TagRFP fluorescent 
proteins were produced (Fig. 4.3A).  
First, flow cytometry was used to examine the cell surface binding of RNA to RAGE 
FL- or RAGE ΔVC1-mCitrine expressing cells (Fig. 4.3B-C). Measurement of 
mCitrine fluorescence confirmed that both cell lines expressed similar amounts of 
RAGE (Fig. 4.3B, lower panel). Cells expressing RAGE FL bound more RNA at their 
surface than non-transduced cells (control) or than cells expressing RAGE ΔVC1 
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after 15 minutes incubation at 37ºC (Fig. 4.3B-C). Interestingly, the amount of RNA 
binding to the cells expressing RAGE FL was positively correlated to the amount of 
RAGE-mCitrine expression (Fig. 4.3B, dotplots). In contrast, RNA binding to RAGE 
ΔVC1 expressing cells did not correlate with the amount of RAGE ΔVC1 expression. 
No significant binding of streptavidin-AlexaFluor647 to the cells was observed when 
added in absence of biotinylated nucleic acids. Together, these findings indicate that 
RAGE enhances RNA binding to cells. However, the recruitment of RNA to non-
transduced cells or to cells expressing RAGE ΔVC1 suggested the presence of one 
or several RNA receptors other than RAGE at the surface of the cells used in this 
experiment.  
 
To corroborate the flow-cytometry results, confocal microscopy was used to study 
the recruitment of labeled RNA to cells expressing either RAGE constructs (Fig. 
4.4A). Cells expressing RAGE FL presented a strong accumulation of fluorescent 
RAGE at the cell-to-cell boundary, which was expected from the crystal structure 
mentioned earlier (Fig. 3.2B). Moreover, cells expressing RAGE ΔVC1 did not show 
such accumulation of fluorescence. When incubating labeled RNA agonist (TLR8-
RNA and ORN Sa19) for 15 minutes with RAGE expressing cells, the fluorescence 
signal from the RNA nearly completely co-localized with that derived from RAGE FL. 
In contrast, cells expressing RAGE ΔVC1 showed almost no surface binding of 
labeled RNA. Interestingly, non-stimulatory RNA (NS-RNA) was also recruited to 
RAGE FL but not RAGE ΔVC1 suggesting that, as observed for DNA, RNA binds to 
RAGE sequence-independently. As expected, labeled single stranded CpG 2006 
bound to RAGE at the cell surface in a similar manner to RNA. Streptavidin-
AlexaFluor488 addition to RAGE FL and RAGE ΔVC1 expressing cells in the 
absence of biotinylated nucleic acids failed to bind to cells. As anticipated, Western 
blot analysis showed that both cell lines expressed a similar amount of RAGE (FL or 
dVC1, Fig. 4.4B).  
 
 
Figure 4.3 RNA binds to cells expressing full-length RAGE but not to cells 
expressing truncated RAGE lacking the V-C1 domain. 
(A) Schematic representation of the RAGE-fluorescent protein fusion constructs used in 
FACS and confocal microscopy. (B) HEK293-XL cells stably expressing TLR7-HA or TLR8-
HA alone (control) or together with RAGE FL or RAGE ΔVC1 fused to mCitrine were 
incubated at 37ºC for 15 min with streptavidin-AlexaFluor647 labeled biotinylated RNA (5 
µM). Cells were incubated with streptavidin-AlexaFluor647 alone (1 µM) to control for binding 
specificity. Dashed lines are representative of non-stimulated cells. Data in (B) represents 
FACS plots from one experiment representative of three independent experiments 
summarized in (C) where data represents the mean ± SEM of median fluorescence intensities 
from three independent experiments. p***  < 0.0001. 
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Figure 4.3 RNA binds to cells expressing full-length RAGE but not to cells 
expressing truncated RAGE lacking the V-C1 domain. 
Note: For detailed legend, please see opposite page. 
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Figure 4.4 RNA binds to cells expressing full-length RAGE but not to cells 
expressing truncated RAGE lacking the V-C1 domain. 
Note: For detailed legend, please see opposite page. 
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Together, these findings demonstrated that, as for DNA, RNA is recruited to RAGE at 
the cell surface through a sequence un-specific interaction of RNA with RAGE V-C1 
domains. 
 
 
4.3 RAGE increases RNA internalization 
 
The previously published manuscript showed that RAGE expression induces 
increased internalization of DNA ((228), please see joined manuscript). The role of 
RAGE in RNA internalization was therefore further studied using confocal 
microscopy.  
To this end, HeLa cell lines expressing RAGE FL or RAGE ΔVC1 fused to TagRFP 
were produced (Fig. 4.5). After 5 minutes incubation with labeled RNA, cells 
expressing RAGE FL already showed a strong recruitment of RNA to the plasma 
membrane that co-localized with RAGE FL forming rounded clusters (Fig. 4.5A). In 
contrast, cells expressing RAGE ΔVC1 did not show any plasma membrane 
recruitment of RNA. After 60 minutes incubation with labeled RNA, cells expressing 
RAGE FL presented a pronounced internalization of RNA in vesicles also positive for 
RAGE, while cells expressing RAGE ΔVC1 showed very little internalization of RNA.  
To quantify RAGE-dependent internalization of RNA, analysis of the co-localization 
between the fluorescence signals corresponding to RNA and RAGE showed that the 
RNA signal strongly correlated to the RAGE signal in cells expressing RAGE FL (Fig. 
4.5B). On the contrary, in cells expressing RAGE ΔVC1, the RNA signal showed only 
a very weak co-localization with RAGE. 
 
 
 
 
Figure 4.4 RNA binds to cells expressing full-length RAGE but not to cells 
expressing truncated RAGE lacking the V-C1 domain. 
(A) HEK293-XL cells stably expressing TLR8-HA together with RAGE FL or RAGE ΔVC1 
fused to TagRFP were stimulated with biotinylated RNA or DNA labeled with streptavidin-
AlexaFluor488 (5 µM) for 15 min at 37°C. DRAQ5 (1:2000) was used as nuclear staining. To 
control for binding specificity, cells were also incubated with streptavidin-AlexaFluor488 
alone. The main images represent merged channels corresponding to RAGE-TagRFP (red), 
labeled RNA (green) and DRAQ5 (blue). Scale bars represent 10 µm. Split channels are 
represented on the right with the same color-coding. (B) HEK-XL TLR8-HA cells used in (A) 
were tested for RAGE FL- and RAGE ΔVC1-TagRFP expression by Western-blot. RAGE 
expression was detected using anti-TagRFP antibodies. Anti-β-actin antibodies were used as 
a loading control. Images are representative of at least two experiments. 
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Figure 4.5 RAGE increases RNA internalization. 
(A) HeLa cells stably expressing RAGE FL or RAGE ΔVC1 fused to TagRFP were 
stimulated with labeled RNA (5 µM) for 5 min or 60 min at 37°C prior to fixation and 
nuclear staining with DRAQ5. To control for binding specificity, cells were also 
incubated for 60 minutes with streptavidin-AlexaFluor488 alone (1 µM). Images are 
representative of one experiment performed three times. The main images represent 
merged channels corresponding to RAGE-TagRFP (red), labeled RNA (green) and 
DRAQ5 (blue). Scale bars are representative of 10 µm. A zoomed area of each 
image is represented on the right side, with merged channels (top left) and separated 
channels with same color coding. (B) Data represents mean ± SEM of median 
correlations of RNA to RAGE from three independent experiments. p* <0.05, p** 
<0.0005 and p*** <0.0001. (C) HeLa cells used for microscopy experiments were 
tested for RAGE-TagRFP expression by western-blot using anti-TagRFP antibodies. 
Anti-β-actin antibodies were used for loading control. Images are representative of at 
least two experiments.  
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Of note, both HeLa cell lines expressed similar amounts of RAGE (FL or ΔVC1) as 
shown by western-blot (Fig. 4.5C). Together these results suggested that, as for 
DNA, RAGE expression increases RNA internalization by acting as a transporter that 
could deliver RNA to RNA-sensing TLRs in endolysosomal compartments. 
 
4.4 RAGE amplifies the TLR-dependent inflammatory 
response induced by RNA stimulation 
 
Following the finding that expression of RAGE at the cell surface increases 
extracellular RNA recruitment and subsequent internalization, the impact of RAGE 
expression on the immune activation induced by RNA was evaluated. HEK293-XL 
cells expressing TLR7, TLR8 or TLR13 were transfected with a plasmid coding for 
full length RAGE or a control plasmid coding for mCherry. 
Cells were concomitantly transfected with a reporter plasmid containing an NFκB 
target promoter flanked by the sequence coding for gaussia luciferase (Fig. 4.6).  
Following overnight RNA stimulation, NFκB activity of cells expressing RAGE was 
stronger than in cells transfected with the control plasmid (Fig. 4.6A). Interestingly, 
RAGE only increased the response of cells stimulated with TLR specific RNA 
agonists. Cells treated with non-stimulatory control RNA (shown previously to bind to 
RAGE at the cell surface, Fig. 4.3D) presented no increase of luciferase secretion 
regardless of RAGE expression. Furthermore, RAGE had no effect on R848 or IL-1β 
stimulation. This suggests that the immune response to stimulatory RNA is TLR 
dependent but can be increased by the presence of RAGE at the cell surface. 
Previous data (Fig. 3.1) showed that a minimum length of 15 nucleotides was 
necessary for DNA to bind to RAGE. The fact that RAGE did not affect TLR7 
activation by R848 was therefore expected since R848 is a small synthetic 
compound. As control, RAGE expression in non-stimulated cells was detected by 
western-blot and showed a similar expression across all experiments (Fig. 4.6B). 
Endogenous expression of RAGE was not detectable in the HEK-XL cells used. 
These results demonstrate that RAGE, by recruiting RNA at the cell surface, 
amplifies the activation of TLRs by single stranded RNA and the ensuing pro-
inflammatory NFκB pathway.   
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Figure 4.6 RAGE amplifies the TLR-dependent inflammatory response induced 
by RNA stimulation. 
(A) HEK293-XL cells stably expressing human TLR7, TLR8 or mouse TLR13 were transiently 
transfected with an NFκB-driven luciferase reporter together with full length non-tagged 
human RAGE or mCherry as control. Cells were stimulated for 16h with a gradient of either 
specific RNA agonist (TLR7-RNA, TLR8-RNA, Sa19-RNA), R848, non-stimulatory RNA (NS-
RNA) or IL-1β. After incubation, cell supernatants were harvested and luciferase activity 
measured. Data is shown as mean ± SD for triple experimental replicates and is 
representative of at least three similar experiments. (B) Unstimulated cells from (A) were 
lysed in LDS-loading buffer after harvest of supernatants. Samples were analyzed by 
Western-blotting for RAGE expression. Anti-β-actin antibodies were used for loading control. 
Images are representative of at least three separate experiments. 
  67 
4.5 RAGE deficiency decreases the response of bone marrow 
cells to RNA 
 
To test the relevance of RAGE-dependent RNA signaling, bone marrow was isolated 
from wild-type (WT) or RAGE deficient (KO) mice (Fig. 4.7).  
 
 
 
Figure 4.7 RAGE deficiency decreases the response of bone marrow cells to 
RNA. 
(A-B) Bone marrow cells isolated from wild-type (WT) or RAGE knockout (KO) mice were 
stimulated with TLR13 agonist (Sa19-RNA, 0.1µg/mL and 0.5µg/mL), TLR9 agonist 
(ODN1826, 0.1 µM) or LPS (0.1µg/mL). TNFα (A) or IL-6 (B) secretion into supernatants was 
sampled over 4h at the indicated time points and quantified using HTRF. (C) Ager, Tlr4, Tlr9 
and Tlr13 mRNA expression from non-stimulated cells was measured by qPCR. mRNA level 
of target genes was normalized to the Hprt mRNA level. Data in (A-C) represents mean ± 
SEM with n = 5 in both WT and KO groups. p* <0.05, p** <0.0005 and p*** <0.0001. Note: in 
(B) IL-6 secretion upon Sa19-RNA at 0.1µg/mL was non-detectable and therefore not 
represented. 
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Murine bone marrow has previously been used to study the effect of RAGE for DNA-
HMGB1 complex sensing without need for differentiation (126). Here, bone marrow 
cells were directly stimulated after isolation either with TLR13 specific agonist (Sa19-
RNA), type-B CpG DNA (1826-DNA) or LPS. TNFα and IL-6 content of supernatants 
was then sampled at indicated time-points. Interestingly, RAGE deficiency resulted in 
decreased and delayed TNFα secretion upon RNA stimulation (Fig. 4.7A, top 
panels), while DNA and LPS-induced cell activation were not affected (Fig. 4.7A, 
lower panels). Similar results were obtained with IL-6 cytokine levels (Fig. 4.7B). 
Indeed, RAGE deficiency resulted in decreased IL-6 secretion from cells stimulated 
with 0.5 µg/mL Sa19-RNA when compared to WT cells. However, cells stimulated 
with 0.1 µg/mL Sa19-RNA did not produce detectable IL-6 at the time points used 
here (data not shown). As seen with TNFα, IL-6 secretion from cells stimulated with 
either 1826-DNA or LPS showed no effect of RAGE deficiency. The lack of an effect 
of RAGE on the response of bone marrow cells to CpG-B DNA was expected since 
previously published data (126) indicated that complex formation of DNA with 
HMGB1 is necessary to detect an effect of RAGE deficiency when stimulating bone 
marrow cells.  
To verify that the effect induced by RAGE deficiency upon RNA stimulation was not 
an artefact due to a possible RAGE-dependent modulation of TLR expression, RNA 
from unstimulated bone marrow cells was isolated and levels of Ager, Tlr4, Tlr9 and 
Tlr13 transcripts were measured by quantitative real-time PCR (Fig. 4.7C). The 
absence of Ager mRNA in knockout cells first confirmed the knockout of RAGE. 
Moreover, both WT and KO cells presented comparable levels of Tlr4, Tlr9 and Tlr13 
transcripts indicating that RAGE does not regulate the gene expression of the TLRs 
stimulated as showed in Fig. 4.7A-B. Together, these results confirmed the 
importance of RAGE in cell surface sensing of extracellular RNA. 
 
 
4.6 RAGE-dependent amplification of the immune response to 
stimulatory RNA is independent of direct RAGE signaling 
 
Truncation of the cytoplasmic domain of RAGE had no negative effect on RAGE-
induced increase of TLR9 activation by ODN 2006 (Fig. 3.5). The increase of NFκB 
induced by RAGE expression upon DNA stimulation was therefore independent of 
the known signaling pathways activated upon binding of other ligands to RAGE. 
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Consequently, involvement of the intracellular domain of RAGE in the RAGE-
dependent increase of NFκB activation upon RNA stimulation was evaluated.  
 
 
 
 
Figure 4.8 RAGE-dependent amplification of the immune response to 
stimulatory RNA is independent of direct RAGE signaling.  
(A) Schematic representation of the RAGE full length (RAGE FL) or cytosolic domain 
truncated (RAGE ΔCyt) constructs used in (B). (B) HEK293-XL cells stably expressing human 
TLR7 or TLR8 were transiently transfected with an NFκB-driven luciferase reporter together 
with human RAGE FL, RAGE ΔCyt or mCherry as control. Cells were stimulated for 16h with 
a gradient of either specific RNA agonist (TLR7-RNA, TLR8-RNA), R848 or non-stimulatory 
RNA (NS-RNA). After incubation, cell supernatants were harvested and luciferase activity 
measured. Data is shown as mean ± SD for double experimental replicates and is 
representative of at least three similar experiments. (C) Expression level of RAGE and RAGE 
ΔCyt in unstimulated cells from (B) was assessed by Western blotting. Anti-β-actin antibodies 
were used for loading control. Images are representative of at least three separate 
experiments. 
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HEK293-XL cells expressing TLR7 or TLR8 were transfected with either RAGE full 
length (RAGE FL), cytoplasmic domain truncated RAGE (RAGE ΔCyt) or a control 
plasmid coding for mCherry (Fig. 4.8A). As for the previous experiment, cells were 
simultaneously transfected with a luciferase NFκB activity reporter. In TLR7 
expressing cells, both RAGE FL and RAGE ΔCyt constructs induced a similar 
increase of NFκB activation upon RNA stimulation when compared to cells 
transfected with the control plasmid (Fig. 4.8B, top left panel). As expected, neither 
RAGE constructs had an effect on NFκB activation upon R848 or non-stimulatory 
RNA treatment. Curiously, in TLR8 expressing cells, RAGE ΔCyt further amplified the 
effect of RAGE FL upon RNA stimulation (Fig. 4.8B, lower left panel). Indeed, while 
RAGE FL induced an increase of NFκB activation similar to the one found before 
(Fig. 4.6A), RAGE ΔCyt induced an even stronger increase of gaussia luciferase 
release by cells stimulated with RNA. However, this amplification effect was absent 
in cells treated with R848 or non-stimulatory RNA. Of note, western-blot analysis of 
protein contents from unstimulated cells showed that both RAGE FL and RAGE ΔCyt 
were expressed at similar levels.  
Together, these results indicated that RAGE-induced increase of NFκB activation is 
independent of direct RAGE downstream signaling. These results also implicated the 
existence of a different regulation mechanism for the effect of RAGE on RNA-
induced TLR8 activation, which relies on RAGE cytoplasmic domain.  
 
 
4.7 RAGE-induced RNA uptake depends on dynamin and actin 
polymerization  
 
To identify the internalization mechanism involved in RAGE-dependent RNA uptake, 
HEK293-XL cells expressing TLR13 were transfected with either RAGE or a control 
plasmid coding for mCherry together with a luciferase NFκB activity reporter. Cells 
were subsequently treated with different inhibitors of cell internalization prior to 
stimulation with ORN Sa19 (Fig. 4.9). Cytochalasin D inhibits actin polymerization 
necessary to certain internalization pathways such as phagocytosis. Dynasore 
directly inhibits activation of dynamin, a major component of phagocytosis but also of 
clathrin- and caveolin-mediated endocytosis pathways. Finally, SecinH3 is a specific 
inhibitor of guanine nucleotide exchange factors (GEFs) necessary to recycle 
  71 
adenosine diphosphate ribosylation factors (ARFs) GTPases such as ARF6, which 
regulate cytoskeletal organization and are involved in certain type of endocytic 
mechanisms. As shown previously, upon ORN Sa19 stimulation, when comparing to 
cells transfected with the control plasmid, RAGE expression induced an increase in 
luciferase expression induced by NFκB activation (Fig. 4.9)  
 
 
 
 
Figure 4.9 RAGE-induced RNA uptake depends on dynamin and actin 
polymerization.  
(A-C) HEK293-XL cells stably expressing mouse TLR13 were transiently transfected with an 
NFκB-driven gaussia luciferase (gLuc) reporter and an EF-1-driven firefly luciferase (fLuc) 
reporter. Cells were concomitantly transfected with un-tagged human RAGE or mCherry as 
control. Cells were then incubated for 1h at 37°C in the presence of a gradient of endocytosis 
inhibitors (Cytochalasin D, Dynasor or SecinH3) or DMSO (0.2%, v/v). Cells were 
subsequently stimulated for 6h with Sa19-RNA (0.5µg/mL) or IL-1β (0.5ng/mL). After 
incubation, cell supernatants were harvested and cells were lysed in passive lysis buffer. 
Finally, gLuc and fLuc activity was measured from cell supernatants and lysates respectively. 
Data is shown as mean ± SD of fold gLuc/fLuc for triple experimental replicates and is 
representative of at least three similar experiments. 
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However, cells treated with Cytochalasin D or Dynasore showed a dose dependent 
decrease in RNA-induced luciferase expression when compared to DMSO treated 
cells (Fig. 4.9A-B). This inhibition affected both RAGE expressing cells and control 
cells. However, RAGE-induced increase of TLR13 activation subsisted even when 
inhibitors were used. Interestingly, the level of luciferase expression after treatment 
with Cytochalasin D and Dynasore was lower than the one found in control cells 
treated with DMSO, implicating that both RAGE-dependent and independent 
pathways were inhibited. Of note, TNFα stimulation showed no RAGE-dependent 
increase in NFκB activity but was also inhibited by Cytochalasin D and Dynasore 
(Fig. 4.9A-B). In stark contrast with the effect of Cytochalasin D or Dynasore, 
treatment with SecinH3 showed no inhibitory effect on ORN Sa19- and TNFα-
induced NFκB activation and subsequent luciferase expression (Fig. 4.9C). Together 
this data showed that the RAGE-induced RNA uptake depends on dynamin activity 
and actin polymerization but not on ARFs. However, the RAGE-dependent RNA 
internalization seemed to depend on the same mechanisms involved in the RAGE-
independent pathway. Further work, using a larger panel of inhibitors, will be 
necessary to determine whether a difference exists between RAGE-dependent and -
independent RNA internalization mechanisms. 
 
 
4.8 RAGE-RNA interaction, the curious case of TLR3 
activation 
 
To have a complete picture of the influence of RAGE on nucleic acid sensing by the 
endosomal TLRs, it was necessary to study the effect of RAGE expression on double 
stranded RNA (dsRNA) sensing and subsequent TLR3 activation. To this end, 
binding of a synthetic TLR3-specific dsRNA (TLR3-RNA, Fig. 4.10A, (230)) to the 
ectodomain of RAGE was assessed by EMSA (Fig. 4.10B, left panel).  
First, electrophoretic mobility of synthetic TLR3-RNA labelled with Oregon green 
showed a more complex profile than seen before with ssRNA (Fig. 4.1). Indeed, 
TLR3-RNA alone yielded several bands with different mobility in the gel. Two main 
bands were visible (indicated by arrow heads) as well as a smeary pattern present in 
the lower part of the gel. This data would suggested that the TLR3-RNA molecules 
are able to form oligomers of heterogeneous size as suggested by the additional 
bands of lower electrophoretic mobility. This could be explained by the more complex 
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nature of this synthetic dsRNA. It is composed of “unit” sequences containing a 15-
mer alignment sequence followed by a 35-mer poly (I) or poly (C) segment. One poly 
(I) unit is hybridized with one poly (C) unit through their complementary alignment 
sequences. Self-assembly of a dsRNA is permitted by hybridization of poly (I) 
segments with poly (C) segments (Fig. 4.10A).  
Nevertheless, incubation of labelled TLR3-RNA with purified RAGE V-C1-C2 induced 
a dose-dependent shift in the mobility of TLR3-RNA in a manner similar to the one 
previously found with ssRNA. Moreover, with an increasing amount of V-C1-C2 
protein, more bands appeared corresponding to RAGE-RNA complexes with even 
lower electrophoretic mobility. These indicated the capacity for RAGE ectodomains 
to form larger oligomers around dsRNA. However, in contrast to the previous results 
described for ssRNA, when labelled TLR3-RNA was placed in competition with 
unlabelled TLR3-RNA for binding to RAGE, only partial competition was observed. In 
fact, only the bands corresponding to the larger RAGE-dsRNA oligomers 
disappeared. This incapacity of un-labelled RNA to completely compete with the 
labelled RNA for binding to RAGE would suggest that the RNA oligomers can 
reorganise and form oligomers containing both labelled and unlabelled RNA 
molecules. This provided more labelled RNA oligomers that bound to RAGE, re-
equilibrating the RAGE/RNA stoichiometry and decreasing the formation of higher 
size RAGE oligomers. 
Furthermore, B-type DNA induced a dose dependent shift of the labelled TLR3-RNA 
to higher electrophoretic mobility comparable to those found with TLR3-RNA alone 
(Fig. 4.10B, right panel). Unlike TLR3-RNA, unlabelled DNA could not be integrated 
to the dsRNA oligomers and was therefore a better competitor. Although labelled 
TLR3-RNA formed more complicated structures of distinct electrophoretic mobility, 
this data demonstrated that, as for ssRNA, dsRNA could bind to RAGE ectodomain 
at a position close to the one used by DNA.  
 
The effect of RAGE expression on dsRNA sensing was further characterised using 
HEK293 cells expressing human TLR3 (Fig. 4.10C). As done previously, cells were 
transfected with a plasmid coding for full length RAGE or a control plasmid coding for 
mCherry, together with a reporter plasmid containing an NFκB target promoter 
flanked by the sequence coding for gaussia luciferase. After 24h incubation at 37°C, 
cells were stimulated for 16h with either TLR3-RNA, a large synthetic mimetic of 
dsRNA, polyinosinic:polycytidylic acid (poly (I:C)), and IL-1β as RAGE- and TLR3-
independent positive control. All stimuli induced robust gaussia luciferase expression 
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following NFκB activation. However, when compared to cells transfected with the 
control plasmid, RAGE expressing cells surprisingly showed a decreased luciferase 
activity upon stimulation with TLR3-RNA. This antagonistic effect of RAGE on dsRNA 
sensing was in opposition to the previous agonistic effect found for RAGE upon 
ssRNA stimulation.  
 
 
 
 
Figure 4.10 RAGE-RNA interaction, the curious case of TLR3 activation.  
Note: For detailed legend, please see opposite page. 
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Interestingly, RAGE expression induced an increase of NFκB activation upon poly 
(I:C) stimulation similar to those found previously with ssRNA. Of note, RAGE 
expression had no effect on IL-1β induced NFκB activation.  
 
This data suggested the existence of a singular mechanism following dsRNA binding 
to RAGE which negatively regulated TLR3 activation by dsRNA but not poly (I:C). 
One explanation for this heterogeneous effect of RAGE upon stimulation with TLR3-
RNA and poly(I:C) is the difference of size. Indeed, the estimated size of the TLR3-
RNA is 115 bases while the size of the high molecular weight poly (I:C) (poly (I:C) 
HMW) used in the previous experiment ranges between 1.5 to 8 kilobases. To test 
this hypothesis, TLR3 expressing HEK293 cells were transfected as described above 
and incubated at 37°C for 24h. Cells were subsequently stimulated with either high 
molecular weight (HMW) or low molecular weight (LMW, 0.2 to 1kb) poly (I:C) as well 
as with TNFα as RAGE-independent positive control. After 16h incubation, NFκB 
activation was assessed by measurement of gaussia luciferase activity (Fig. 4.10D). 
When compared to cells transfected with the control plasmid, RAGE expression 
induced an increased luciferase expression upon high molecular weight poly (I:C) 
stimulation. Unexpectedly, RAGE expression induced a similar increase in luciferase 
expression upon stimulation with low molecular weight poly (I:C). Of note, RAGE 
expression had no effect on TNFα stimulation. RAGE expression was similar in both 
experiments presented in figures 3.10C and D as shown by western-blot (Fig. 
4.10E).  
 
Figure 4.10 RAGE-RNA interaction, the curious case of TLR3 activation.  
(A) Schematic representation of the structure of the TLR3-RNA agonist used in (B-C). (B) 
RAGE binding to TLR3-RNA agonist was assessed by electrophoretic mobility shift assay 
(EMSA). Oregon green labeled RNA oligonucleotides (Fluo-RNA, 250nM) were incubated 
with increasing amounts of recombinant RAGE extracellular domain (V-C1-C2; 1-10 µM) or 
BSA (10 µM). Increasing concentration of the corresponding un-labeled RNA (RNA, left 
panel) or ODN 2006 (2006-DNA, right panel) (0.63-40 µM) were added to constant 
concentration of Fluo-RNA (250 nM) and with RAGE (2.5 µM). Shift in labeled RNA mobility 
was measured by fluorescence detection. (C) HEK293-XL cells stably expressing human 
TLR3 were transiently transfected with an NFκB-driven luciferase reporter together with full 
length non-tagged human RAGE or mCherry (Control). Cells were stimulated for 16h with a 
gradient of either TLR3-RNA agonist, high molecular weight (HMW) poly (I:C), or IL-1β. After 
incubation, cell supernatants were harvested and luciferase activity measured. Data is shown 
as mean ± SD for triple experimental replicates and is representative of at least three similar 
experiments. (D) HEK293-XL cells stably expressing human TLR3 were transfected as in (C). 
Cells were then stimulated for 16h with a gradient of either high molecular weight (HMW) or 
low molecular weight (LMW) poly (I:C) and TNFα (0.5 ng/mL) as RAGE-independent control. 
After incubation, luciferase activity was measured in supernatants. (E) Unstimulated cells 
from (C-D) were lysed in LDS-loading buffer after harvest of supernatants. Samples were 
analyzed by Western-blotting for RAGE expression. Anti-β-actin antibodies were used for 
loading control. Images are representative of at least three separate experiments. 
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Together, this data showed opposite roles for RAGE towards real dsRNA and the 
mimetic poly (I:C) molecule. The difference of size did not explain these distinct 
effects since RAGE also amplified NFκB activation upon stimulation with a lower size 
form of poly (I:C), with a size comparable to the dsRNA.  
 
 
4.9 Conclusion to Results – Part2 
 
In this result segment, data showed that as for DNA, RNA binds to RAGE V-C1 
domains in a sequence independent manner. The recruitment of ssRNA at the 
surface of cells expressing RAGE induced increased internalization that led to 
stronger immune activation. RAGE-dependent increase of the response to ssRNA 
was dependent on specific stimulation of endosomal TLRs. The cytoplasmic domain 
of RAGE was dispensable, indicating that direct RAGE signaling upon RNA-binding 
is negligible. RAGE internalization was essential and depended on dynamin and 
actin-polymerization. Finally, in stark contrast with its effect on ssRNA sensing, 
RAGE had an antagonistic effect on sensing of dsRNA by TLR3.  
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5. Discussion 
 
Nucleic acid sensing is critical for the organism to detect infection. In the case of 
virus infection, it is often the only molecule detectable by the innate immune system. 
All nucleic acid specific PRRs are situated inside the cells, either in the cytoplasm or 
in the endosome. Nucleic acids mostly reach these receptors after internalization of 
the microorganism itself. This is the reason why much of the research done in the 
area of nucleic acid sensing has used liposome based transfection reagents to 
stimulate the diverse panel of intracellular receptors. However, it has become evident 
that extracellular nucleic acids exist and their concentration increases upon infection 
(92). Perhaps more importantly, extracellular nucleic acids of endogenous origin 
have been found in conditions of cell stress and tissue damage. Hence, 
comprehending how such extracellular molecules are internalized prior to being 
sensed by their putative receptor is an important step in the general understanding of 
the effects of infection or sterile injury on host immunity.  
The work presented in this thesis supplies further clues on the mechanisms involved 
in extracellular nucleic acid entry and strengthens the crucial role of RAGE in the 
development of inflammation. 
 
 
5.1 RAGE transports nucleic acids to their putative 
endosomal receptor  
 
The finding that RAGE recruits nucleic acids at the surface of cells before insuring 
their internalization supports the idea of the existence of mechanisms that evolved to 
sense the abnormal presence of nucleic acids in the extracellular milieu. In fact, 
RAGE is not the only cell surface receptor capable of recruiting nucleic acids. 
Indeed, the endocytic C-type lectin receptor DEC-205 was previously shown to bind 
CpG-rich DNA at the surface of dendritic cells and B lymphocytes, thereby promoting 
a TLR9-dependent immune activation and cell maturation (9). Interestingly, as for 
RAGE, the CpG motif was dispensable for binding to DEC-205. This implicates a 
common sequence-unspecific mechanism for sensing extracellular DNA that would 
enable recognition of a larger array of nucleic acids from the surface, entrusting 
specificity to the intracellular PRR. The scavenger receptors SR-A and MARCO are 
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further examples of cell surface receptors for nucleic acid. Indeed, both were shown 
to bind CpG-rich DNA as well as RNA at the cell surface and promoted endosomal 
TLR stimulation (101, 102, 231).  
 
Another common trait that these cell surface nucleic acid receptors seem to share 
with RAGE is the apparent absence of direct downstream signaling and the need of 
other putative signaling receptors for immune activation. Results presented in this 
thesis show that RAGE merely recruits nucleic acids at the cell surface and 
enhances their internalization. Use of a mutant of RAGE lacking the intracellular 
signaling domain showed a similar increase in NFκB activation upon stimulation with 
DNA or RNA than found with full-length RAGE. Furthermore, when expressed in cells 
lacking TLR9, RAGE alone produced no detectable immune activation. In a similar 
manner, cells expressing RAGE together with either TLR7 or TLR8 showed no 
responsiveness towards non-stimulatory RNA even though this RNA was found to 
bind efficiently to RAGE. Interestingly, a previous study reached a similar conclusion 
for S100B-dependent nitric-oxide (NO) production by microglial cells (232). Although 
RAGE was necessary for NO production upon stimulation with S100B, the cytosolic 
domain of RAGE was dispensable. It would thus appear that RAGE behaves in a 
‘double-standard’ manner towards its ligands inducing either (1) a direct activation of 
pro-inflammatory pathways upon ligand binding or (2) the internalization of ligands 
such as nucleic acids towards a secondary receptor able to trigger downstream pro-
inflammatory pathways. 
Microscopy data presented in this thesis showed the concomitant cell internalization 
of RNA together with RAGE, further reinforcing the idea of RAGE acting as 
transporter of nucleic acid towards endosomal TLRs (Fig. 5.1). Interestingly, others 
had already pointed out the importance of RAGE internalization upon ligand binding 
(126, 224, 227). Here, experiments using endocytosis inhibitors demonstrated that 
RAGE-dependent RNA endocytosis requires actin polymerization and dynamin 
activity. Strikingly, these inhibitors repressed both RAGE-dependent and 
independent NFκB activation. This would suggest that nucleic acid internalization 
upon binding to various cell surface receptors is regulated by the same mechanisms. 
Even though this data provides a first clue about the mechanisms involved in RAGE-
mediated nucleic acid internalization, a deeper study of these mechanisms will be 
necessary. The identification of the different players involved in nucleic acid 
endocytosis would provide a better picture of the involvement of RAGE in the 
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regulation of this crucial process and will help pinpoint potentially different receptor-
mediated nucleic acid internalization pathways.  
The surprising inhibiting effect of RAGE on TLR3 activation by dsRNA further 
underlined the need for a better understanding of the regulation mechanisms 
involved in RAGE internalization and trafficking (Fig. 5.2). The antagonistic effect of 
RAGE upon stimulation with dsRNA could be explained in several ways. One of the 
more plausible possibilities would be for RAGE trafficking to be directed towards a 
TLR7, TLR8 or TLR9 positive compartment while being unable to traffic towards 
TLR3 containing endosomes and therefore sequestrating dsRNA away from TLR3. In 
fact, some evidence exists for TLR3 distinctive trafficking that would sustain this 
theory. Indeed, several studies described the possible plasma membrane localization 
of TLR3 (233, 234). These studies suggest that TLR3 localization at the cell surface 
enables ligand binding and is a pre-requisite for TLR3 activation. Expression of 
RAGE at the cell surface and binding to dsRNA would thus compete with TLR3 for 
ligand binding and thereby antagonize TLR3-dependent immune activation (Fig. 5.2).  
 
 
Figure 5.1 RAGE transports nucleic acids to their putative endosomal receptor.  
Binding of nucleic acids by RAGE at the cell surface promotes their internalization and 
trafficking towards TLR9 (DNA), TLR7, TLR8 and TLR13 (ssRNA). This amplified 
internalization of nucleic acids increases the activation of the TLRs and their downstream 
signaling cascades, resulting in a strengthened expression of type-I IFN and pro-inflammatory 
cytokines.  
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5.2 RAGE and cytosolic nucleic acid sensing 
 
While investigating the role of RAGE in dsRNA sensing, a striking discrepancy 
appeared concerning the effect of RAGE on immune activation induced by either real 
dsRNA or its synthetic analog poly (I:C). In fact, while antagonizing TLR3 activation 
by specific dsRNA agonist, RAGE expression enhanced NFκB activation upon 
stimulation with poly (I:C) (Fig. 5.2). It is important to note that poly (I:C) has been 
described as an agonist of PRRs other than TLR3, namely MDA5 (235) and protein 
kinase R (PKR, (236, 237)). These cytosolic receptors are known inducers of 
downstream NFκB signaling. Hence, upon poly(I:C) treatment, RAGE might play a 
similar role to the one previously described for stimulation of TLR7, TLR8 and TLR13 
by ssRNA. RAGE would increase dsRNA internalization and, following transfer to the 
cytoplasm, would promote activation of MDA5 or PKR (Fig. 5.2). A recent study 
supports this hypothesis. Indeed Liu and colleagues recently found a role for RAGE 
in activation of AIM2 by the HMGB1-poly(dAdT) complex (238).  
 
 
Figure 5.2 RAGE inhibits dsRNA-induced TLR3 activation and favors 
stimulation of cytosolic receptors.  
The presence of RAGE at the cell surface competes with TLR3 for ligand binding and thereby 
inhibits TLR3 activation and its downstream signaling. While antagonising TLR3, the cell 
surface binding of dsRNA to RAGE might promote the activation of cytosolic nucleic acid 
receptors such as PKR and MDA5.  
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The authors show that RAGE expression amplifies early activation of AIM2. This 
would indicate that RAGE-dependent activation of cytosolic receptors by nucleic acid 
is possible. The activation of such cytosolic receptors by extracellular RNA through 
RAGE will therefore deserve further attention in the future. 
Interestingly, recent publications presented DNA-RNA hybrids as agonists of TLR9 
(239) and cGAS-STING (240). When placed in parallel with the results presented in 
this thesis, these publications call for further investigation into the role of RAGE in 
sensing these byproducts of viral replication and so for both TLR9- and cGAS-
dependent pathways.  
 
 
5.3 HMGB1, RAGE and nucleic acids 
 
As described before, RAGE is a crucial sentinel for tissue damage and cellular 
stress. Indeed, RAGE senses many molecules released by damaged cells such as 
S100 proteins and HMGB1. HMGB1 is an important nuclear associated protein that 
acts as alarmin when actively or passively released by stressed cells (152, 241-243). 
HMGB1 has been shown to trigger inflammation in the context of infection and 
sepsis, but perhaps most importantly in the context of sterile tissue damage such as 
are found in reperfusion injury or trauma. HMGB1 triggers inflammation upon binding 
to several receptors such as TLR2, TLR4, IL-1R and RAGE. Interestingly, HMGB1 
often interacts with these receptors while in complex with other molecules that are 
the primary ligand for the targeted receptor. In fact, HMGB1 was shown to interact 
with nucleosome or LPS thereby activating TLR2 or TLR4 respectively (244, 245). 
HMGB1 was also found to increase IL-1R avidity for IL-1β and thereby increase IL-
1R activation (246). As mentioned earlier, similar results were found for HMGB1 in 
complex with DNA where RAGE-dependent inflammatory pathways were highly 
amplified by the presence of HMGB1 (126, 238). Importantly, HMGB1 is known to 
bind RNA and was previously shown to enhance the pro-inflammatory potential of 
RNA to activate both endosomal TLRs and cytosolic RNA receptors (247, 248). Data 
presented in this thesis together with the numerous studies implicating HMGB1 with 
DNA and RNA sensing, all point towards the function of the collaboration of RAGE 
and HMGB1 in amplifying sensing of DNA and RNA. While the cooperation of 
HMGB1 with RAGE in the exacerbation of DNA-induced TLR9 and AIM2 activation is 
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known, no data has yet been published that makes the link between HMGB1-RNA 
binding and RAGE-dependent internalization prior to a pro-inflammatory immune 
response. It would therefore be of great importance to test the effect of HMGB1 in 
the system presented herein.  
 
 
5.4 RAGE, nucleic acid and disease development  
 
Extracellular nucleic acids have been implicated in many inflammatory settings such 
as infection and auto-inflammatory diseases (249). One of the best described 
pathologies mediated by extracellular nucleic acids is systemic lupus erythematosus 
(SLE). This rare autoimmune disease involves the production of antibodies against 
the host’s own nucleic acids when these are released in the extracellular milieu after 
cell apoptosis or necrosis. Cell death occurs in both physiological and pathological 
settings. The development of autoimmune diseases such as SLE therefore depends 
on multifactorial events that will trigger more cell death or a defective clearance of 
generated cell debris. Nevertheless, production of auto-antibodies allows formation 
of immune complexes (ICs) that contain nucleic acids and facilitates their entry into 
the cells leading to the activation of endosomal or cytosolic nucleic-acid sensors 
(249, 250). Entry of these immune complexes depends on cell surface receptors 
which, depending on the cell type, can be Fc-receptors, the B-cell receptor or RAGE. 
Indeed, as previously mentioned, RAGE is involved in the sensing of ICs that not 
only contain DNA but also contain HMGB1 (126). Interestingly, SLE has been shown 
to not only depend on the formation of DNA-ICs and TLR9 activation but also on the 
presence of extracellular RNA (251). In fact, TLR7 was shown to be an important 
mediator of inflammation during SLE and evidence pledges for the importance of 
RNA and RNA-containing immune complexes in the development of SLE. TLR 
deficiency studies found a surprising exaggeration of pDC activation and IFN-α 
release in TLR9-/- lupus mice (252). On the contrary, TLR7 deficiency or inhibition 
decreased the immune activation in these mice (252, 253). Furthermore, TLR7 
expression in B cells was shown to exacerbate anti-RNA antibody production and 
disease in SLE mice (254). This data argues for the importance of extracellular RNA 
and RNA-ICs in the development of SLE. Together with the present results 
demonstrating RAGE as receptor for RNA, these studies underline the idea of a 
possible role for RAGE in the internalization of RNA-ICs and increase of TLR7-
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dependent immune activation. However, to date, there is no published data proving 
this hypothesis. It would therefore be of interest to study RAGE involvement in the 
deleterious effect of RNA-IC in SLE. 
 
The source of nucleic acids involved in autoimmune disease has mainly been 
attributed to a nuclear origin. However, on their own, endogenous nucleic acids are 
considered to be weak activators of the endosomal TLRs because of their modified 
state (255-257). This is why it is commonly believed that endogenous nucleic acids 
must be associated with other factors such as HMGB1 or other nuclear proteins to 
induce autoimmune responses. At present, how such endogenous nucleic acids 
acquire the potential to activate TLRs is still unclear. Providing clues on how this 
might happen, drug-induced SLE was found after use of hydralazine and 
procainamide, drugs that were shown to inhibit DNA methylation (258). On the other 
hand, mitochondrial RNA (mtRNA) possesses very little pseudouridine and 2’-O-
methylated nucleosides, which makes them similar to bacterial RNA. Interestingly, 
mtRNA was shown to potentiate TLR-dependent immune responses (257). During 
tissue damage, it is therefore likely that mtRNA would act as a danger signal with a 
potential involvement of RAGE. This is supported by data showing RAGE 
contribution to the TLR9-depedent immune recognition of mitochondrial DNA in 
complex with Mitochondrial Transcription Factor A (TFAM, (259)) 
 
The role of extracellular RNA as pro-inflammatory danger signal was recently 
reinforced by a study showing that the micro-RNA (miRNA) let-7 is a potent TLR7 
agonist (260). In fact, in Alzheimer’s patients, let-7 was found to be increased in the 
cerebrospinal fluid. Moreover, let-7 was shown to activate TLR7 in neurons and 
induced neurodegeneration. Importantly, RAGE is expressed in neurons were it was 
shown to mediate part of Aβ deleterious effects (124, 149, 160). Together with the 
data presented in this thesis, the study by Lehmann and colleagues calls for further 
investigation of RAGE binding to let-7 and its involvement in TLR7 activation. 
 
 
5.5 RAGE and cell to cell communication  
 
Not all extracellular nucleic acids signal danger or tissue damage. Since only 1-2% of 
the mammalian genome is translated to proteins, great interest went into 
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understanding the function of such a large array of transcript deprived from 
translational function. Several classes of non-coding RNA (ncRNA) species ranging 
from 20 nucleotides to more than 200 nucleotides have been shown to regulate a 
large array of cellular mechanisms from gene expression to protein function (261, 
262). These include the miRNA previously mentioned but also small interfering RNA 
(siRNA) and long non-coding RNA (lncRNA). Interestingly, certain ncRNAs were 
found to be secreted by cells (263). Astonishingly, plant miRNAs were also found to 
affect mammalian cells upon ingestion and proved that miRNAs may be involved in 
cross-kingdom regulation (264). However, most of the data on the existence of 
extracellular ncRNA is focused on miRNA and shows that such extracellular RNA are 
packaged into extracellular vesicles (EVs) (265, 266). Nevertheless, some evidence 
exists that suggests a possible regulatory effect of EV-free ncRNA present in the 
extracellular milieu. Initial evidence has been drawn from more primitive kingdoms. 
For example, the transmembrane protein SID-1 has previously been shown to 
mediate entry of siRNA into nematode cells enabling systemic gene silencing as a 
general gene expression regulation mechanism (267). SID-1 homologue proteins 
were later found to function in a similar way by promoting entry of siRNA and dsRNA 
into insect cells (268) or mammalian cells (269). Both plants and nematodes use the 
transfer of non-coding RNA from cell to cell as a communication mechanism enabling 
systemic control of gene expression (270). Furthermore, recent analysis of human 
plasma and blood showed the presence of EV-free miRNA (271-274). Vickers and 
colleagues found that plasma miRNA could be associated with high-density 
lipoproteins (HDL) and thereby be delivered to cells (274). Other studies found that 
the majority of extracellular miRNA bound to protein complexes rather than EVs. 
These protein complexes had a protecting effect for miRNA against RNases. For 
example, extracellular miRNAs were found to associate with proteins of the RNA-
induced silencing complex (RISC), Argonaute 1 and 2 (Ago1/2) (271-273). These 
studies therefore reveal the emerging importance of ncRNA as tool for cell-to-cell 
communication. As mentioned earlier with the example of HMGB1, the protection of 
extracellular RNA by proteins could potentiate their stability and upon binding to 
RAGE further amplify their effect. Together with the studies described in this 
paragraph, ncRNA in complex with chaperone proteins such as Ago1 or Ago2 could 
be internalised through interaction with RAGE. Hence, the role of RAGE in such 
long-distance communication mechanisms would also be worth of further attention. 
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5.6 Conclusion and future directions  
 
The localization of the nucleic acid sensing PRRs to the cytoplasm or the 
endolysosomal compartment is thought to help the organism to differentiate between 
self and non-self nucleic acids. This compartmentalization of signaling receptors 
ensures that these PRRs are only triggered under conditions where ligands achieve 
access to the subcellular compartment. However, under conditions of infection or 
tissue damage, mechanisms must be in place for the host to initiate an immune 
response. Thus, the presence of nucleic acid sensors or nucleic acid delivery 
molecules at the cell surface would sensitize cells and allow a decrease in the 
cellular activation threshold, enabling a faster or more pronounced response against 
pathogen-derived nucleic acids (Fig. 5.3). This model of an adjustable cellular 
threshold is in agreement with previous reports implicating the involvement of RAGE 
in sepsis or sterile injury but also in auto-inflammatory pathologies such as diabetes 
and atherosclerosis. Indeed, at steady state, the expression of RAGE in immune 
cells or vascular endothelial and smooth muscle cells is low but can be increased in 
pathologies where RAGE ligands accumulate. 
 
 
Figure 5.3 RAGE lowers the cellular threshold for immune activation by nucleic 
acids.  
Upon cellular stress induced by infection or tissue damage, extracellular PAMPs and DAMPs 
stimulate RAGE expression through activation of PRRs and downstream NFκB or AP-1 
transcription factors (TF). Increased expression of RAGE sensitizes the cells by lowering the 
threshold of immune activation induced by RAGE ligands such as extracellular nucleic acids 
resulting in increased inflammation. 
 
The first hint of the involvement of RAGE in nucleic acid-derived immune stimulation 
came from the finding that RAGE binds DNA/HMGB1-containing immune complexes 
and thereby promotes their internalization and TLR9-dependent immune response. 
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Data presented in the first result part of this thesis, which was part of collaborative 
work published in 2013, further implicated RAGE in DNA sensing. These results 
showed that DNA can directly bind to RAGE and thereby is recruited at the surface of 
cells expressing RAGE. This promoted cell internalization of such DNA and a 
stronger immune activation upon stimulation with TLR9-specific DNA agonists (Fig. 
5.1). RAGE was also found to interact directly with TLR9 and this interaction was 
amplified by DNA stimulation. The increase of RAGE expression found during the 
onset of inflammation could therefore act as regulatory switch enabling immune cells 
to lower their threshold of activation by microbial nucleic acids. This system might 
have evolved to reduce the risk of secondary infection. 
Since RAGE sensing of DNA is controlled by sequence-unspecific interaction with 
the DNA phosphate backbone, RNA binding to RAGE and similar amplification of 
RNA-sensing appeared probable. In fact, the results presented in the second part of 
this thesis demonstrated this hypothesis to be true (Fig. 5.1). RNA was recruited to 
cells expressing RAGE and this strikingly promoted RNA internalization by these 
cells. Furthermore, in a similar manner to DNA, RAGE over-expression induced an 
increase of TLR7-, TLR8- or TLR13-dependent NFκB activation. This was confirmed 
in primary cells isolated from mouse bone marrow, where RAGE deficiency induced 
a marked decrease of TNFα and IL-6 secretion induced by specific stimulation of 
TLR13. Surprisingly, while the effect of RAGE on stimulation of all ssRNA-specific 
TLRs was very similar, the effect of RAGE on dsRNA proved to be different. Indeed, 
RAGE expression had an antagonistic effect on TLR3 specific activation. However, 
when using a less specific dsRNA analog, RAGE expression induced an increase of 
immune activation very similar to the one found with ssRNA. These results shed 
some light upon the importance of RAGE trafficking for regulation of endosomal 
TLRs activity and opened the door for a possible RAGE-dependent regulation of 
cytosolic RNA sensing. 
 
In light of the role of HMGB1 in DNA sensing by RAGE, and knowing that HMGB1 is 
a published RNA binding protein that was shown to increase endosomal TLR 
activation, it would be crucial to study the effect of HMGB1 on RNA sensing through 
RAGE. Since HMGB1 is an important alarmin released by cells upon stress or 
damage, the role of the HMGB1-RAGE axis in nucleic acid sensing attests again to 
the function of RAGE as a central switch dropping the threshold of the immune 
activation in conditions of inflammation and cellular stress (Fig. 5.3).  
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Furthermore, by demonstrating the binding of extracellular RNA to RAGE, the results 
presented here could suggest the importance of investigating possible new roles of 
RAGE involving extracellular RNA sensing as a mechanism not only promoting anti-
microbial immune response but also cell-to-cell communication via internalization of 
regulatory non-coding RNA molecules of microbial or endogenous origin. 
It would also be critical to better characterise the mechanisms involved in RAGE 
internalization and trafficking. Is RAGE internalised upon ligand binding or is it merely 
following recycling pathways independently of ligand? Where is RAGE trafficking 
following endocytosis? Is the trafficking route dependent on the nature of RAGE 
ligands? What mechanisms other than actin polymerisation and dynamin activity 
control RAGE internalization? These questions must be answered in order to better 
comprehend the diverse function of RAGE in immune activation or potentially in cell 
communication. 
 
As discussed earlier, RAGE was previously demonstrated to be involved in several 
pathologies where it was shown to promote the chronic and aberrant activation of the 
immune system. The data presented here further supports this fact. Targeting of 
RAGE by pharmacological molecules could therefore be of interest with the aim of 
blocking these RAGE-dependent aberrant inflammation mechanisms. Soluble forms 
of RAGE or RAGE-specific antibodies have been used before to block RAGE-ligand 
binding and proved some degree of efficiency (123, 218-220, 275). Some already 
optimise the production of recombinant sRAGE with a use for therapy as the end-
goal (276, 277). In parallel with such a therapeutic strategy, the use of non-
stimulatory nucleic acid such as the one used in experiments presented in this thesis 
could potentially be considered since nucleic acids are already in clinical use (278). 
These would target RAGE and thus inhibit ligand binding and alleviate RAGE-
induced aggravation of inflammation. 
 
In conclusion, the data presented herein established RAGE as a new cell surface 
sensor for nucleic acid, which promotes their recruitment and internalization into 
cells, thereby enhancing activation of the nucleic acid-specific TLR receptors. These 
findings reinforce the idea of RAGE as a central mediator of inflammation and will 
hopefully foster investigation into possible new roles of RAGE involving extracellular 
DNA/RNA sensing as a mechanism to activate either anti-microbial or danger-
associated immune responses or even to promote cell-to-cell communication. Hence, 
the presented findings could promote RAGE as pharmacological target against 
devastating diseases such as Alzheimer’s disease, diabetes, SLE and cancer.   
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7. Annexes 
7.1 Plasmid and gene sequences 
 
Note: bold underlined sequences correspond to the restriction sites described in the 
Material and Method section. 
pRP plasmid sequence 
GACGGATCGGGAGATCTCCCGATCCCCTATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGTATCTGCTC
CCTGCTTGTGTGTTGGAGGTCGCTGAGTAGTGCGCGAGCAAAATTTAAGCTACAACAAGGCAAGGCTTGACCGACAATTGCATGAA
GAATCTGCTTAGGGTTAGGCGTTTTGCGCTGCTTCGCGAGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGG
TCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCG
CCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGT
AAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGG
CATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCG
GTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTT
TGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGG
TGGGAGGTCTATATAAGCAGAGCTCAATAAAAGAGCCCACAACCCCTCACTCCGCGCGCCAGTCTTCCGATAGACTGCGTCGCCCG
GGTACCCGTATTCCCAATAAAGCCTCTTGCTGTTTGCATCCGAATCGTGGTCTCGCTGTTCCTTGGGAGGGTCTCCTCTGAGTGAT
TGACTACCCACGACGGGGGTCTTTCATTTGGGGGCTCGTCCGGGATTTGGAGACCCCTGCCCAGGGACCACCGACCCACCACCGGG
AGGTAAGCTGGCCAGCAACTTATCTGTGTCTGTCCGATTGTCTAGTGTCTATGTTTGATGTTATGCGCCTGCGTCTGTACTAGTTA
GCTAACTAGCTCTGTATCTGGCGGACCCGTGGTGGAACTGACGAGTTCTGAACACCCGGCCGCAACCCTGGGAGACGTCCCAGGGA
CTTTGGGGGCCGTTTTTGTGGCCCGACCTGAGGAAGGGAGTCGATGTGGAATCCGACCCCGTCAGGATATGTGGTTCTGGTAGGAG
ACGAGAACCTAAAACAGTTCCCGCCTCCGTCTGAATTTTTGCTTTCGGTTTGGAACCGAAGCCGCGCGTCTTGTCTGCTGCAGCGC
TGCAGCATCGTTCTGTGTTGTCTCTGTCTGACTGTGTTTCTGTATTTGTCTGAAAATTAGGGCCAGACTGTTACCACTCCCTTAAG
TTTGACCTTAGGTCACTGGAAAGATGTCGAGCGGATCGCTCACAACCAGTCGGTAGATGTCAAGAAGAGACGTTGGGTTACCTTCT
GCTCTGCAGAATGGCCAACCTTTAACGTCGGATGGCCGCGAGACGGCACCTTTAACCGAGACCTCATCACCCAGGTTAAGATCAAG
GTCTTTTCACCTGGCCCGCATGGACACCCAGACCAGGTCCCCTACATCGTGACCTGGGAAGCCTTGGCTTTTGACCCCCCTCCCTG
GGTCAAGCCCTTTGTACACCCTAAGCCTCCGCCTCCTCTTCCTCCATCCGCCCCGTCTCTCCCCCTTGAACCTCCTCGTTCGACCC
CGCCTCGATCCTCCCTTTATCCAGCCCTCACTCCTTCTCTAGGCGCCTCCGGTATGACCGAGTACAAGCCCACGGTGCGCCTCGCC
ACCCGCGACGACGTCCCCAGGGCCGTACGCACCCTCGCCGCCGCGTTCGCCGACTACCCCGCCACGCGCCACACCGTCGATCCGGA
CCGCCACATCGAGCGGGTCACCGAGCTGCAAGAACTCTTCCTCACGCGCGTCGGGCTCGACATCGGCAAGGTGTGGGTCGCGGACG
ACGGCGCCGCGGTGGCGGTCTGGACCACGCCGGAGAGCGTCGAAGCGGGGGCGGTGTTCGCCGAGATCGGCCCGCGCATGGCCGAG
TTGAGCGGTTCCCGGCTGGCCGCGCAGCAACAGATGGAAGGCCTCCTGGCGCCGCACCGGCCCAAGGAGCCCGCGTGGTTCCTGGC
CACCGTCGGCGTCTCGCCCGACCACCAGGGCAAGGGTCTGGGCAGCGCCGTCGTGCTCCCCGGAGTGGAGGCGGCCGAGCGCGCCG
GGGTGCCCGCCTTCCTGGAGACCTCCGCGCCCCGCAACCTCCCCTTCTACGAGCGGCTCGGCTTCACCGTCACCGCCGACGTCGAG
GTGCCCGAAGGACCGCGCACCTGGTGCATGACCCGCAAGCCCGGTGCCTGAGGATCGATCCGGCCATTAGCCATATTATTCATTGG
TTATATAGCATAAATCAATATTGGCTATTGGCCATTGCATACGTTGTATCCATATCATAATATGTACATTTATATTGGCTCATGTC
CAACATTACCGCCATGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATG
GAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTA
TGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATC
AAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTA
TGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCG
TGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGG
ACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCT
CGTTTAGTGAACCGTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCCTCCG
CGGCCCCAAGCTTTGCTAGCCAATTGTCGCGCGCGTCTTCTAGAGGATCTGGTACCTCTTCTGGATCCTCTTCTGGCGCGCCTTCT
TCTGCGGCCGCTAAACCTAGGAGACTCGAGTCTTCTCCATCTGGCTGGTCTTCTGGGCCCTAATTAGTTGAACGCCGGCGGTCGAG
GCCGCATCGATAAAATAAAAGATTTTATTTAGTCTCCAGAAAAAGGGGGGAATGAAAGACCCCACCTGTAGGTTTGGCAAGCTAGC
TTAAGTAACGCCATTTTGCAAGGCATGGAAAAATACATAACTGAGAATAGAGAAGTTCAGATCAAGGTCAGGAACAGATGGAACAG
CTGAATATGGGCCAAACAGGATATCTGTGGTAAGCAGTTCCTGCCCCGGCTCAGGGCCAAGAACAGATGGAACAGCTGAATATGGG
CCAAACAGGATATCTGTGGTAAGCAGTTCCTGCCCCGGCTCAGGGCCAAGAACAGATGGTCCCCAGATGCGGTCCAGCCCTCAGCA
GTTTCTAGAGAACCATCAGATGTTTCCAGGGTGCCCCAAGGACCTGAAATGACCCTGTGCCTTATTTGAACTAACCAATCAGTTCG
CTTCTCGCTTCTGTTCGCGCGCTTCTGCTCCCCGAGCTCAATAAAAGAGCCCACAACCCCTCACTCGGGGCGCCAGTCCTCCGATT
GACTGAGTCGCCCGGGTACCCGTGTATCCAATAAACCCTCTTGCAGTTGCATCCGACTTGTGGTCTCGCTGTTCCTTGGGAGGGTC
TCCTCTGAGTGATTGACTACCCGTCAGCGGGGGTCTTTCATTTGGGGGCTCGTCCGGGATCGGGAGACCCCTGCCCAGGGACCACC
GACCCACCACCGGGAGGTAAGCTGGGAACTAATTCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAG
GCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAA
AGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTC
TCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCTGCCTCTGAGCTATTCCAGAAGTAGTGAGGAG
GCTTTTTTGGAGGCCTAGTACCGTCGACCTCTAGCTAGAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTAT
CCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAAT
TGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCG
GTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCAC
TCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAA
CCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGT
GGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTT
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ACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCAATGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGT
CGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCA
ACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAG
TTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAA
AAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAA
AAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTC
ATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAAC
TTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCC
CCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCT
CCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTAT
TAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGT
CACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAA
GCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAA
TTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGC
GACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGT
TCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGC
ATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAAT
GTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGT
ATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTC 
 
RAGE FL coding sequence 
GGCGCGCCTGCCACCATGGCAGCCGGAACAGCAGTTGGAGCCTGGGTGCTGGTCCTCAGTCTGTGGGGGGCAGTAGTAGGTGCTCA
AAACATCACAGCCCGGATTGGCGAGCCACTGGTGCTGAAGTGTAAGGGGGCCCCCAAGAAACCACCCCAGCGGCTGGAATGGAAAC
TGAACACAGGCCGGACAGAAGCTTGGAAGGTCCTGTCTCCCCAGGGAGGAGGCCCCTGGGACAGTGTGGCTCGTGTCCTTCCCAAC
GGCTCCCTCTTCCTTCCGGCTGTCGGGATCCAGGATGAGGGGATTTTCCGGTGCCAGGCAATGAACAGGAATGGAAAGGAGACCAA
GTCCAACTACCGAGTCCGTGTCTACCAGATTCCTGGGAAGCCAGAAATTGTAGATTCTGCCTCTGAACTCACGGCTGGTGTTCCCA
ATAAGGTGGGGACATGTGTGTCAGAGGGAAGCTACCCTGCAGGGACTCTTAGCTGGCACTTGGATGGGAAGCCCCTGGTGCCTAAT
GAGAAGGGAGTATCTGTGAAGGAACAGACCAGGAGACACCCTGAGACAGGGCTCTTCACACTGCAGTCGGAGCTAATGGTGACCCC
AGCCCGGGGAGGAGATCCCCGTCCCACCTTCTCCTGTAGCTTCAGCCCAGGCCTTCCCCGACACCGGGCCTTGCGCACAGCCCCCA
TCCAGCCCCGTGTCTGGGAGCCTGTGCCTCTGGAGGAGGTCCAATTGGTGGTGGAGCCAGAAGGTGGAGCAGTAGCTCCTGGTGGA
ACCGTAACCCTGACCTGTGAAGTCCCTGCCCAGCCCTCTCCTCAAATCCACTGGATGAAGGATGGTGTGCCCTTGCCCCTTCCCCC
CAGCCCTGTGCTGATCCTCCCTGAGATAGGGCCTCAGGACCAGGGAACCTACAGCTGTGTGGCCACCCATTCCAGCCACGGGCCCC
AGGAAAGCCGTGCTGTCAGCATCAGCATCATCGAACCAGGCGAGGAGGGGCCAACTGCAGGCTCTGTGGGAGGATCAGGGCTGGGA
ACTCTAGCCCTGGCCCTGGGGATCCTGGGAGGCCTGGGGACAGCCGCCCTGCTCATTGGGGTCATCTTGTGGCAAAGGCGGCAACG
CCGAGGAGAGGAGAGGAAGGCCCCAGAAAACCAGGAGGAAGAGGAGGAGCGTGCAGAACTGAATCAGTCGGAGGAACCTGAGGCAG
GCGAGAGTAGTACTGGAGGGCCT(TGA)GCGGCCGC 
 
RAGE ΔCyt coding sequence 
GGCGCGCCTGCCACCATGGCAGCCGGAACAGCAGTTGGAGCCTGGGTGCTGGTCCTCAGTCTGTGGGGGGCAGTAGTAGGTGCTCA
AAACATCACAGCCCGGATTGGCGAGCCACTGGTGCTGAAGTGTAAGGGGGCCCCCAAGAAACCACCCCAGCGGCTGGAATGGAAAC
TGAACACAGGCCGGACAGAAGCTTGGAAGGTCCTGTCTCCCCAGGGAGGAGGCCCCTGGGACAGTGTGGCTCGTGTCCTTCCCAAC
GGCTCCCTCTTCCTTCCGGCTGTCGGGATCCAGGATGAGGGGATTTTCCGGTGCCAGGCAATGAACAGGAATGGAAAGGAGACCAA
GTCCAACTACCGAGTCCGTGTCTACCAGATTCCTGGGAAGCCAGAAATTGTAGATTCTGCCTCTGAACTCACGGCTGGTGTTCCCA
ATAAGGTGGGGACATGTGTGTCAGAGGGAAGCTACCCTGCAGGGACTCTTAGCTGGCACTTGGATGGGAAGCCCCTGGTGCCTAAT
GAGAAGGGAGTATCTGTGAAGGAACAGACCAGGAGACACCCTGAGACAGGGCTCTTCACACTGCAGTCGGAGCTAATGGTGACCCC
AGCCCGGGGAGGAGATCCCCGTCCCACCTTCTCCTGTAGCTTCAGCCCAGGCCTTCCCCGACACCGGGCCTTGCGCACAGCCCCCA
TCCAGCCCCGTGTCTGGGAGCCTGTGCCTCTGGAGGAGGTCCAATTGGTGGTGGAGCCAGAAGGTGGAGCAGTAGCTCCTGGTGGA
ACCGTAACCCTGACCTGTGAAGTCCCTGCCCAGCCCTCTCCTCAAATCCACTGGATGAAGGATGGTGTGCCCTTGCCCCTTCCCCC
CAGCCCTGTGCTGATCCTCCCTGAGATAGGGCCTCAGGACCAGGGAACCTACAGCTGTGTGGCCACCCATTCCAGCCACGGGCCCC
AGGAAAGCCGTGCTGTCAGCATCAGCATCATCGAACCAGGCGAGGAGGGGCCAACTGCAGGCTCTGTGGGAGGATCAGGGCTGGGA
ACTCTAGCCCTGGCCCTGGGGATCCTGGGAGGCCTGGGGACAGCCGCCCTGCTCATTGGGGTCATCTTGTGGCAAAGGCGGTGAGC
GGCCGC 
 
RAGE ΔVC1 coding sequence 
GGCGCGCCTGCCACCATGGCAGCCGGAACAGCAGTTGGAGCCTGGGTGCTGGTCCTCAGTCTGTGGGGGGCAGTAGTAGGTCCCCG
TGTCTGGGAGCCTGTGCCTCTGGAGGAGGTCCAATTGGTGGTGGAGCCAGAAGGTGGAGCAGTAGCTCCTGGTGGAACCGTAACCC
TGACCTGTGAAGTCCCTGCCCAGCCCTCTCCTCAAATCCACTGGATGAAGGATGGTGTGCCCTTGCCCCTTCCCCCCAGCCCTGTG
CTGATCCTCCCTGAGATAGGGCCTCAGGACCAGGGAACCTACAGCTGTGTGGCCACCCATTCCAGCCACGGGCCCCAGGAAAGCCG
TGCTGTCAGCATCAGCATCATCGAACCAGGCGAGGAGGGGCCAACTGCAGGCTCTGTGGGAGGATCAGGGCTGGGAACTCTAGCCC
TGGCCCTGGGGATCCTGGGAGGCCTGGGGACAGCCGCCCTGCTCATTGGGGTCATCTTGTGGCAAAGGCGGCAACGCCGAGGAGAG
GAGAGGAAGGCCCCAGAAAACCAGGAGGAAGAGGAGGAGCGTGCAGAACTGAATCAGTCGGAGGAACCTGAGGCAGGCGAGAGTAG
TACTGGAGGGCCTGCGGCCGC 
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Linker-mCitrine coding sequence 
GCGGCCGCTTTTTTCCCGCTCGAGGGAGGCGGTGGGAGTGGAGGCGGTGGCAGATCCGTGAGCAAGGGCGAGGAGCTGTTCACCGG
GGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCT
ACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCTTCGGCTACGGC
CTGATGTGCTTCGCCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCG
CACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATG
GCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTA
CCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCTACCAGTCCAAGCTGAGCAAAGACC
CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGACT
AGGCCATCTGGCTGG 
 
Linker-TagRFP coding sequence 
GCGGCCGCTGAGGGAGGCGGTGGGAGTGGAGGCGGTGGCCCTGCAGGGGTGTCTAAGGGCGAAGAGCTGATTAAGGAGAACATGCA
CATGAAGCTGTACATGGAGGGCACCGTGAACAACCACCACTTCAAGTGCACATCCGAGGGCGAAGGCAAGCCCTACGAGGGCACCC
AGACCATGAGAATCAAGGTGGTCGAGGGCGGCCCTCTCCCCTTCGCCTTCGACATCCTGGCTACCAGCTTCATGTACGGCAGCAGA
ACCTTCATCAACCACACCCAGGGCATCCCCGACTTCTTTAAGCAGTCCTTCCCTGAGGGCTTCACATGGGAGAGAGTCACCACATA
CGAAGACGGGGGCGTGCTGACCGCTACCCAGGACACCAGCCTCCAGGACGGCTGCCTCATCTACAACGTCAAGATCAGAGGGGTGA
ACTTCCCATCCAACGGCCCTGTGATGCAGAAGAAAACACTCGGCTGGGAGGCCAACACCGAGATGCTGTACCCCGCTGACGGCGGC
CTGGAAGGCAGAAGCGACATGGCCCTGAAGCTCGTGGGCGGGGGCCACCTGATCTGCAACTTCAAGACCACATACAGATCCAAGAA
ACCCGCTAAGAACCTCAAGATGCCCGGCGTCTACTATGTGGACCACAGACTGGAAAGAATCAAGGAGGCCGACAAAGAGACCTACG
TCGAGCAGCACGAGGTGGCTGTGGCCAGATACTGCGACCTCCCTAGCAAACTGGGGCACAAACTTAATTGAGGGCCCTAATTAGTT
GAACGCCGGCG 
 
NFκB-gLuc plasmid sequence 
GGTACCGCCAAGNTAGGGGACTTTCCGCTTGGGGACTTTCCGCTGGGGACTTTCCGCTGGGGACTTTCCGCTGGGGACTTTCCGCG
GAGACTCTAGAGGGTATATAATGGAAGCTCGAATTGATCTGCGATCTAAGTAAGCTTGGCATTCCGGTACTGTTGGTAAAGCCACC
ATGGGAGTCAAAGTTCTGTTTGCCCTGATCTGCATCGCTGTGGCCGAGGCCAAGCCCACCGAGAACAACGAAGACTTCAACATCGT
GGCCGTGGCCAGCAACTTCGCGACCACGGATCTCGATGCTGACCGCGGGAAGTTGCCCGGCAAGAAGCTGCCGCTGGAGGTGCTCA
AAGAGATGGAAGCCAATGCCCGGAAAGCTGGCTGCACCAGGGGCTGTCTGATCTGCCTGTCCCACATCAAGTGCACGCCCAAGATG
AAGAAGTTCATCCCAGGACGCTGCCACACCTACGAAGGCGACAAAGAGTCCGCACAGGGCGGCATAGGCGAGGCGATCGTCGACAT
TCCTGAGATTCCTGGGTTCAAGGACTTGGAGCCSATGGAGCAGTTCATCGCACAGGTCGATCTGTGTGTGGACTGCACAACTGGCT
GCCTCAAAGGGCTTGCCAACGTGCAGTGTTCTGACCTGCTCAAGAAGTGGCTGCCGCAACGCTGTGCGACCTTTGCCAGCAAGATC
CAGGGCCAGGTGGACAAGATCAAGGGGGCCGGTGGTGACTAATCTAGAGTCGGGGCGGCCGGCCGCTTCGAGCAGACATGATAAGA
TACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATT
TGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGG
TTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTAAAATCGATAAGGATCCGTCGACCGATGCCCTTGAGAGCCTTCAACCCAGT
CAGCTCCTTCCGGTGGGCGCGGGGCATGACTATCGTCGCCGCACTTATGACTGTCTTCTTTATCATGCAACTCGTAGGACAGGTGC
CGGCAGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGC
GGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAA
AGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAAC
CCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATA
CCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCT
CCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTA
AGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAA
GTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTG
GTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGA
TCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATT
ATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTG
ACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTG
TAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTT
ATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTT
GCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCG
TCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAG
CTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTA
CTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGT
TGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGG
GCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTA
CTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATA
CTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAA
AAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTG
TGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACG
TTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAA
ACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTA
ATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCG
GCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGCTTACAATTTGCCATTCGCC
ATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCCCAAGCTACCATGATAAGTAAGTA
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ATATTAAGGTACGGGAGGTACTTGGAGCGGCCGCAATAAAATATCTTTATTTTCATTACATCTGTGTGTTGGTTTTTTGTGTGAAT
CGATAGTACTAACATACGCTCTCCATCAAAACAAAACGAAACAAAACAAACTAGCAAAATAGGCTGTCCCCAGTGCAAGTGCAGGT
GCCAGAACATTTCTCTATCGATA 
 
EF-1α-fLuc plasmid sequence  
AATGTAGTCTTATGCAATACTCTTGTAGTCTTGCAACATGGTAACGATGAGTTAGCAACATGCCTTACAAGGAGAGAAAAAGCACC
GTGCATGCCGATTGGTGGAAGTAAGGTGGTACGATCGTGCCTTATTAGGAAGGCAACAGACGGGTCTGACATGGATTGGACGAACC
ACTGAATTGCCGCATTGCAGAGATATTGTATTTAAGTGCCTAGCTCGATACATAAACGGGTCTCTCTGGTTAGACCAGATCTGAGC
CTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTC
TGTTGTGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGTGGCGCCCGAACAGGGACT
TGAAAGCGAAAGGGAAACCAGAGGAGCTCTCTCGACGCAGGACTCGGCTTGCTGAAGCGCGCACGGCAAGAGGCGAGGGGCGGCGA
CTGGTGAGTACGCCAAAAATTTTGACTAGCGGAGGCTAGAAGGAGAGAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAAT
TAGATCGCGATGGGAAAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAAAACATATAGTATGGGCAAGCAGGGAGC
TAGAACGATTCGCAGTTAATCCTGGCCTGTTAGAAACATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAG
ACAGGATCAGAAGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAAAGGATAGAGATAAAAGACACCAA
GGAAGCTTTAGACAAGATAGAGGAAGAGCAAAACAAAAGTAAGACCACCGCACAGCAAGGCCATTACGGCCTGATCTTCAGACCTG
GAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCCACC
AAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAG
CACTATGGGCGCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGA
GGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGA
TACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTG
GAGTAATAAATCTCTGGAACAGATTTGGAATCACACGACCTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGCTTAATAC
ACTCCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAGAATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAAT
TGGTTTAACATAACAAATTGGCTGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTTTTGC
TGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTATCGTTTCAGACCCACCTCCCAACCCCGAGGGGACCCGACA
GGCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAGACAGAGACAGATCCATTCGATTAGTGAACGGATCTCGACGGTATCGATGC
GGATACTGCAGACAAATGGCAGTATTCATCCACAATTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAGAATAGT
AGACATAATAGCAACAGACATACAAACTAAAGAATTACAAAAACAAATTACAAAAATTCAAAATTTTCGGGTTTATTACAGGGACA
GCAGAGATCCAGTGGCGCGCCCGACGATAAGCTTTGCAAAGATGGATAAAGTTTTAAACAGAGAGGAATCTTTGCAGCTAATGGAC
CTTCTAGGTCTTGAAAGGAGTGGGAATTGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
GGGGAGGGGTCGGCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTT
TTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACA
GGTAAGTGCCGTGTGTGGTTCCCGCGGGCCTGGCCTCTTTACGGGTTATGGCCCTTGCGTGCCTTGAATTACTTCCACTGGCTGCA
GTACGTGATTCTTGATCCCGAGCTTCGGGTTGGAAGTGGGTGGGAGAGTTCGAGGCCTTGCGCTTAAGGAGCCCCTTCGCCTCGTG
CTTGAGTTGAGGCCTGGCCTGGGCGCTGGGGCCGCCGCGTGCGAATCTGGTGGCACCTTCGCGCCTGTCTCGCTGCTTTCGATAAG
TCTCTAGCCATTTAAAATTTTTGATGACCTGCTGCGACGCTTTTTTTCTGGCAAGATAGTCTTGTAAATGCGGGCCAAGATCTGCA
CACTGGTATTTCGGTTTTTGGGGCCGCGGGCGGCGACGGGGCCCGTGCGTCCCAGCGCACATGTTCGGCGAGGCGGGGCCTGCGAG
CGCGGCCACCGAGAATCGGACGGGGGTAGTCTCAAGCTGGCCGGCCTGCTCTGGTGCCTGGCCTCGCGCCGCCGTGTATCGCCCCG
CCCTGGGCGGCAAGGCTGGCCCGGTCGGCACCAGTTGCGTGAGCGGAAAGATGGCCGCTTCCCGGCCCTGCTGCAGGGAGCTCAAA
ATGGAGGACGCGGCGCTCGGGAGAGCGGGCGGGTGAGTCACCCACACAAAGGAAAAGGGCCTTTCCGTCCTCAGCCGTCGCTTCAT
GTGACTCCACGGAGTACCGGGCGCCGTCCAGGCACCTCGATTAGTTCTCGAGCTTTTGGAGTACGTCGTCTTTAGGTTGGGGGGAG
GGGTTTTATGCGATGGAGTTTCCCCACACTGAGTGGGTGGAGACTGAAGTTAGGCCAGCTTGGCACTTGATGTAATTCTCCTTGGA
ATTTGCCCTTTTTGAGTTTGGATCTTGGTTCATTCTCAAGCCTCAGACAGTGGTTCAAAGTTTTTTTCTTCCATTTCAGGTGTCGT
GAGGAATTTCGACCCTGCAGGTGATCTACTAGTGCGGATATCTAGTGAACCGTCAGATCCGCTAGCGCTACCGGACTCAGATCTCG
AGCTCAAGCTTCGAATTCTGCAGTCGAGGTCGACGCCACCATGGAAGATGCCAAAAACATTAAGAAGGGCCCAGCGCCATTCTACC
CACTCGAAGACGGGACCGCCGGCGAGCAGCTGCACAAAGCCATGAAGCGCTACGCCCTGGTGCCCGGCACCATCGCCTTTACCGAC
GCACATATCGAGGTGGACATTACCTACGCCGAGTACTTCGAGATGAGCGTTCGGCTGGCAGAAGCTATGAAGCGCTATGGGCTGAA
TACAAACCATCGGATCGTGGTGTGCAGCGAGAATAGCTTGCAGTTCTTCATGCCCGTGTTGGGTGCCCTGTTCATCGGTGTGGCTG
TGGCCCCAGCTAACGACATCTACAACGAGCGCGAGCTGCTGAACAGCATGGGCATCAGCCAGCCCACCGTCGTATTCGTGAGCAAG
AAAGGGCTGCAAAAGATCCTCAACGTGCAAAAGAAGCTACCGATCATACAAAAGATCATCATCATGGATAGCAAGACCGACTACCA
GGGCTTCCAAAGCATGTACACCTTCGTGACTTCCCATTTGCCACCCGGCTTCAACGAGTACGACTTCGTGCCCGAGAGCTTCGACC
GGGACAAAACCATCGCCCTGATCATGAACAGTAGTGGCAGTACCGGATTGCCCAAGGGCGTAGCCCTACCGCACCGCACCGCTTGT
GTCCGATTCAGTCATGCCCGCGACCCCATCTTCGGCAACCAGATCATCCCCGACACCGCTATCCTCAGCGTGGTGCCATTTCACCA
CGGCTTCGGCATGTTCACCACGCTGGGCTACTTGATCTGCGGCTTTCGGGTCGTGCTCATGTACCGCTTCGAGGAGGAGCTATTCT
TGCGCAGCTTGCAAGACTATAAGATTCAATCTGCCCTGCTGGTGCCCACACTATTTAGCTTCTTCGCTAAGAGCACTCTCATCGAC
AAGTACGACCTAAGCAACTTGCACGAGATCGCCAGCGGCGGGGCGCCGCTCAGCAAGGAGGTAGGTGAGGCCGTGGCCAAACGCTT
CCACCTACCAGGCATCCGCCAGGGCTACGGCCTGACAGAAACAACCAGCGCCATTCTGATCACCCCCGAAGGGGACGACAAGCCTG
GCGCAGTAGGCAAGGTGGTGCCCTTCTTCGAGGCTAAGGTGGTGGACTTGGACACCGGTAAGACACTGGGTGTGAACCAGCGCGGC
GAGCTGTGCGTCCGTGGCCCCATGATCATGAGCGGCTACGTTAACAACCCCGAGGCTACAAACGCTCTCATCGACAAGGACGGCTG
GCTGCACAGCGGCGACATCGCCTACTGGGACGAGGACGAGCACTTCTTCATCGTGGACCGGCTGAAGAGCCTGATCAAATACAAGG
GCTACCAGGTAGCCCCAGCCGAACTGGAGAGCATCCTGCTGCAACACCCCAACATCTTCGACGCCGGGGTCGCCGGCCTGCCCGAC
GACGATGCCGGCGAGCTGCCCGCCGCAGTCGTCGTGCTGGAACACGGTAAAACCATGACCGAGAAGGAGATCGTGGACTATGTGGC
CAGCCAGGTTACAACCGCCAAGAAGCTGCGCGGTGGTGTTGTGTTCGTGGACGAGGTGCCTAAAGGACTGACCGGCAAGTTGGACG
CCCGCAAGATCCGCGAGATTCTCATTAAGGCCAAGAAGGGCGGCAAGATCGCCGTGTGAGCGGCCGCGACTCTAGATCATAATCAG
CCATACCACATTTGACGCGTGTCATATGATAATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGT
TGCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCGTATGGCTTTCATTTTCTCCTCCT
TGTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGAC
GCAACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTTCGCTTTCCCCCTCCCTATTGCCACGGCGGA
ACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGA
CGTCCTTTCCATGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCCA
GCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCT
TTGGGCCGCCTCCCCGCATCGGTACGTACGCGTACCGGTTAGTAATGAGTTTGGAATTAATTCTGTGGAATGTGTGTCAGTTAGGG
TGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCC
AGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGC
CCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCTGCC
  110 
TCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTCCCGGGAGCTTGTATATCCATTTT
CGGATCTGATCAGCACGTGTTGACAATTAATCATCGGCATAGTATATCGGCATAGTATAATACGACAAGGTGAGGAACTAAACCAT
GGCCAAGCCTTTGTCTCAAGAAGAATCCACCCTCATTGAAAGAGCAACGGCTACAATCAACAGCATCCCCATCTCTGAAGACTACA
GCGTCGCCAGCGCAGCTCTCTCTAGCGACGGCCGCATCTTCACTGGTGTCAATGTATATCATTTTACTGGGGGACCTTGTGCAGAA
CTCGTGGTGCTGGGCACTGCTGCTGCTGCGGCAGCTGGCAACCTGACTTGTATCGTCGCGATCGGAAATGAGAACAGGGGCATCTT
GAGCCCCTGCGGACGGTGCCGACAGGTGCTTCTCGATCTGCATCCTGGGATCAAAGCCATAGTGAAGGACAGTGATGGACAGCCGA
CGGCAGTTGGGATTCGTGAATTGCTGCCCTCTGGTTATGTGTGGGAGGGCTAAGCACAATTCGAGCTCGGTACCTTTAAGACCAAT
GACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAAGGGCTAATTCACTCCCAACGAAGACAAG
ATCTGCTTTTTGCTTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTT
AAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTCAGACC
CTTTTAGTCAGTGTGGAAAATCTCTAGCAGTAGTAGTTCATGTCATCTTATTATTCAGTATTTATAACTTGCAAAGAAATGAATAT
CAGAGAGTGAGAGGAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTT
TTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGGCTCTAGCTATCCCGCCCCTAACTCCG
CCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGC
CGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGGACGTACCCAATTCGCCCTATAGTGAGTC
GTATTACGCGCGCTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCAC
ATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGG
GACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCC
CGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGT
TCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACG
GTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGT
CTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATT
TTAACAAAATATTAACGCTTACAATTTAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATAC
ATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACAT
TTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGC
TGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAAC
GTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGC
CGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATT
ATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTT
TTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGAC
ACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAAT
AGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAG
CCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGG
AGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGT
TTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGA
CCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTT
CTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTT
TCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACT
CTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTG
GACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGAC
CTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAA
GCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCAC
CTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTT
CCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGT
GAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCG
CCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAAT
TAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGAT
AACAATTTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCGCGCAATTAACCCTCACTAAAGGGAACAAAAGCTGGAGCTG
CAAGCTT 
 
VSV-G plasmid sequence  
GAGCTTGGCCCATTGCATACGTTGTATCCATATCATAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCCATGTTGACA
TTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTA
CGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATA
GGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTAC
GCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGT
ACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGG
GGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAA
CTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCG
CCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCCTCCGGTCGACCGATCCTGAGAACTTC
AGGGTGAGTTTGGGGACCCTTGATTGTTCTTTCTTTTTCGCTATTGTAAAATTCATGTTATATGGAGGGGGCAAAGTTTTCAGGGT
GTTGTTTAGAATGGGAAGATGTCCCTTGTATCACCATGGACCCTCATGATAATTTTGTTTCTTTCACTTTCTACTCTGTTGACAAC
CATTGTCTCCTCTTATTTTCTTTTCATTTTCTGTAACTTTTTCGTTAAACTTTAGCTTGCATTTGTAACGAATTTTTAAATTCACT
TTTGTTTATTTGTCAGATTGTAAGTACTTTCTCTAATCACTTTTTTTTCAAGGCAATCAGGGTATATTATATTGTACTTCAGCACA
GTTTTAGAGAACAATTGTTATAATTAAATGATAAGGTAGAATATTTCTGCATATAAATTCTGGCTGGCGTGGAAATATTCTTATTG
GTAGAAACAACTACACCCTGGTCATCATCCTGCCTTTCTCTTTATGGTTACAATGATATACACTGTTTGAGATGAGGATAAAATAC
TCTGAGTCCAAACCGGGCCCCTCTGCTAACCATGTTCATGCCTTCTTCTCTTTCCTACAGCTCCTGGGCAACGTGCTGGTTGTTGT
GCTGTCTCATCATTTTGGCAAAGAATTCCTCGACGGATCCCTCGAGGAATTCTGACACTATGAAGTGCCTTTTGTACTTAGCCTTT
TTATTCATTGGGGTGAATTGCAAGTTCACCATAGTTTTTCCACACAACCAAAAAGGAAACTGGAAAAATGTTCCTTCTAATTACCA
TTATTGCCCGTCAAGCTCAGATTTAAATTGGCATAATGACTTAATAGGCACAGCCTTACAAGTCAAAATGCCCAAGAGTCACAAGG
CTATTCAAGCAGACGGTTGGATGTGTCATGCTTCCAAATGGGTCACTACTTGTGATTTCCGCTGGTATGGACCGAAGTATATAACA
CATTCCATCCGATCCTTCACTCCATCTGTAGAACAATGCAAGGAAAGCATTGAACAAACGAAACAAGGAACTTGGCTGAATCCAGG
CTTCCCTCCTCAAAGTTGTGGATATGCAACTGTGACGGATGCCGAAGCAGTGATTGTCCAGGTGACTCCTCACCATGTGCTGGTTG
ATGAATACACAGGAGAATGGGTTGATTCACAGTTCATCAACGGAAAATGCAGCAATTACATATGCCCCACTGTCCATAACTCTACA
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ACCTGGCATTCTGACTATAAGGTCAAAGGGCTATGTGATTCTAACCTCATTTCCATGGACATCACCTTCTTCTCAGAGGACGGAGA
GCTATCATCCCTGGGAAAGGAGGGCACAGGGTTCAGAAGTAACTACTTTGCTTATGAAACTGGAGGCAAGGCCTGCAAAATGCAAT
ACTGCAAGCATTGGGGAGTCAGACTCCCATCAGGTGTCTGGTTCGAGATGGCTGATAAGGATCTCTTTGCTGCAGCCAGATTCCCT
GAATGCCCAGAAGGGTCAAGTATCTCTGCTCCATCTCAGACCTCAGTGGATGTAAGTCTAATTCAGGACGTTGAGAGGATCTTGGA
TTATTCCCTCTGCCAAGAAACCTGGAGCAAAATCAGAGCGGGTCTTCCAATCTCTCCAGTGGATCTCAGCTATCTTGCTCCTAAAA
ACCCAGGAACCGGTCCTGCTTTCACCATAATCAATGGTACCCTAAAATACTTTGAGACCAGATACATCAGAGTCGATATTGCTGCT
CCAATCCTCTCAAGAATGGTCGGAATGATCAGTGGAACTACCACAGAAAGGGAACTGTGGGATGACTGGGCACCATATGAAGACGT
GGAAATTGGACCCAATGGAGTTCTGAGGACCAGTTCAGGATATAAGTTTCCTTTATACATGATTGGACATGGTATGTTGGACTCCG
ATCTTCATCTTAGCTCAAAGGCTCAGGTGTTCGAACATCCTCACATTCAAGACGCTGCTTCGCAACTTCCTGATGATGAGAGTTTA
TTTTTTGGTGATACTGGGCTATCCAAAAATCCAATCGAGCTTGTAGAAGGTTGGTTCAGTAGTTGGAAAAGCTCTATTGCCTCTTT
TTTCTTTATCATAGGGTTAATCATTGGACTATTCTTGGTTCTCCGAGTTGGTATCCATCTTTGCATTAAATTAAAGCACACCAAGA
AAAGACAGATTTATACAGACATAGAGATGAACCGACTTGGAAAGTAACTCAAATCCTGCACAACAGATTCTTCATGTTTGGACCAA
ATCAACTTGTGATACCATGCTCAAAGAGGCCTCAATTATATTTGAGTTTTTAATTTTTATGAAAAAAAAAAAAAAAAACGGAATTC
CTCGAGGGATCCGTCGAGGAATTCACTCCTCAGGTGCAGGCTGCCTATCAGAAGGTGGTGGCTGGTGTGGCCAATGCCCTGGCTCA
CAAATACCACTGAGATCTTTTTCCCTCTGCCAAAAATTATGGGGACATCATGAAGCCCCTTGAGCATCTGACTTCTGGCTAATAAA
GGAAATTTATTTTCATTGCAATAGTGTGTTGGAATTTTTTGTGTCTCTCACTCGGAAGGACATATGGGAGGGCAAATCATTTAAAA
CATCAGAATGAGTATTTGGTTTAGAGTTTGGCAACATATGCCCATATGCTGGCTGCCATGAACAAAGGTTGGCTATAAAGAGGTCA
TCAGTATATGAAACAGCCCCCTGCTGTCCATTCCTTATTCCATAGAAAAGCCTTGACTTGAGGTTAGATTTTTTTTATATTTTGTT
TTGTGTTATTTTTTTCTTTAACATCCCTAAAATTTTCCTTACATGTTTTACTAGCCAGATTTTTCCTCCTCTCCTGACTACTCCCA
GTCATAGCTGTCCCTCTTCTCTTATGGAGATCCCTCGACGGATCGGCCGCAATTCGTAATCATGTCATAGCTGTTTCCTGTGTGAA
ATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTC
ACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGG
GAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTAT
CAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAG
GCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAG
TCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCC
TGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCG
GTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCT
TGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTG
CTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACC
TTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTAC
GCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGA
TTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATAT
GAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGC
CTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCT
CACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATC
CAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCAT
CGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGT
GCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCA
CTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTG
TATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTG
GAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGA
TCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGAC
ACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATAT
TTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTAAATTGTAAGCGTTAATATTT
TGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAA
GAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCAACGTCAAAGGGCG
AAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAA
ATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAA
GGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCGCTACAGGG
CGCGTCCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGCGAAAG
GGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAGCGCGCG
TAATACGACTCACTATAGGGCGAATTGGAGCTCCACCGCGGTGGCGGCCGCTCTAGA 
 
Gag-pol plasmid sequence  
GAGCTTGGCCCATTGCATACGTTGTATCCATATCATAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCCATGTTGACA
TTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTA
CGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATA
GGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTAC
GCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGT
ACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGG
GGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAA
CTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCG
CCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCCTCCCCTCGAAGCTTACATGTGGTACC
GAGCTCGGATCCTGAGAACTTCAGGGTGAGTCTATGGGACCCTTGATGTTTTCTTTCCCCTTCTTTTCTATGGTTAAGTTCATGTC
ATAGGAAGGGGAGAAGTAACAGGGTACACATATTGACCAAATCAGGGTAATTTTGCATTTGTAATTTTAAAAAATGCTTTCTTCTT
TTAATATACTTTTTTGTTTATCTTATTTCTAATACTTTCCCTAATCTCTTTCTTTCAGGGCAATAATGATACAATGTATCATGCCT
CTTTGCACCATTCTAAAGAATAACAGTGATAATTTCTGGGTTAAGGCAATAGCAATATTTCTGCATATAAATATTTCTGCATATAA
ATTGTAACTGATGTAAGAGGTTTCATATTGCTAATAGCAGCTACAATCCAGCTACCATTCTGCTTTTATTTTATGGTTGGGATAAG
GCTGGATTATTCTGAGTCCAAGCTAGGCCCTTTTGCTAATCATGTTCATACCTCTTATCTTCCTCCCACAGCTCCTGGGCAACGTG
CTGGTCTGTGTGCTGGCCCATCACTTTGGCAAAGAATTCATGGGCCAGACTGTTACCACTCCCTTAAGTTTGACCTTAGGTCACTG
GAAAGATGTCGAGCGGATCGCTCACAACCAGTCGGTAGATGTCAAGAAGAGACGTTGGGTTACCTTCTGCTCTGCAGAATGGCCAA
CCTTTAACGTCGGATGGCCGCGAGACGGCACCTTTAACCGAGACCTCATCACCCAGGTTAAGATCAAGGTCTTTTCACCTGGCCCG
CATGGACACCCAGACCAGGTCCCCTACATCGTGACCTGGGAAGCCTTGGCTTTTGACCCCCCTCCCTGGGTCAAGCCCTTTGTACA
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CCCTAAGCCTCCGCCTCCTCTTCCTCCATCCGCCCCGTCTCTCCCCCTTGAACCTCCTCGTTCGACCCCGCCTCGATCCTCCCTTT
ATCCAGCCCTCACTCCTTCTCTAGGCGCCAAACCTAAACCTCAAGTTCTTTCTGACAGTGGGGGGCCGCTCATCGACCTACTTACA
GAAGACCCCCCGCCTTATAGGGACCCAAGACCACCCCCTTCCGACAGGGACGGAAATGGTGGAGAAGCGACCCCTGCGGGAGAGGC
ACCGGACCCCTCCCCAATGGCATCTCGCCTACGTGGGAGACGGGAGCCCCCTGTGGCCGACTCCACTACCTCGCAGGCATTCCCCC
TCCGCGCAGGAGGAAACGGACAGCTTCAATACTGGCCGTTCTCCTCTTCTGACCTTTACAACTGGAAAAATAATAACCCTTCTTTT
TCTGAAGATCCAGGTAAACTGACAGCTCTGATCGAGTCTGTCCTCATCACCCATCAGCCCACCTGGGACGACTGTCAGCAGCTGTT
GGGGACTCTGCTGACCGGAGAAGAAAAACAACGGGTGCTCTTAGAGGCTAGAAAGGCGGTGCGGGGCGATGATGGGCGCCCCACTC
AACTGCCCAATGAAGTCGATGCCGCTTTTCCCCTCGAGCGCCCAGACTGGGATTACACCACCCAGGCAGGTAGGAACCACCTAGTC
CACTATCGCCAGTTGCTCCTAGCGGGTCTCCAAAACGCGGGCAGAAGCCCCACCAATTTGGCCAAGGTAAAAGGAATAACACAAGG
GCCCAATGAGTCTCCCTCGGCCTTCCTAGAGAGACTTAAGGAAGCCTATCGCAGGTACACTCCTTATGACCCTGAGGACCCAGGGC
AAGAAACTAATGTGTCTATGTCTTTCATTTGGCAGTCTGCCCCAGACATTGGGAGAAAGTTAGAGAGGTTAGAAGATTTAAAAAAC
AAGACGCTTGGAGATTTGGTTAGAGAGGCAGAAAAGATCTTTAATAAACGAGAAACCCCGGAAGAAAGAGAGGAACGTATCAGGAG
AGAAACAGAGGAAAAAGAAGAACGCCGTAGGACAGAGGATGAGCAGAAAGAGAAAGAAAGAGATCGTAGGAGACATAGAGAGATGA
GCAAGCTATTGGCCACTGTCGTTAGTGGACAGAAACAGGATAGACAGGGAGGAGAACGAAGGAGGTCCCAACTCGATCGCGACCAG
TGTGCCTACTGCAAAGAAAAGGGGCACTGGGCTAAAGATTGTCCCAAGAAACCACGAGGACCTCGGGGACCAAGACCCCAGACCTC
CCTCCTGACCCTAGATGACTAGGGAGGTCAGGGTCAGGAGCCCCCCCCTGAACCCAGGATAACCCTCAAAGTCGGGGGGCAACCCG
TCACCTTCCTGGTAGATACTGGGGCCCAACACTCCGTGCTGACCCAAAATCCTGGACCCCTAAGTGATAAGTCTGCCTGGGTCCAA
GGGGCTACTGGAGGAAAGCGGTATCGCTGGACCACGGATCGCAAAGTACATCTAGCTACCGGTAAGGTCACCCACTCTTTCCTCCA
TGTACCAGACTGTCCCTATCCTCTGTTAGGAAGAGATTTGCTGACTAAACTAAAAGCCCAAATCCACTTTGAGGGATCAGGAGCTC
AGGTTATGGGACCAATGGGGCAGCCCCTGCAAGTGTTGACCCTAAATATAGAAGATGAGTATCGGCTACATGAGACCTCAAAAGAG
CCAGATGTTTCTCTAGGGTCCACATGGCTGTCTGATTTTCCTCAGGCCTGGGCGGAAACCGGGGGCATGGGACTGGCAGTTCGCCA
AGCTCCTCTGATCATACCTCTGAAAGCAACCTCTACCCCCGTGTCCATAAAACAATACCCCATGTCACAAGAAGCCAGACTGGGGA
TCAAGCCCCACATACAGAGACTGTTGGACCAGGGAATACTGGTACCCTGCCAGTCCCCCTGGAACACGCCCCTGCTACCCGTTAAG
AAACCAGGGACTAATGATTATAGGCCTGTCCAGGATCTGAGAGAAGTCAACAAGCGGGTGGAAGACATCCACCCCACCGTGCCCAA
CCCTTACAACCTCTTGAGCGGGCTCCCACCGTCCCACCAGTGGTACACTGTGCTTGATTTAAAGGATGCCTTTTTCTGCCTGAGAC
TCCACCCCACCAGTCAGCCTCTCTTCGCCTTTGAGTGGAGAGATCCAGAGATGGGAATCTCAGGACAATTGACCTGGACCAGACTC
CCACAGGGTTTCAAAAACAGTCCCACCCTGTTTGATGAGGCACTGCACAGAGACCTAGCAGACTTCCGGATCCAGCACCCAGACTT
GATCCTGCTACAGTACGTGGATGACTTACTGCTGGCCGCCACTTCTGAGCTAGACTGCCAACAAGGTACTCGGGCCCTGTTACAAA
CCCTAGGGAACCTCGGGTATCGGGCCTCGGCCAAGAAAGCCCAAATTTGCCAGAAACAGGTCAAGTATCTGGGGTATCTTCTAAAA
GAGGGTCAGAGATGGCTGACTGAGGCCAGAAAAGAGACTGTGATGGGGCAGCCTACTCCGAAGACCCCTCGACAACTAAGGGAGTT
CCTAGGGACGGCAGGCTTCTGTCGCCTCTGGATCCCTGGGTTTGCAGAAATGGCAGCCCCCTTGTACCCTCTCACCAAAACGGGGA
CTCTGTTTAATTGGGGCCCAGACCAACAAAAGGCCTATCAAGAAATCAAGCAAGCTCTTCTAACTGCCCCAGCCCTGGGGTTGCCA
GATTTGACTAAGCCCTTTGAACTCTTTGTCGACGAGAAGCAGGGCTACGCCAAAGGTGTCCTAACGCAAAAACTGGGACCTTGGCG
TCGGCCGGTGGCCTACCTGTCCAAAAAGCTAGACCCAGTAGCAGCTGGGTGGCCCCCTTGCCTACGGATGGTAGCAGCCATTGCCG
TACTGACAAAGGATGCAGGCAAGCTAACCATGGGACAGCCACTAGTCATTCTGGCCCCCCATGCAGTAGAGGCACTAGTCAAACAA
CCCCCCGACCGCTGGCTTTCCAACGCCCGGATGACTCACTATCAGGCCTTGCTTTTGGACACGGACCGGGTCCAGTTCGGACCGGT
GGTAGCCCTGAACCCGGCTACGCTGCTCCCACTGCCTGAGGAAGGGCTGCAACACAACTGCCTTGATATCCTGGCCGAAGCCCACG
GAACCCGACCCGACCTAACGGACCAGCCGCTCCCAGACGCCGACCACACCTGGTACACGGATGGAAGCAGTCTCTTACAAGAGGGA
CAGCGTAAGGCGGGAGCTGCGGTGACCACCGAGACCGAGGTAATCTGGGCTAAAGCCCTGCCAGCCGGGACATCCGCTCAGCGGGC
TGAACTGATAGCACTCACCCAGGCCCTAAAGATGGCAGAAGGTAAGAAGCTAAATGTTTATACTGATAGCCGTTATGCTTTTGCTA
CTGCCCATATCCATGGAGAAATATACAGAAGGCGTGGGTTGCTCACATCAGAAGGCAAAGAGATCAAAAATAAAGACGAGATCTTG
GCCCTACTAAAAGCCCTCTTTCTGCCCAAAAGACTTAGCATAATCCATTGTCCAGGACATCAAAAGGGACACAGCGCCGAGGCTAG
AGGCAACCGGATGGCTGACCAAGCGGCCCGAAAGGCAGCCATCACAGAGACTCCAGACACCTCTACCCTCCTCATAGAAAATTCAT
CACCCTACACCTCAGAACATTTTCATTACACAGTGACTGATATAAAGGACCTAACCAAGTTGGGGGCCATTTATGATAAAACAAAG
AAGTATTGGGTCTACCAAGGAAAACCTGTGATGCCTGACCAGTTTACTTTTGAATTATTAGACTTTCTTCATCAGCTGACTCACCT
CAGCTTCTCAAAAATGAAGGCTCTCCTAGAGAGAAGCCACAGTCCCTACTACATGCTGAACCGGGATCGAACACTCAAAAATATCA
CTGAGACCTGCAAAGCTTGTGCACAAGTCAACGCCAGCAAGTCTGCCGTTAAACAGGGAACTAGGGTCCGCGGGCATCGGCCCGGC
ACTCATTGGGAGATCGATTTCACCGAGATAAAGCCCGGATTGTATGGCTATAAATATCTTCTAGTTTTTATAGATACCTTTTCTGG
CTGGATAGAAGCCTTCCCAACCAAGAAAGAAACCGCCAAGGTCGTAACCAAGAAGCTACTAGAGGAGATCTTCCCCAGGTTCGGCA
TGCCTCAGGTATTGGGAACTGACAATGGGCCTGCCTTCGTCTCCAAGGTGAGTCAGACAGTGGCCGATCTGTTGGGGATTGATTGG
AAATTACATTGTGCATACAGACCCCAAAGCTCAGGCCAGGTAGAAAGAATGAATAGAACCATCAAGGAGACTTTAACTAAATTAAC
GCTTGCAACTGGCTCTAGAGACTGGGTGCTCCTACTCCCCTTAGCCCTGTACCGAGCCCGCAACACGCCGGGCCCCCATGGCCTCA
CCCCATATGAGATCTTATATGGGGCACCCCCGCCCCTTGTAAACTTCCCTGACCCTGACATGACAAGAGTTACTAACAGCCCCTCT
CTCCAAGCTCACTTACAGGCTCTCTACTTAGTCCAGCACGAAGTCTGGAGACCTCTGGCGGCAGCCTACCAAGAACAACTGGACCG
ACCGGTGGTACCTCACCCTTACCGAGTCGGCGACACAGTGTGGGTCCGCCGACACCAGACTAAGAACCTAGAACCTCGCTGGAAAG
GACCTTACCCAGTCCTGCTGACCACCCCCACCGCCCTCAAAGTAGACGGCATCGCAGCTTGGATACACGCCGCCCACGTGAAGGCT
GCCGACCCCGGGGGTGGACCATCCTCTAGACTGACATGGCGCGTTCAACGCTCTCAAAACCCCTTAAAAATAAGGTTAACCCGCGA
GGCCCCCGTGGCTCAAATCCTGCACAACAGATTCTTCATGTTTGGACCAAATCAACTTGTGATACCATGCTCAAAGAGGCCTCAAT
TATATTTGAGTTTTTAATTTTTATGAAAAAAAAAAAAAAAAACGGAATTCCTCGAGGGATCCGTCGAGGAATTCACTCCTCAGGTG
CAGGCTGCCTATCAGAAGGTGGTGGCTGGTGTGGCCAATGCCCTGGCTCACAAATACCACTGAGATCTTTTTCCCTCTGCCAAAAA
TTATGGGGACATCATGAAGCCCCTTGAGCATCTGACTTCTGGCTAATAAAGGAAATTTATTTTCATTGCAATAGTGTGTTGGAATT
TTTTGTGTCTCTCACTCGGAAGGACATATGGGAGGGCAAATCATTTAAAACATCAGAATGAGTATTTGGTTTAGAGTTTGGCAACA
TATGCCCATATGCTGGCTGCCATGAACAAAGGTTGGCTATAAAGAGGTCATCAGTATATGAAACAGCCCCCTGCTGTCCATTCCTT
ATTCCATAGAAAAGCCTTGACTTGAGGTTAGATTTTTTTTATATTTTGTTTTGTGTTATTTTTTTCTTTAACATCCCTAAAATTTT
CCTTACATGTTTTACTAGCCAGATTTTTCCTCCTCTCCTGACTACTCCCAGTCATAGCTGTCCCTCTTCTCTTATGGAGATCCCTC
GACGGATCGGCCGCAATTCGTAATCATGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAG
CCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAG
TCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTC
CTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAG
AATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTT
TTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATA
CCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTT
CGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCAC
GAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACT
GGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCT
ACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAA
CAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGAT
CTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCT
AGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATC
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AGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGA
GGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAG
CCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGT
AGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATT
CAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCG
TTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGA
TGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAAT
ACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCT
TACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGG
TGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCA
ATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTC
CGCGCACATTTCCCCGAAAAGTGCCACCTAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCT
CATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTT
TGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGA
ACCATCACCCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTT
GACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTC
ACGCTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCCCATTCGCCATTCAGGCTGCGCAACTGTTG
GGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGC
CAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAGCGCGCGTAATACGACTCACTATAGGGCGAATTGGAGCTCCAC
CGCGGTGGCGGCCGCTCTAGA 
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